



WORLD  
HEALTH  
SUMMIT

SCIENCE · INNOVATION · POLICIES

WORLD HEALTH SUMMIT  
BERLIN, GERMANY  
OCTOBER 09-11, 2016

---

FEDERAL FOREIGN OFFICE | BERLIN

SUMMIT VENUE

VENUE  
Federal Foreign Office  
Werderscher Markt 1  
10117 Berlin  
ENTRANCE  
Unterwasserstraße 10



---

---

WORLD HEALTH SUMMIT  
BERLIN, GERMANY  
OCTOBER 09-11, 2016

SUNDAY | OCTOBER 09, 2016

	PLENARY HALL WELTSAAAL	ROOM 1 EUROPASAAL	ROOM 2 BRANDT	ROOM 3 ADENAUER	ROOM 4 STRESEMANN	ROOM 5 RATHENAU
08:45–10:15		PD 00   Page 42 <b>Governance for Health</b> Transparency International				WS 00   Page 44 <b>Chronic Kidney Disease in Sri Lanka</b> Government of Sri Lanka German Federal Foreign Office
10:30–12:00		PD 01   Page 46 <b>Noncommunicable Diseases</b> M8 Alliance: Charité	WS 01   Page 48 <b>Medical Education</b> M8 Alliance: Charité   Monash University   National University of Singapore   University of Geneva   University of Montreal	WS 02   Page 50 <b>Ending the AIDS Epidemic as a Public Health Threat by 2030</b> German Healthcare Partnership UNAIDS	WS 03   Page 52 <b>Delivering Mobile Health in Remote Regions</b> Protestant Church of the Rheinland WWF Germany	WS 04   Page 54 <b>Neglected Tropical Diseases</b> German Network against Neglected Tropical Diseases M8 Alliance: University of São Paulo
Lunch Break (60 min)						
13:00–14:30		PD 02   Page 56 <b>Infectious Diseases</b> Sabin Vaccine Institute Sanofi	WS 05   Page 58 <b>Aging &amp; Primary Care</b> M8 Alliance: Coimbra Health   Kyoto University   National Taiwan University	WS 06   Page 60 <b>The Science of Addiction</b> M8 Alliance: Charité   Imperial College London   Monash University	WS 07   Page 62 <b>From Archeology and Genomes to Evolutionary Medicine</b> Humboldt Forum Berlin World Health Summit	WS 08   Page 64 <b>Conflict and Health</b> British Medical Journal Case Reports International Committee of the Red Cross International Institute for Strategic Studies
Coffee Break (30 min)						
15:00–16:30		PD 03   Page 66 <b>Global Health Security</b> Munich Security Conference Foundation National Academy of Medicine	Press Conference	WS 09   Page 68 <b>Access to Medicines and Intellectual Property Rights</b> World Health Organization	WS 10   Page 70 <b>Patient Safety</b> M8 Alliance: National University of Singapore VAMED AG	WS 11   Page 72 <b>Personalized Healthcare Vision in Oncology</b> F. Hoffmann-La Roche Ltd. M8 Alliance: Charité
17:00–18:30	KEY 01   Page 74 <b>Opening Ceremony</b> M8 Alliance German Federal Foreign Office German Federal Ministry of Health World Health Organization					
18:30–21:30	Welcome Reception					

MONDAY | OCTOBER 10, 2016

	PLENARY HALL WELTSAAAL	ROOM 1 EUROPASAAL	ROOM 2 BRANDT	ROOM 3 ADENAUER	ROOM 4 STRESEMANN	ROOM 5 RATHENAU
09:00 – 10:30		PD 04   Page 78 <b>Universal Health Coverage</b> German Healthcare Partnership <b>M3</b> Alliance: The Graduate Institute Geneva Rabin Martin	WS 12   Page 80 <b>Improving Processes for Access to Medicines</b> European Federation of Pharmaceutical Industries and Associations Sanofi	WS 13   Page 82 <b>Coalition for Epidemic Preparedness Innovations</b> Coalition for Epidemic Preparedness Innovations Government of Norway Department of Biotechnology, Government of India	WS 14   Page 84 <b>Tuberculosis and Migration</b> Koch-Metschnikow-Forum e.V. Friends of the Global Fund	WS 15   Page 86 <b>Migration, Cultures and Health</b> All European Academies World Health Summit
	Coffee Break (30 min)					
11:00 – 12:30	KEY 02   Page 88 <b>Migration and Refugee Health</b> International Committee of the Red Cross International Organization for Migration <b>M3</b> Alliance: Johns Hopkins Bloomberg School of Public Health					
	Lunch Break (90 min) WHS Startup Track Pitch Competition (Europa-Foyer/Main Hall)					
14:00 – 15:30		PD 05   Page 90 <b>Planetary Health</b> Leopoldina <b>M3</b> Alliance: London School of Hygiene & Tropical Medicine	WS 16   Page 92 <b>Global Mental Health</b> Max Planck Institute for Psychiatry University Hospital Tübingen	WS 17   Page 94 <b>One Health</b> <b>M3</b> Alliance: InterAcademy Partnership for Health One Health Platform	WS 18   Page 96 <b>Fostering Open Science in Global Health</b> Centre Virchow-Villermé for Public Health	WS 19   Page 98 <b>Next Generation Medical Logistics</b> KfW Development Bank
	Coffee Break (30 min)					
16:00 – 18:00	KEY 03   Page 100 <b>Technological Innovation for Health</b> <b>M3</b> Alliance: Clinical Research Institute Montreal Royal Philips NV	PD 05a   Page 102 <b>The Contribution of Biologic Medicines to Public Health</b> F. Hoffmann-La Roche Ltd. World Health Summit				
16:00 – 18:30						
19:00 – 23:00	WHS Night   Page 104 Allianz Forum, Pariser Platz 6, 10117 Berlin Allianz Deutschland AG <b>M3</b> Alliance					

TUESDAY | OCTOBER 11, 2016

	PLENARY HALL WELTSAAAL	ROOM 1 EUROPASAAL	ROOM 2 BRANDT	ROOM 3 ADENAUER	ROOM 4 STRESEMANN	ROOM 5 RATHENAU
09:00 – 10:30		PD 06   Page 108  Value in Healthcare The Boston Consulting Group World Economic Forum	WS 20   Page 110  Better Leadership: Improved Healthcare European School of Management and Technology InterAcademy Partnership for Health M8 Alliance Young Physician Leaders	WS 21   Page 112  Strengthening Health Systems for Education and Training Association of Research-Based Pharmaceutical Companies (vfa) Joint Conference Church and Development	WS 22   Page 114  Polio Eradication M8 Alliance: The Graduate Institute Geneva	WS 23   Page 116  Cardiovascular Diseases M8 Alliance: Charité
	Coffee Break (30 min)					
11:00 – 12:30	KEY 04   Page 118  Translational Research Berlin Institute of Health M8 Alliance: Monash University   National University of Singapore					
	Lunch Break (90 min)				12:45 – 13:45	WS 28   Page 120  Action:SDG – All for Health Equity World Health Organization
14:00 – 15:30	PD 07   Page 122  Antimicrobial Resistance German Federal Ministry of Health	WS 24   Page 124  Strategic Priorities in R&D for Global Health European Commission and the Horizon 2020 Scientific Panel for Health KU Leuven University	WS 25   Page 126  Data Warehouse Systems as a Basis for Precision Medicine German Centers for Health Research (DZG)	WS 26   Page 128  Gender Responsive Governance Women in Global Health USAID	WS 27   Page 130  Implementing the Health-Related SDGs M8 Alliance: The Graduate Institute Geneva Think Tank Initiative Canada	
	Coffee Break (30 min)					
16:00 – 18:00	KEY 05   Page 132  Women, Empowerment and Health: Equity and Agency M8 Alliance: Clinical Research Institute Montreal   The Graduate Institute Geneva   University Hospital Geneva   University of Geneva   University of Montreal					

---

## TABLE OF CONTENTS

---

Program Overview	4
Welcome Messages	8
WHS Participants & Key Facts	18
Central Topics 2016	19
WHS Vision, Mission, Goals	20
WHS Presidents	22
WHS Scientific Committee & Ambassadors	23
WHS Council	24
M8 Alliance	27
WHS Startup Track	34
New Voices in Global Health	36
WHS Night	38
WHS Community & Social Media	39
Summit Program, Sunday, October 09, 2016	41
Summit Program, Monday, October 10, 2016	77
Summit Program, Tuesday, October 11, 2016	107
Summit Venue	136
Accommodation	138
City of Berlin	140
Federal Foreign Office	142
General Information	146
Media Information	150
Contacts	151
Keynote Speakers and Chairs	152
Speaker Index with Pictures	163
Speaker List	176
Supporting Institutions	178
Summit Partners	180



Angela Merkel

The individual desire for health and wellbeing is something we all share. With this in mind, one of the aims of the 2030 Agenda for Sustainable Development is to encourage people across the globe to live lives that are as healthy as possible at every stage of their existence. We committed ourselves to this goal last year within the framework of the United Nations. Now we have to implement this ambitious objective. That involves fighting epidemics and poverty related diseases and also extends to improving prevention and treatment of complaints of modern civilisation such as diabetes and cardiovascular disorders.

Germany plays a very active role in global health policy. To bring about further progress, we must strengthen healthcare systems worldwide and reform the global healthcare structure. We sharpened the focus on both these issues during Germany's G7 Presidency. We intend to build on this when our country assumes the G20 Presidency at the end of this year.

Whether we are talking about institutional factors or other global health issues such as a joint approach to tackling antimicrobial resistance, we can only be effective in overcoming the challenges they present if scientists, policymakers and society work together side by side. This is why dialogue forums such as the World Health Summit are particularly important. As the patron of the Summit, I would like to welcome all participants to Berlin. This message comes with my hope that you will enjoy a fruitful exchange of new insights. I would like to thank you most sincerely for your remarkable commitment to advancing healthcare throughout the world.

A handwritten signature in black ink, which appears to read 'Angela Merkel'.

**Angela Merkel**  
Chancellor of the  
Federal Republic of Germany



Alle Menschen eint das individuelle Bedürfnis nach Gesundheit und Wohlbefinden. Folgerichtig beinhaltet die Agenda 2030 für nachhaltige Entwicklung das globale Ziel, ein möglichst gesundes Leben in jedem Alter zu fördern. Dazu haben wir uns im Rahmen der Vereinten Nationen im vergangenen Jahr verpflichtet. Nun gilt es, diesem ehrgeizigen Anspruch gerecht zu werden. Das fängt mit dem Kampf gegen Epidemien oder armutsassoziierte Krankheiten an und reicht bis hin zur besseren Vorbeugung und Behandlung von Zivilisationsleiden wie Diabetes und Herz-Kreislauf-Erkrankungen.

Deutschland bringt sich in die globale Gesundheitspolitik sehr engagiert ein. Weitere Fortschritte setzen sowohl eine weltweite Stärkung der jeweiligen Gesundheitssysteme als auch Reformen der globalen Gesundheitsarchitektur voraus. Beides haben wir bereits während der deutschen G7-Präsidentschaft stärker ins Blickfeld gerückt. Daran werden wir auch anknüpfen, wenn unser Land Ende dieses Jahres den G20-Vorsitz übernimmt.

Ob es um institutionelle oder andere globale Gesundheitsfragen wie etwa ein gemeinsames Vorgehen gegen Antibiotikaresistenzen geht: Den damit verbundenen Herausforderungen können wir nur im engen wissenschaftlichen, politischen und gesellschaftlichen Schulterschluss wirksam begegnen. Darin zeigt sich die besondere Bedeutung von Dialogforen wie dem World Health Summit. Alle, die daran teilnehmen, heiße ich als Schirmherrin in Berlin herzlichen willkommen. Diesen Gruß verbinde ich mit dem Wunsch eines ertragreichen Austauschs neuer Erkenntnisse. Für Ihr verdienstvolles Engagement um die Weiterentwicklung der Gesundheitsversorgung weltweit danke ich Ihnen von Herzen.

**Angela Merkel**

Bundeskanzlerin der  
Bundesrepublik Deutschland



François Hollande

The themes discussed during this eighth World Health Summit are both ambitious and strategic. They also reflect the deep changes we are seeing in the world. The terms of globality and universality are now, more than ever, associated with health: quality care for all, accessible to all; international preventive measures; renewed support for health as a driver of development, growth and stability; and an ambitious research policy, which is a source of progress. These are principles to which France is committed, and which it supports in international bodies. France thus obtained, during the last G7, that reflection will take place at international level on access to expensive medicines. This Summit is a forum for discussion and dialogue, bringing together men and women "of good will". That means it is a place of peace.

I wish you all excellent meetings.

A handwritten signature in black ink, which appears to be 'F. Hollande'.

**François Hollande**  
President of the French Republic

Les thèmes abordés lors de cette 8ème édition du Sommet Mondial de la Santé sont à la fois ambitieux et stratégiques. Ils sont aussi le reflet des profonds bouleversements que connaît le Monde. Plus que jamais les termes de globalité et d'universalité sont associés à la Santé: des soins de qualité pour tous, accessibles à tous; des mesures internationales de prévention; un soutien renouvelé à la santé, facteur de développement, de croissance et de stabilité; une politique ambitieuse de la recherche, source de progrès. Tels sont des principes auxquels la France est attachée et qu'elle soutient auprès des instances internationales. C'est ainsi que la France a obtenu, lors du dernier G7, qu'une réflexion s'engage au niveau international sur l'accès aux médicaments onéreux. Ce sommet est un lieu d'échange et de dialogue, réunissant des femmes et des hommes «de bonne volonté». Il est donc un lieu de paix.

Je vous souhaite à toutes et à tous d'excellentes rencontres.

**François Hollande**  
Président de la République

It is impossible to talk about health issues in the past year in Europe without reflecting on the refugee crisis, and the challenges and opportunities that it has presented for Europe. Over one million children, women and men arrived at our shores and borders last year.

The European Union had a common responsibility to ensure that these persons, many of them physically and mentally exhausted, were offered care and support, including through the provision of healthcare when required. Their journeys were punishing, and we cannot imagine the impossible choice they had to make between staying in their countries in extreme danger and the unenviable alternative of risking their lives at the hands of people smugglers. Europe's number one task was to offer these people a humane reception in Europe, which the Commission helped to achieve by the setting up of hotspots in Greece and Italy, and through financial and practical assistance to our Member States under our emergency asylum funding and through the EU's Civil Protection Mechanism.

Our next priority is to ensure the effective integration of those that are granted international protection. For some that will mean receiving access to our health services. At the same time, the people who arrive in Europe must be given the

opportunity to pay their way, through access to the labour market. And there is an obvious counterbalance to the demands they make of our healthcare system with the contributions that they can make to it. I hear of many medical professionals coming to Europe seeking to rebuild their lives; doctors and nurses, pharmacists and researchers, carers and therapists. In the next year I hope to hear heart-warming stories of their integration into our national health services, care homes, research institutes and universities and the valuable contribution they are making.

And one reason to welcome these new arrivals is the reason I gave you in my message for last year's World Health Summit – Europe's population is getting older, which makes it increasingly difficult to provide for our healthcare needs. I know that you will again address the healthcare challenges of an aging population at this year's Summit. Setting strategic research priorities will be of fundamental importance, and I am pleased that the European Commission continues to make an important contribution through our Horizon 2020 funding program.

Another area where we are making an important contribution is eHealth. More and more people are taking steps to monitor their own health and lifestyles



Jean-Claude Juncker

through wearable devices and smart-phones. These form an excellent contribution to prevent and monitor diseases. Through the Connecting Europe Facility, we are contributing to building Europe's digital health infrastructure. So far, 20 of our Member States have applied for funding to connect their systems and exchange health data and patient information or to offer e-prescriptions and reduce the administrative burden on our care systems.

Let me conclude by mentioning the health-care industry, which is one of the major drivers of jobs, growth and innovation in Europe. We need a successful economy to sustain our European social model, and you are an intrinsic part of this with the

many thousands of jobs you create and sustain. The world is getting older, and the world is in need of health technology to sustain us as we go through a major demographic change. Europe must lead the way in looking after its own citizens, and it must generate a competitive advantage in the global market for health-care services and products.

I wish you a fruitful Summit, and another year of success.

A stylized, handwritten signature in black ink, consisting of a series of connected loops and a long horizontal stroke extending to the right.

**Jean-Claude Juncker**  
President of the European Commission







Antoine Flahault



Detlev Ganten

This year's meeting finds us face-to-face with a challenge of unprecedented scale: for the first time ever, more than 60 million people are fleeing war, terror and persecution. The effects have been profound. Europe, seen for decades as a model for cooperation and friendship, is diverging from its blueprint. Social norms and contracts are dissolving under the weight of mistrust and short-term interests. In many countries, health systems are struggling hard with the duty of providing care for those in need.

Experience shows that there is only one way to confront these paramount issues: we have to build up trust again and intensify international cooperation. Last year's G7 summit emphasized these issues and the German government ties its G20 Presidency at the end of 2016 to sharpening this focus and working on reforming the global healthcare structure, as Chancellor Angela Merkel expresses in her Welcome Message. This strong political will is being accompanied by

the internationally endorsed Sustainable Development Goals (SDG) and highly promising developments in translational research that cross the boundaries between science and medicine, as well as increasing accessibility of data and powerful new tools.

This spirit of cooperation permeated the WHS Geneva Meeting in April 2016, held on the occasion of the Geneva Health Forum's (GHF) sixth edition and 10 year anniversary. It emphasized the continuous commitment of the Swiss government and the GHF organizers to global health and peace, thus providing a sterling example of partnership and friendship and sounding a clear call for collaboration of all health-related sectors.

To continue this call, the World Health Summit 2016 will draw more international experts from academia, politics, the private sector, and civil society than ever before. Their deliberations will focus on topics including:

- Migration and Refugee Health:  
From Care to Policy
- Technological Innovation for Health:  
Improving Healthcare Delivery
- Women, Empowerment and Health:  
Equality and Agency
- Translational Research:  
Advancing Innovative Treatment
- Infectious Diseases:  
Lessons Learned from Ebola to Zika
- Sustainable Development Goals:  
Transforming the Health Agenda

Supported by the M8 Alliance of Academic Health Centers, Universities, and National Academies, this meeting will serve as an example of the way trust and cooperation can improve lives worldwide.

What better goal could we collectively contribute than the hope for longer, healthier lives that can be lived out in peace? Please join us as we work toward this goal.



**Antoine Flahault**

WHS President



**Detlev Ganten**

WHS President



Karl Max Einhäupl



Axel Radlach Pries

Since its foundation in 2009, the mission of the World Health Summit (WHS) has always been ambitious and unique: to translate cutting edge research and best practice patient care into an international agenda that will ultimately lead to improved worldwide health and a higher quality of life for all. As scientists and representatives of Berlin institutions working in precisely these areas of health, we could not agree more with this strategic goal. However, to ensure the success of this endeavor, strong national and international political support is essential. Already during its 2015 meeting, the G7 stressed the importance of global health. Chancellor Angela Merkel has subsequently confirmed that this approach will continue at the G20 level under her presidency. We applaud this determination and are delighted to observe that over the course of the last eight years, the WHS has become the ideal forum to develop topics that will shape this political agenda. Indeed, the WHS has been instrumental in bringing together experts in health-related sectors across the world who have now assumed an advisory role for political decision makers in times of crisis.


The Berlin Institute of Health (BIH) significantly enhances the cooperative health-care environment that reaches far beyond Berlin. The young institute (since 2013) brings together the excellent patient care of the Charité – Universitätsmedizin Berlin and the pioneering basic research of the Max Delbrück Center for Molecular Medicine in the Helmholtz Association. The BIH merges existing research units of the MDC and the Charité whilst augmenting the research space with world-class faculty and cutting-edge platforms. This has resulted in the creation of a unique ecosystem for excellent research and innovation which in turn facilitates the swift translation of research results into concrete benefits for our patients and the global population at large.

The World Health Summit has been instrumental in creating and maintaining the impact of this approach. It is built on the strong foundation of the M8 Alliance of Academic Health Centers, Universities and National Academies, a global network of leading academic institutions. Each year in October, the combined expertise of the WHS partners convenes in Berlin where WHS participants (experts



from the fields of academia, politics, the private sector, and civil society) are invited to tackle current and impending health issues. The WHS has thus become the foremost strategic forum for addressing questions relating to global health.

On behalf of the Berlin Institute of Health, the Charité – Universitätsmedizin Berlin and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association, we welcome you to this year's WHS, its sessions and its social events. To find sustainable answers to the challenges ahead we need reliable, resourceful, creative partners. This meeting provides the perfect platform to forge new alliances and nourish truly innovative healthcare solutions.



**Karl Max Einhäupl**  
Chief Executive Officer  
Charité – Universitätsmedizin Berlin



**Axel Radlach Pries**  
Dean  
Charité – Universitätsmedizin Berlin



**Erwin Böttinger**  
Chief Executive Officer  
Berlin Institute of Health (BIH)



**Martin Lohse**  
Chair of the Board and Scientific Director  
Max Delbrück Center for Molecular  
Medicine in the Helmholtz Association  
(MDC)



Erwin Böttinger



Martin Lohse

PARTICIPANTS AND KEY FACTS

Participants Profile

The World Health Summit brings together more than 1,500 decision makers and representatives of all health-related fields from more than 80 countries to address the most pressing issues that medicine and healthcare systems will face over the next decade and beyond.

KEY FACTS


**DATE:** October 09-11, 2016  
**VENUE:** German Federal Foreign Office  
Werderscher Markt 1, 10117 Berlin  
**Entrance:** Unterwasserstraße 10

The World Health Summit will be taking place at the Federal Foreign Office. Please be advised that due to security reasons, all delegates will be subject to a security check including a passport identification confirmation.

Please be aware: You will not be able to enter the Summit venue, if you are not able to present your passport or ID-card. Unfortunately, this procedure may produce a slight delay for entrance into the building. We therefore kindly ask you to refrain from bringing your luggage to the Summit venue, as this will slow down the security check process.

Who will attend the WHS 2016?

- Top-level researchers and members of the scientific community
- High-profile political decision-makers
- Executives and representatives from the healthcare system
- Leaders of the health-related industry and technology sector
- Representatives of civil society and foundations
- Students and young professionals from all health-related fields



---

**Migration and Refugee Health:  
From Care to Policy**

The current wave of migration – the biggest since the end of World War II – is putting issues of migrant health at the top of government agendas. Basic care is no longer enough. We now need new concepts for adapting health policy strategies that take into account transformative processes, both in migrant countries of origin and in the nations to which they emigrate.

**Technological Innovation for Health:  
Improving Healthcare Delivery**

Successful healthcare quality and delivery depends on effective medical devices – the tools for prevention, diagnosis, treatment and rehabilitation. Technological innovations in the field are helping reduce inefficiencies in healthcare delivery, while at the same time streamlining access, reducing costs, improving quality and making medicine more personalized and precise.

**Women, Empowerment and Health:  
Equality and Agency**

It's grown strikingly clear that empowering women is a crucial component in achieving sustainable health and development objectives. Attaining greater equality for girls when it comes to health, nutrition and education is the first step towards ensuring that women will later be able to realize their full potential as equal partners in development.

**Translational Research:  
Advancing Innovative Treatment**

Translational research is advancing innovation, making it even more attractive for further investment and development. A central aspect of this process is the effective translation of knowledge, mechanisms and techniques generated by advances in fundamental scientific research, turning them into novel approaches for prevention, diagnosis and treatment.

**Infectious Diseases:  
Lessons Learned from Ebola to Zika**

In the wake of the Ebola epidemic in Africa, the WHO has now declared another global public health emergency based on clustered conditions thought to be caused by the Zika virus. Several key lessons from the Ebola response can already be applied to this new threat. Chief among them is that public health teams must ensure that prevention/treatment methods are accepted by people at risk of contracting the disease. Broader societal concerns also have to be addressed more effectively.

**Sustainable Development Goals:  
Transforming the Health Agenda**

The Sustainable Development Goals (SDGs) address social, economic and environmental challenges that can only be solved through integrated approaches. All of these aspects also have an impact on health, so they are critical contributors to the changes that will have to occur in pursuing global well-being.

---

The World Health Summit (WHS) is the annual conference of the M8 Alliance of Academic Health Centers, Universities and National Academies. Through the InterAcademy Partnership (IAP) for Health, it is organized in collaboration with national academies of science in more than 67 countries.

**VISION**

---

The vision behind the World Health Summit is to improve health all over the planet, catalyzing that process through collaboration and open dialogue, and steering tomorrow’s agenda to improve research, education, healthcare, and policy outcomes.

**MISSION**

---

The WHS mission is to bring together researchers, physicians, key government officials, and representatives from industry – as well as from NGOs and healthcare systems all over the world – to address the most pressing issues facing every facet of healthcare and medicine in the upcoming decade and beyond.

**GOALS**

---

- To bring together all stakeholders at the level of equals
- To establish a unique and sustainable high-level forum and network
- To help define the future of medicine, research and healthcare
- To find answers to major health challenges – both today and tomorrow
- To make global recommendations and set health agendas worldwide







## PRESIDENTS



**ANTOINE FLAHAULT**

Director

Institute of Global Health,  
University of Geneva,  
Switzerland



**DETLEV GANTEN**

Honorary Chairman  
of the Board  
Charité Foundation,  
Germany



**HÉLÈNE BOISJOLY**  
Incoming International  
President

Dean

Faculty of Medicine,  
University of Montreal,  
Canada

## FORMER PRESIDENTS



2015

**SHUNICHI FUKUHARA**

Dean

School of Public Health,  
Kyoto University,  
Japan



2014

**JOSÉ OTÁVIO AULER JR.**

Dean

University of São Paulo  
Medical School,  
Brazil



2013

**JOHN EU LI WONG**

Chief Executive Officer

National University  
Health System,  
Singapore



2012

**MICHAEL J. KLAG**

Dean

Johns Hopkins Bloomberg  
School of Public Health,  
USA



2011

**STEVE WESSELINGH**

Dean

Monash University,  
Melbourne,  
Australia



2010

**STEVEN K. SMITH**

Pro Rector (Health)

Imperial College London,  
United Kingdom



2009

**AXEL KAHN**

President

Paris Descartes University,  
France

## WHS SCIENTIFIC COMMITTEE

The WHS Scientific Committee consists of the M8 Alliance Executive Committee (see page 29) and these members of the WHS Council:



**RIFAT ATUN**

Director, Global Health  
Systems Cluster  
Harvard T.H. Chan  
School of Public Health



**DAVID DE KRETZER**

Professor  
(Reproductive  
Endocrinology)  
Monash University



**BÄRBEL-MARIA KURTH**

Director, Epidemiology  
and Health Monitoring  
Robert Koch Institute  
(RKI)



**KLAUS LINDPAINTNER**

VP and Global Head  
Human Genetics and  
Computational Bio-  
medicine, Pfizer Inc.



**EDUARDO PISANI**

Executive Director  
International Federation  
of Pharmaceutical  
Manufacturers &  
Associations



**ERICH R. REINHARDT**

Chairman  
Medical Valley  
EMN e.V.



**HEINZ RIEDERER**

Managing Director  
iNG innovation.  
Nachhaltigkeit.  
Gesundheit



**GÜNTER STOCK**

President, ALLEA  
All European Academies



**MANFRED DIETEL**

Director, Institute  
of Pathology  
Charité – Universitäts-  
medizin Berlin



**ECKART VON  
HIRSCHHAUSEN**

Medical Doctor  
and Cabaret  
Germany



**RAINER SAUERBORN**

Director  
Institute of Public Health,  
Heidelberg University



**REINHARD SCHÄFERS**

(former) Ambassador  
Federal Republic  
of Germany



**CHARLES YANKAH**

Chairman of the Board  
Afrika Kulturinstitut  
e.V., Berlin



## COUNCIL

### ALA ALWAN

Regional Director,  
Eastern Mediterranean  
World Health Organization

### RIFAT ATUN

Director, Global Health  
Systems Cluster  
Harvard T.H. Chan School  
of Public Health

### GERD BINNIG

Director  
Definiens AG

### ZULFIQAR BHUTTA

Chair, Global Child Health  
University of Toronto

### ERWIN BÖTTINGER\*

Chief Executive Officer  
Berlin Institute of Health

### JAMES CHAU

Anchorman, CCTV News  
UNAIDS Goodwill Ambassador

### PIERRE CORVOL

Professor (Experimental Medicine)  
Collège de France

### THOMAS CUENI

Secretary General,  
Interpharma

### MANFRED DIETEL\*

Director, Institute of Pathology  
Charité – Universitätsmedizin Berlin

### GUDRUN DOLL-TEPPER

Vice-President Education  
German Olympic Sports  
Confederation

### GEORG DUDA\*

Director, Julius Wolff Institut  
Charité – Universitätsmedizin Berlin

### KLAUS DUGI

Corporate Sen. Vice-President  
Medicine  
Boehringer Ingelheim

### THOMAS ESCHENHAGEN

Director  
German Centers for  
Health Research (DZG)

### TIMOTHY G. EVANS

Director, Health Nutrition  
& Population  
The World Bank

### ARMIN FIDLER

President  
European Health  
Management Association

### TEDROS GHEBREYESUS

Minister of Foreign Affairs  
Federal Democratic Republic  
of Ethiopia

### JÖRG HACKER

President  
German Academy of Sciences  
Leopoldina

### ANDY HAINES

Professor (Public Health)  
London School of Hygiene  
& Tropical Medicine

### ZSUZSANNA JAKAB

Regional Director, Europe  
World Health Organization

### STEFAN KAUFMANN

Director  
Max Planck Institute for  
Infection Biology

### ILONA KICKBUSCH

Director, Global Health Program  
Graduate Institute Geneva

### DAVID DE KRETZER

Professor  
(Reproductive Endocrinology)  
Monash University

### BÄRBEL-MARIA KURTH\*

Director, Epidemiology and  
Health Monitoring  
Robert Koch Institut (RKI)

### KLAUS LINDPAINTNER

VP and Global Head  
Human Genetics and Computational  
Biomedicine, Pfizer Inc.

### PHILIPPE MEYER

Professor Emeritus  
French Academy of Sciences

### JOEL MENARD

Professor, Faculty of Medicine  
Paris Descartes



**JÜRGEN MLYNEK**  
Chairman of the Board of Trustees  
Falling Walls Foundation gGmbH

**TIKKI PANG**  
Visiting Professor for Public Policy  
National University of Singapore

**ANDREAS PENK**  
Head  
Pfizer Oncology Europe, Africa,  
and Middle East

**EDUARDO PISANI**  
Executive Director  
International Federation of Pharma-  
ceutical Manufacturers & Associations

**WOLFGANG PLISCHKE**  
Member of the Board of Management  
Evotec AG

**MARTINA POETSCHKE-LANGER**  
Director, Cancer Prevention  
German Cancer Research Center

**OLIVIER RAYNAUD**  
Independent Advisor

**ERICH R. REINHARDT**  
Chairman of the Board  
Medical Valley EMN e.V.

**HEINZ RIEDERER**  
Managing Director  
iNG innovation.Nachhaltigkeit.  
Gesundheit

**MATHIAS SCHELLER\***  
Chief Executive Officer  
Albertinen-Diakoniewerk

**HANS-J. SCHELLNHUBER**  
Director  
Potsdam Institute for Climate  
Change Research

**THOMAS SOMMER\***  
Deputy Scientific Director  
Max Delbrück Center for Molecular  
Medicine (MDC)

**GÜNTER STOCK**  
President,  
ALLEA All European Academies

**TIMO ULRICH**  
Head, Tuberculosis Division  
Koch-Metschnikow-Forum

**SUSANNE WEBER-MOSDORF**  
Former Assistant Director-General  
World Health Organization

**SONJA WEINREICH**  
Senior Health Advisor  
Bread for the World

**VERA ZYLKA-MENHORN**  
Senior Medical Editor  
Deutsches Ärzteblatt

\* = Berlin Chapter





## MISSION

The M8 Alliance's vision is to harness academic excellence to improve global health.

The M8 Alliance of Academic Health Centres, Universities and National Academies is a collaboration between academic institutions committed to improving global health. Working together with political and economic decision-makers, its primary goal is to develop science-based solutions to health challenges all over the world.

This international network is the outstanding academic foundation upon which the World Health Summit – the pre-eminent annual forum for healthcare dialogue – is built. It functions as a permanent platform for framing the future considerations of global medical developments and health challenges in an equitable fashion.

The M8 Alliance promotes both “bench-to-bed-side” translation of research and the transformation of current medical care approaches to treating the ill. It is seeking to accomplish this through the creation of a healthcare system focused on the effective prevention of diseases, as well as the adaptation of health-related solutions to rapidly changing living conditions through research in priority areas like shifting demographics, urbanization and climate.

## GOALS

The M8 Alliance is improving global health through pursuit of five strategic goals:

- Developing a worldwide network of academic health science centers, and bringing together universities and healthcare providers;
- Facilitating dialogue through the World Health Summit across a global network of stakeholders who are engaged with academic health science centers. These stakeholders include (among others) individuals and institutions active in government, industry and commerce, inter-governmental agencies, healthcare providers, academies of medicine and science, professional associations and the media;
- Setting an agenda for global health improvement by addressing issues of interest to academic health science centers, and conveying findings and recommendations based on scientific evidence through the generation of key statements;
- Positioning the M8 Alliance as an authoritative, credible and respected influence when it comes to decision-making in global health; and
- Creating a knowledge base amongst M8 Alliance members, which directly involves the promotion of mutual learning, research collaboration, the enrichment of educational capabilities and enhanced clinical outcomes.

M8Alliance  
Academic Health Centers, Universities and National Academies



---

**M8 ALLIANCE EXECUTIVE COMMITTEE**

---



**ANTOINE FLAHAULT**  
**Acting International President**

Director, Institute of Global Health, University of Geneva



**DETLEV GANTEN**  
**Founding President**

Honorary Chairman of the Board, Charité Foundation, Germany



**HÉLÈNE BOISJOLY**  
**Incoming International President**

Dean, Faculty of Medicine, University of Montreal, Canada



**SHUNICHI FUKUHARA**  
**Past International President**

Dean, School of Public Health, Kyoto University



**AXEL RADLACH PRIES**  
**Dean of Host Institution**

Charité – Universitätsmedizin Berlin



**MICHAEL J. KLAG**  
**Strategic Co-operation and Stakeholder Liaison**

Dean, Johns Hopkins Bloomberg School of Public Health, Baltimore



**BEN CANNY**  
**Governance and Fundraising**

Head, School of Medicine, University of Tasmania



**JOSÉ OTÁVIO AULER JR.**  
**Officer at large**

Dean, University of São Paulo Faculty of Medicine



## M8 ALLIANCE HEADS OF DELEGATION

### Australia

#### CHRISTINA MITCHELL

Dean, Monash University, Melbourne

### Brazil

#### JOSÉ OTÁVIO AULER JR.

Dean, University of São Paulo,  
Faculty of Medicine

#### EDUARDO KRIEGER

Former President,  
Brazilian Academy of Sciences

### Canada

#### HÉLÈNE BOISJOLY

Dean, Faculty of Medicine,  
University of Montreal

#### TARIK MÖRÖY

President, Clinical Research  
Institute Montreal (IRCM)

### China

#### XUETAO CAO

President, Chinese Academy  
of Medical Sciences &  
Peking Union Medical College

#### DEPEI LIU

Chinese Academy of Engineering

### France

#### FRÉDÉRIC DARDEL

President, Paris Descartes  
(Paris 5), Sorbonne Paris Cité

#### GÉRARD FRIEDLANDER

Dean, Faculty of Medicine, University  
of Paris Descartes

#### JEAN-YVES MÉRINDOL

President, Sorbonne Paris Cité

### Germany

#### KARL MAX EINHÄUPL

Chief Executive Officer,  
Charité – Universitätsmedizin Berlin

#### AXEL RADLACH PRIES

Dean, Charité –  
Universitätsmedizin Berlin

### Italy

#### LUCIANO SASO

Vice-Rector for European  
University Networks,  
Sapienza University

### Japan

#### SHUNICHI FUKUHARA

Dean, School of Public Health,  
Kyoto University

### Portugal

#### JOSÉ MARTINS NUNES

President, Executive Board,  
Coimbra Academic Clinical Center  
CHUC-UC – Coimbra Health

#### JOÃO GABRIEL SILVA

Rector, University of Coimbra

### Russian Federation

#### IVAN DEDOV

President, Russian Academy  
of Medical Sciences

#### EVGENY SIDORENKO

Vice-President, Russian Academy  
of Medical Sciences

### Singapore

#### JOHN EU LI WONG

Chief Executive Officer,  
National University Health System  
Senior Vice-President (Health Affairs),  
National University of Singapore

#### KHAY GUAN YEOH

Dean, Yong Loo Lin School of Medicine,  
National University of Singapore

---

**Switzerland**
**HENRI BOUNAMEAUX**

Dean, Faculty of Medicine,  
University of Geneva

**ANTOINE FLAHAULT**

Professor for Public Health,  
University of Geneva and Descartes,  
University Sorbonne Paris Cité

**ILONA KICKBUSCH**

Director, Global Health Programme,  
Graduate Institute of International  
and Development Studies, Geneva

**BERTRAND LEVRAT**

Chief Executive Officer,  
Geneva University Hospitals

**CLAUDINE MATHIEU-THIÉBAUD**

Director, National and International  
Affairs, the Geneva University  
Hospitals (HUG)

---

**Taiwan**
**CHANG-CHUAN CHAN**

Associate Dean,  
National Taiwan University (NTU)

---

**Uganda**
**NELSON K. SEWANKAMBO**

Principal, Makerere University

---

**United Kingdom**
**PETER PIOT**

Director, London School of Hygiene  
& Tropical Medicine

**ELIO RIBOLI**

Director, School of Public Health,  
Imperial College London

---

**USA**
**MICHAEL J. KLAG**

Dean, Johns Hopkins  
Bloomberg School of  
Public Health, Baltimore

---

**International**
**LAI-MENG LOOI**

Co-Chair, InterAcademy Partnership  
(IAP) for Health

**LEONEL VALDIVIA**

President, World Federation of  
Academic Institutions for Global  
Health (WFAIGH)

**STEVEN A. WARTMAN**

President & Chief Executive Officer,  
Association of Academic Health  
Centers (AAHC), USA

---

**Individual Members**
**RIFAT ATUN**

Director, Global Health Systems  
Cluster, Harvard T.H. Chan School  
of Public Health

**BEN CANNY**

Head, School of Medicine,  
University of Tasmania







## STARTUP TRACK 2016



WORLD  
HEALTH  
SUMMIT

### WHS STARTUP TRACK 2016



#### Held under the high patronage of:

##### **Hermann Gröhe**

Federal Minister of Health  
Germany

The WHS Startup Track highlights and showcases outstanding ideas and innovative business concepts that have the potential to revolutionize healthcare and improve

Global Health. Attending the WHS offers young entrepreneurs three days of access to world leaders in science, industry and politics. The event gives them the chance to exchange ideas with leading minds in the global healthcare sector and the Global Health community, set up future collaborations, and get to know potential mentors, investors and advisory board members.

80 applications from 22 countries were assessed by the jury to select the 25 shortlisted organizations, which were subsequently invited to the World Health Summit 2016.

Of these, 10 finalists will pitch their ideas in front of the audience and jury on Monday, October 10. The Winner of the WHS Startup Track 2016 will be awarded by German Federal Minister of Health Hermann Gröhe at the WHS Night (see page 38 for details).

#### **Pitch & Award**

Finalists will pitch their ideas on Monday, October 10, at 13:00 in the "Europasaal". The winner will be awarded by Minister of Health Hermann Gröhe at the "WHS Night" on the evening of the same day.

#### **Benefits**

The ten finalists will receive their certificates from German Federal Minister of Health Hermann Gröhe during the WHS Night on October 10.

The winner will be given special access to the WHS and M8 Alliance network and receive an exclusive coaching from FLYING HEALTH. The best international startup will be invited for the Berlin Partner "Start Alliance Program Berlin 2017".

The "WHS Startup Track" offers participants the chance to display their business ideas and to network with the world's leading minds in the healthcare sector. They will establish strategic partnerships to improve their visibility and credibility with potential investors, industry, political decision makers, doctors, and patients.

Further information on the WHS Startup Track, the shortlisted companies and the finalists is available at:

[www.worldhealthsummit.org/the-summit/startup-track.html](http://www.worldhealthsummit.org/the-summit/startup-track.html)



## THE 10 FINALISTS

**Care Across** | Greece  
Business Area: Cancer  
[www.careacross.com](http://www.careacross.com)



**midge medical UG** | Germany  
Business Area:  
Pain free, safe and easy blood extraction  
[www.midgemedical.com](http://www.midgemedical.com)



**Cold Plasmatech** | Germany  
Business Area: Medical Devices/  
Plasma Wound Therapy  
[www.coldplasmatech.de](http://www.coldplasmatech.de)



**OneWorldDoctors** | Germany   
Business Area:  
Médecins Sans Frontières (MSF) from home  
<https://oneworlddoctors.org>

**evivecare** | Germany  
Business Area: Digital Health  
[www.evivecare.com](http://www.evivecare.com)



**Pelvifly** | Poland  
Business Area: Telemedicine,  
E-Health  
[www.pelvifly.com](http://www.pelvifly.com)



**Glasschair** | Germany  
Business Area:  
Smart Medical Technology  
[www.glasschair.de](http://www.glasschair.de)



**Symptoma** | Austria  
Business Area:  
Diagnostic Decision Support System  
[www.symptoma.com](http://www.symptoma.com)



**iFeel Healthy** | Israel  
Business Area:  
Respiratory Digital Therapy  
[www.ifeellabs.com](http://www.ifeellabs.com)



**WinSenga** | Uganda  
Business Area:  
mHealth/Prenatal Care  
[www.winsenga.org](http://www.winsenga.org)



## THE JURY

**Kai Uwe Bindseil**  
(Berlin Partner for Business and Technology GmbH)  
**Andreas Gebhard**  
(re:publica GmbH)  
**Jutta Klauer**  
(Pfizer Deutschland GmbH)  
**Karin Knufmann-Happe**  
(German Federal Ministry of Health)

**Jörn Krupa**  
(Helmholtz Association)  
**Shari Langemak**  
(Medscape Germany)  
**Markus Müschenich**  
(Bundesverband Internetmedizin – BiM)  
**Klaus Stöckemann**  
(Peppermint VenturePartners GmbH)

---

**NEW VOICES IN GLOBAL HEALTH - POSTER EXHIBITION**

---

**OCTOBER 09-11, 2016**  
**09:00 - 17:30**

The New Voices in Global Health (NVGH) initiative promotes the active participation of young scientists in the World Health Summit. It is supported by the M8 Alliance of Academic Health Centers, Universities and National Academies. The NVGH is aimed at empowering research, policy and advocacy initiatives among future leaders in global health, who are invited to send in abstracts of their scientific work and ideas.

The M8 Alliance Executive Committee (see page 29) identified the best applications based on international academic standards. The selected candidates will be able to display their work in a special poster exhibition, thus playing an active role in the World Health Summit.

The selected “New Voices” are:

**Skyler Jayden Dembe**

[Green World I Uganda](#)

The Influence of Male Circumcision on the Threat of HIV Infection in Uganda

**Christian Akem Dimala**

[London School of Hygiene and Tropical Medicine I UK](#)

The Association between Highly Active Antiretroviraltherapy (HAART), Hypertension and Diabetes Risk

**Andrea Gelemanovic**

[University of Split I Croatia](#)

Can Existing Knowledge Help Us Prepare in Case of an Epidemic Crisis? Emergency Exercise on Zika Virus

**Sandra Goldlust**

[Princeton University I USA](#)

Malaria Control in the Greater Mekong Subregion: Immune Dynamics and Artemisinin Resistance

**Kirstin Grosse Frie**

[Martin-Luther University Halle \(Saale\) | Germany](#)

Tackling Late-Stage Diagnosis and Treatment of Breast Cancer in Africa – a Case Study from Mali, Western Africa

**Mohammad Mainul Islam**

[University of Dhaka | Bangladesh](#)

Effects of Remittances on Health Expenditure and Types of Treatment of International Migrants' Households in Bangladesh

**Roxanne Keynejad**

[King's College London | UK](#)

Building the Capacity of Policy-Makers and Planners to Strengthen Mental Health Systems in Low- and Middle-Income Countries: A Systematic Review

**Jessica Snyder**

[Massachusetts Institute of Technology | USA](#)

Health Census Method using a Wastewater-derived Microbiome

**Masresha Soressa**

[Southern Nations Nationalities and Peoples Region | Ethiopia](#)

Integrating Youth-Friendly Sexual and Reproductive Health Services (YFS) in Public Health Facilities: Achievements/Successes, Challenges and Lessons Learned in Southern Region, Ethiopia

**Lukas Winter**

[Max Delbrück Center for Molecular Medicine | Germany](#)

Open Source Imaging Initiative (OSI<sup>2</sup>): Bringing Affordable Magnetic Resonance Imaging (MRI) to the World

---

## WHS NIGHT 2016

---

DATE: October 10  
OPENING: 6:30pm  
BEGINNING: 7pm  
LOCATION: Allianz Forum,  
Pariser Platz 6, 10117 Berlin



After two days of intense work with fellow World Health Summit participants from all over the world, take an evening to relax at the WHS Night – at a venue right next to the Brandenburg Gate.

The highlight of this event will be the WHS Startup Track Award Ceremony, when German Federal Minister of Health Hermann Gröhe will announce the competition's finalists and winner.

Afterwards, snacks and drinks will be served, and a DJ will be on hand to provide musical

entertainment for those who want to dance. A shuttle service from the WHS venue will be available.

Please note that you must register separately ([www.registration-whs.com](http://www.registration-whs.com)) to attend the WHS Night. There is a €39 entrance fee.

---

## WHS COMMUNITY

The World Health Summit provides an ideal framework for networking with like-minded experts from all over the world. The WHS Community has been designed to ease the way for participants to get in touch prior to, during, and after the Summit.

This networking tool offers contact details, CV, pictures, and presentations of many speakers and attendants. Reserve your admission to this exclusive part of the WHS and optimize your WHS experience:

- Enhance your networking opportunities prior to the Summit
- Gain access to profiles of other registered participants
- Promote your presence by publishing your personalized profile
- Register for following WHS easily via your World Health Summits Community profile

Simply click on the “Community” button at the top-right corner of our homepage’s navigation bar and log in or sign up.

[www.worldhealthsummit.org/community](http://www.worldhealthsummit.org/community)

---

## SOCIAL MEDIA

The vision of the World Health Summit is improved health worldwide – catalyzed through collaboration and open dialogue. This dialogue already starts before the meeting and does not end when participants leave Berlin after three days of intense and fruitful discussions.

Stay in touch with fellow participants and the World Health Summit team via our social media outlets and be informed 365 days a year. We are looking forward to exchanging opinions and insights before, during, and after the World Health Summit via:

[www.facebook.com/worldhealthsummit](https://www.facebook.com/worldhealthsummit)  
[www.twitter.com/WorldHealthSmt](https://www.twitter.com/WorldHealthSmt)  
[www.linkedin.com/company/whs-foundation-gmbh](https://www.linkedin.com/company/whs-foundation-gmbh)

This year’s Twitter handle is:  
[#WHS2016](https://twitter.com/WorldHealthSmt)

To access the complimentary Wi-Fi within the venue, please use:  
[W-LAN: WorldHealthSummit](#)  
Password: [#WHS2016](#)





---

SUMMIT PROGRAM

---

**SUNDAY, OCTOBER 09**

**PD00**

ROOM 1 | EUROPASAAL

08:45 – 10:15

OVERFLOW SCREEN 1



## PANEL DISCUSSION

**GOVERNANCE FOR HEALTH**

TACKLING CORRUPTION IN THE HEALTHCARE SECTOR

## HOST

**Transparency International**

## CHAIR

**Cobus de Swardt**Transparency International |  
Managing Director | Germany

## SPEAKERS

**Agnès Couffinhall****Tackling Integrity Violations in Health:  
Experience from OECD Countries**Organisation for Economic Cooperation  
and Development (OECD) | Senior  
Economist, Health Division | France**Andrew Daniels****The Corruption Challenge,  
a View for Industry**GlaxoSmithKline Pharmaceuticals Europe |  
Director, Global Integrity Enhancement |  
United Kingdom**Suzanne Hill****Good Governance for Medicines  
and Access 2030**World Health Organization (WHO) |  
Director, Essential Medicines and Health  
Products | Switzerland**Tewodros Melesse****Social Accountability:  
Core to Achieving Sexual and  
Reproductive Health and Rights**The International Planned Parenthood  
Federation (IPPF) | Director-General |  
United Kingdom

Corruption is defined as the abuse of entrusted power for private gain. Its presence in society causes public funds to be wasted and trust in government to be lost.

In the healthcare sector corruption can take many forms and actors in the sector experience it in different ways. However, regardless of the type, corruption in the healthcare sector has a direct impact on its victims. From falsified medicines

entering the supply chain to doctors demanding bribes from patients, the various types of corruption in the healthcare sectors puts lives at risk.

The session will begin by hearing the experiences of the panelists in dealing with corruption and anti-corruption in the health sector. The Chair will then take questions for the panel from the audience with an emphasis on this being an interactive session.



Agnès  
Couffinhall



Suzanne  
Hill



Andrew  
Daniels



Tewodros  
Melesse



Cobus  
de Swardt

**WS00**

ROOM 5 | RATHENAU  
08:45 – 10:15  
OVERFLOW SCREEN 5



Federal Foreign Office

---

## WORKSHOP

---

# CHRONIC KIDNEY DISEASE IN SRI LANKA

A PUBLIC HEALTH CRISIS OF UNKNOWN AETIOLOGY

---

## HOSTS

**Government of Sri Lanka**

**German Federal Foreign Office**

## CHAIR

**Asela Iddawela**

Government of the Democratic Socialist Republic of Sri Lanka | Project Director, Presidential Task Force on Prevention of Chronic Kidney Disease | Sri Lanka

## SPEAKERS

**Kai-Uwe Eckardt**

**CKD of Unknown Origin –  
A Global Phenomenon?**

University Hospital Erlangen | Director, Nephrology and Hypertension | Germany

**Sachie Panawela**

**Recommendations of the WHO Expert Consultation Conference Held in Colombo in April 2016**

The Coordinating Secretariat for Science, Technology and Innovation (COSTI) | Minister of Science Technology and Research | Sri Lanka

**Asanga Ranasinghe**

**Introduction/ Present Status of CKDu in Sri Lanka**

Anuradhapura General Hospital | Director, Renal Disease Prevention Unit | Sri Lanka

There is a mystery kidney disease that for years has been killing thousands of farmers in Sri Lanka's rice basket – and as it spreads, locals are becoming increasingly fearful. In 20 years the disease has killed up to 20,000 people and sickened up to 400,000 more; some villages report it causes as many as 10 deaths a month.

As the disease progresses and kidneys fail, sufferers become unable to pass liquids on their own and are prohibited from drinking more than just a bottle of water a day – their extremities retain water and become fat with fluid. Its cause is not yet known, though there are long-held suspicions that agrochemicals are to blame, and Sri Lanka is lacking in the dialysis required to effectively treat the many sufferers.

Though no cases have been reported outside of the North Central province's dry zone, where farming was transformed in the 1960's and 70's following the introduction of modern techniques, the disease has slowly spread from two districts to seven. A report published by the World Health Organisation two years ago could not find a clear cause for the disease, though it pointed to cadmium, pesticides and other factors, such as arsenic, as possibilities.

This Workshop will bring together experts in order to discuss the growing problem and figure out possible avenues for finding solutions.



Kai-Uwe  
Eckardt



Sachie  
Panawela



Asela  
Iddawela



Asanga  
Ranasinghe

**PD01**

ROOM 1 | EUROPASAAL  
10:30 - 12:00  
OVERFLOW SCREEN 1

**PANEL DISCUSSION****NONCOMMUNICABLE DISEASES**

ACCESSIBILITY AND AFFORDABILITY OF CARDIOVASCULAR SERVICES

**HOSTS**

M8 Alliance:  
**Charité – Universitätsmedizin Berlin**

**CHAIRS**

**Volkmar Falk**  
German Heart Institute Berlin (DHZB) |  
Medical Director | Germany

**Charles Yankah**  
African Cultural Institute (ACI) |  
President | Germany

**SPEAKERS**

**Fiona Adshead**  
**The Role of Workplaces in NCDs**  
BUPA | Chief Officer, Wellbeing and  
Public Health | United Kingdom

**Ann Aerts**  
**Cardiovascular Diseases in Low-Income  
Settings Demand Innovation in Health-  
care Delivery more than Delivering  
Innovations in Healthcare**  
Novartis Foundation | Director |  
Switzerland

**Oleg Chestnov**

**Access to NCD Management:  
An Essential Element of the WHO  
Global NCD Action Plan**

World Health Organization (WHO) |  
Assistant Director-General, Noncommu-  
nicable Diseases and Mental Health |  
Switzerland

**Jayasree Iyer**

**Engaging the Pharmaceutical Industry  
to Improve Access to NCD Medicine**

Access to Medicine Foundation |  
Executive Director | Netherlands

**Francis E. Smit**

**Accessibility and Affordability  
of Cardiac Services in Africa**

University of the Free State (UOFS) |  
Head, Cardiothoracic Surgery |  
South Africa

All age groups and all regions are affected by NCDs. NCDs are often associated with older age groups, but evidence shows that 16 million of all deaths attributed to noncommunicable diseases (NCDs) occur before the age of 70. Of these “premature” deaths, 82% occurred in low- and middle-income countries. Children, adults and the elderly are all vulnerable to the risk factors that contribute to noncommunicable diseases, whether from unhealthy diets, physical inactivity, exposure to tobacco smoke or the effects of the harmful use of alcohol.

These diseases are driven by forces that include ageing, rapid unplanned urbanization, and the globalization of unhealthy

lifestyles. NCDs threaten progress towards the UN Millennium Development Goals and post-2015 development agenda. Poverty is closely linked with NCDs. The rapid rise in NCDs is predicted to impede poverty reduction initiatives in low-income countries, particularly by increasing household costs associated with health care.

Cardiovascular diseases and accessibility and affordability to cardiovascular services have become a global concern. Due to prohibitively high costs and limited access to medical and surgical services, easily treatable cardiovascular conditions often develop to become chronic and deadly diseases.



Fiona  
Adshead

Jayasree  
Iyer



Ann  
Aerts

Francis E.  
Smit



Oleg  
Chestnov

Charles  
Yankah



Volkmar  
Falk

**WS01**

ROOM 2 | BRANDT  
10:30 - 12:00  
OVERFLOW SCREEN 2

**WORKSHOP****MEDICAL EDUCATION**

GLOBAL HEALTH CURRICULUM – STUDENT-LED INITIATIVES

**HOSTS**

M8 Alliance:  
**Charité – Universitätsmedizin Berlin**

M8 Alliance:  
**Monash University**

M8 Alliance:  
**National University of Singapore (NUS)**

M8 Alliance:  
**University of Geneva**

M8 Alliance:  
**University of Montreal**

**CHAIRS**

**Ben Canny**  
University of Tasmania | Head, School  
of Medicine | Tasmania

**Axel Radlach Pries**  
Charité – Universitätsmedizin Berlin |  
Dean | Germany

**SPEAKERS**

**Keith Lim**  
**Developments in the M8 Global Health  
Curriculum**

National University of Singapore (NUS) |  
Assistant Dean (Education), Yong Loo Lin  
School of Medicine | Singapore

**Rafael Ruiz de Castaneda**  
**Development of MOOCs to Inform  
Global Health Curricula**

University of Geneva | Researcher and  
Lecturer, Institute of Global Health |  
Switzerland

**Amirhossein Takian**  
**Development of a Global Health  
Curriculum in an Emerging Nation**  
Tehran University of Medical Sciences |  
Chair and Professor, Global Health and  
Public Policy | Iran



## DISCUSSANTS

### Paul Freund

Charité – Universitätsmedizin Berlin |  
Student | Germany

### Maxime Leroux-La Pierre

University of Montreal | Student | Canada

### Shi Hui Ng

National University of Singapore (NUS) |  
Student | Singapore

### Neal Smith

Monash University | Student | Australia

### Sean Tsi

National University of Singapore (NUS) |  
Student | Singapore

There is a growing recognition that the modern health care professional, irrespective of their background and practice intentions, need to have specified competence in Global Health.

This session will outline what learning we can obtain by looking at the achievements of our students in developing their own Global Health Curricula. In addition, updates and perspectives in the development of methods for the delivery of Global Health Curricula will be discussed.



Ben  
Canny



Rafael  
Ruiz de Castaneda



Keith  
Lim



Amirhossein  
Takia



Axel  
Radlach Pries

**WS02**

ROOM 3 | ADENAUER  
10:30 - 12:00  
OVERFLOW SCREEN 3

**WORKSHOP**

## ENDING THE AIDS EPIDEMIC AS A PUBLIC HEALTH THREAT BY 2030

**HOSTS**

**German Healthcare Partnership (GHP)**

**UNAIDS**

**CHAIRS**

**Roland Göhde**

German Healthcare Partnership (GHP) |  
Chairman of the Board | Germany

**Luiz Loures**

UNAIDS | Deputy Executive Director |  
Switzerland

**SPEAKERS**

**Raymonde Goudou Coffie**

Ministry of Health and Public Hygiene |  
Minister of Health and Public Hygiene |  
Ivory Coast

**Ricardo Augustus Guerreiro Baptista Leite**

Catholic University Portugal |  
Head Public Health, Institute of Health  
Sciences | Portugal

**Bernard S. Haufiku**

Ministry of Health and Social Services |  
Minister of Health and Social Services |  
Namibia

**Cleopa Mailu**

Ministry of Health | Cabinet Secretary |  
Kenya

**Elisabeth Pott**

German AIDS Foundation | Chairman  
of the Board | Germany

**DISCUSSANT**

**Till Bärnighausen**

Harvard T.H. Chan School of Public Health |  
Associate Professor, Global Health and  
Population | United States of America

United Nations Member States have declared their political support for the Sustainable Development Goal of ending the AIDS epidemic by 2030. This is based on a Fast-Track approach to meeting ambitious targets by 2020 for HIV prevention, testing, treatment and care and support – and eliminating discrimination. In addition to political leadership, this session will identify other essential factors necessary to meet these targets and review the latest results in HIV diagnostics and treatment, investment and social engagement.

A broad spectrum of private sector, community, scientific and political representatives will draw on their experiences and discuss progress and obstacles in achieving the end of AIDS. How should countries, cities and communities prioritize? What policy frameworks are needed? What innovative and alternative investment sources can be developed and utilized? How can health systems be strengthened to end AIDS and meet other SDGs without leaving behind the people in greatest need?

This Workshop will explore:

- The new targets for ending the AIDS epidemic, arising from the 2016 UN General Assembly Political Declaration on HIV and AIDS.
- The implications of the FastTrack AIDS response, including prevention tools, diagnostics, treatment and care and support services and eliminating discrimination.
- Research results from prevention and treatment trials.
- Latest research on HIV prevention, testing and treatment services, including in West Africa.



Roland  
Göhde

Luiz  
Loures



Raymonde  
Goudou Coffie

Cleopa  
Mailu



Ricardo Augustus  
Guerreiro Baptista  
Leite

Elisabeth  
Pott



Berhard S.  
Haufiku

## WS03

ROOM 4 | STRESEMANN

10:30 - 12:00

OVERFLOW SCREEN 4



### WORKSHOP

## DELIVERING MOBILE HEALTH IN REMOTE REGIONS

INSIGHT INTO INTEGRATED CONSERVATION AND DEVELOPMENT STRATEGIES

### HOSTS

**Protestant Church of the Rheinland  
(EKIR)**

**WWF Germany**

### CHAIR

**Yoursen Bosolo**

Bolenge Hospital | Coordinator, Medical  
Service | Congo

### SPEAKERS

**Yoursen Bosolo**

**A Boat as the Only Health Service  
Access for 70 Villages in the  
Congo Backwaters in the Ngiri  
Conservation Area**

Bolenge Hospital | Coordinator, Medical  
Service | Congo

**Eva Greitemann**

**Access to Medicines: Delivering Medical  
Aid to Remote Regions**

action medeor e. V. | Coordinator, Export,  
Supplies and Partner Development |  
Germany

**Johannes Kirchgatter**

**Why Does a Conservation Organization  
Work on Health Service?**

WWF Germany | Officer, Africa Projects |  
Germany

**Dorothea Philipps**

**Successful Civil Society Cooperation to  
Build Health Support in Weak States**

Protestant Church Dortmund |  
Former Pastor, Partnership Bolenge |  
Germany

Why would a conservation organization focus on health service in remote regions of the world? Because it would be absurd to discuss sustainability and protection of natural resources when people are dying from easily treatable diseases as a result of the next doctor being 300km away.

In order to address this evident prioritization, the WWF seeks cooperation with strong partners to develop integrated strategies for health service access and sustainable development alongside WWF's priority areas.

In this panel, we will discuss with these partners how such strategies can work practically, what we can learn from existing projects, how civil society actors can build strong cooperation in areas where the state is more or less absent and what support is needed from donors and international organizations.

Representatives from field projects, long-term supporters, project developers and global medical supply specialists will give an insight view and discuss the model character of such projects for the least developed areas of the world.



Yoursen  
Bosolo

Johannes  
Kirchgatter



Eva  
Greitemann

Dorothea  
Philipps

**WS04**

ROOM 5 | RATHENAU  
10:30 - 12:00  
OVERFLOW SCREEN 5

**WORKSHOP****NEGLECTED TROPICAL DISEASES**

FROM EMERGENCY TO SUSTAINABILITY

**HOSTS**

**German Network against Neglected Tropical Diseases (DNTDs)**

M8 Alliance:  
**University of São Paulo (USP)**

**CHAIRS**

**Eduardo Moacyr Krieger**

Faculty of Medicina of the University of São Paulo (FMUSP) | Executive Director, International Relations Committee | Brazil

**Carsten Köhler**

University Hospital Tübingen |  
Director Center of Competence,  
Institute for Tropical Medicine | Germany

**SPEAKERS**

**Ayola Akim Adegnika**

**Know How Transfer: From Germany to Gabon to the Local Population**

Centre de Recherches Medicales de Lambarene | Co-Director, Infectious Diseases | Gabon

**John Amuasi**

**Fighting NTDs to Achieve the SDGs – A Glance At From the African Perspective**

African Research Network for Neglected Tropical Diseases (ARNTD) | Executive Director | Ghana

**Klaus Brill**

**What Strategies do we Need to Successfully Combat NTDs and Achieve the SDG Goals in Partnership with the WHO**

Bayer AG | Vice-President, Corporate Commercial Relations | Germany

**Dirk Engels**

**What is the Main Focus of WHO to Achieve the 2030 Agenda?**

World Health Organization (WHO) | Director, Control of Neglected Tropical Diseases | Switzerland

**Eva-Maria Schwienhorst-Stich**

**What are the Challenges in Implementing Interventions Against NTDs?**

DAHW German Leprosy and Tuberculosis Relief Association | Medical Councillor, Medical and Social Relief Programs | Germany

## DISCUSSANTS

### Ren Minghui

World Health Organization (WHO) |  
Assistant Director-General, HIV/AIDS,  
Tuberculosis, Malaria and Neglected  
Tropical Diseases | Switzerland

### Daria Mochly-Rosen

Stanford University School of Medicine |  
Founder and Co-Director, SPARK Trans-  
lational Research Program | United  
States of America

More than 1.4 billion people around the world are infected with at least one NTD, but because of their low mortality rate and because mainly poor and marginalized people are affected, these diseases don't get much attention on the global stage.

But it seems that slowly it is recognized that controlling and eliminating NTDs is critical to ending extreme poverty. NTDs are seen as "indicator diseases" for underdevelopment because their occurrence is a sign of population groups and regions that have been particularly "neglected". Thus the NTDs are included in the SDGs. But what has to be undertaken to fight NTDs successfully?



Ayola Akim  
Adegnika



Eduardo Moacyr  
Krieger



John  
Amuasi



Carsten  
Köhler



Klaus  
Brill



Ren  
Minghui



Dirk  
Engels



Eva-Maria  
Schwienhorst-Stich

## PD02

ROOM 1 | EUROPASAAL  
13:00 - 14:30  
OVERFLOW SCREEN 1



## PANEL DISCUSSION

## INFECTIOUS DISEASES

LESSONS LEARNED FROM EBOLA TO ZIKA

## HOSTS

Sabin Vaccine Institute

Sanofi

## CHAIR

**Peter J. Hotez**

Sabin Vaccine Institute | President |  
United States of America

## SPEAKERS

**Christian Bréchet**

**From Ebola to Zika: Areas of Action  
to Limit the Impact of Future Infectious  
Disease Outbreaks**

Institut Pasteur | President | France

**Stefan Kaufmann**

**New Culprits and Old Foes:  
How to Combat Both**

Max Planck Institute for Infection Biology |  
Director | Germany

**Hon. Suresh Kumar**

**Access, Innovation and Price are  
Prerequisites to Preempt Disease, and  
all Stakeholders Must Play their Parts  
to Make this Happen**

Sanofi | Head, Government Relations US  
ad interim | United States of America

**Joy Phumaphi**

**Accountability at Community Level**

African Leaders Malaria Alliance (ALMA) |  
Executive Secretary | Tanzania

**Rolf Zinkernagel**

**Why are Vaccines Efficient Against  
Acute Lethal but not Against Persistent  
Chronic Infections**

University Hospital Zurich | Professor  
Emeritus, Experimental Immunology |  
Switzerland



The World Health Organization has declared the Zika virus a global public health emergency. This designation gives the WHO and member states the ability to recommend limits on travel to prevent the potential spread of disease and to call for emergency measures and resources to combat an outbreak. The last time the WHO used this mechanism was during the recent Ebola crisis in West Africa.

The close involvement of the WHO, while there is still a lot of uncertainty about the disease, may tell us two things: that the WHO is seeking to learn from its failure to Ebola, after it was heavily criticized for its slow response; and that BRIC countries, such as Brazil, may be playing an increasingly important role in global health – their health priorities now have a global audience.

Good outbreak control relies on applying a package of interventions, namely case management, surveillance and contact tracing, a good laboratory service, safe burials, and social mobilization. Community engagement is key to successfully controlling outbreaks and to reduce human transmission.

One key lesson from the Ebola response can be applied to Zika – that the success of any intervention will depend on community acceptance. Public health teams must work with community organizations from the start to ensure that prevention and treatment methods are accepted by those who are at risk of the disease and that broader societal concerns are addressed.



Christian  
Bréchet



Hon. Suresh  
Kumar



Peter J.  
Hotez



Joy  
Phumaphi



Stefan  
Kaufmann



Rolf  
Zinkernagel

**WS05**

ROOM 2 | BRANDT

13:00 - 14:30

OVERFLOW SCREEN 2

**KYOTO UNIVERSITY**  
GRADUATE SCHOOL OF MEDICINE**國立臺灣大學**  
National Taiwan University**COIMBRAHEALTH**  
CLINICAL, ACADEMICAL CENTER OF COIMBRA, CHC/UC**M8Alliance**  
Academic Health Centers, Universities and National Academies**WORKSHOP****AGING & PRIMARY CARE**

HEALTHY AGING AND END OF LIFE ISSUES

**HOSTS**

M8 Alliance:

**Coimbra Health**

M8 Alliance:

**Kyoto University**

M8 Alliance:

**National Taiwan University****CHAIRS****Chang-Chuan Chan**National Taiwan University (NTU) |  
Associate Dean | Taiwan**Shunichi Fukuhara**Kyoto University | Dean, School  
of Public Health | Japan**SPEAKERS****Ana Abrunhosa****The importance of Ageing @Coimbrato  
the Center Region of Portugal**European Commission | President,  
Development Commission CCDRC |  
Portugal**Chang-Chuan Chan****Overview of the Action Initiative**National Taiwan University (NTU) |  
Associate Dean | Taiwan**Shunichi Fukuhara****Overview of the Action Initiative**Kyoto University | Dean, School  
of Public Health | Japan**Rei Goto****Longterm Care Policy in Japan**Keio University | Associate Professor |  
Japan**Sheng-Jean Huang****Comfort Care in the End of Life Project  
in Taipei City**Taipei City Hospital | Superintendent |  
Taiwan**Catarina Resende de Oliveira****Growing Old in Portugal -****A Translational Perspective on  
Coping with Cognitive Changes**Hospital and University Center Coimbra |  
Member, Executive Board | Portugal

The need to promote and maintain health will intensify with larger numbers of older adults seeking not just a long life but a healthy life as well. With a shift from a model of illness and cure to a model of wellness and care, the advanced practice nurse is the ideal health professional to implement a model of health care shaped by a philosophy of both primary and long-term care for the older population.

This model must include thoroughly integrated strategies for health promotion and disease prevention, interdisciplinary, comprehensive geriatric assessment, care management for integration and coordination of services, and an emphasis on function and quality of life as outcomes of treatment.



Ana  
Abrunhosa



Rei  
Goto



Chang-Chuan  
Chan



Sheng-Jean  
Huang



Shunichi  
Fukuhara



Catarina  
Resende de Oliveira

## WS06

ROOM 3 | ADENAUER  
13:00 – 14:30  
OVERFLOW SCREEN 3



---

**Imperial College  
London**



---

### WORKSHOP

## THE SCIENCE OF ADDICTION

DRUGS, BRAINS AND BEHAVIOR

---

### HOSTS

M8 Alliance:  
**Charité – Universitätsmedizin Berlin**

M8 Alliance:  
**Imperial College London**

M8 Alliance:  
**Monash University**

### CHAIR

**Antonio Verdejo-Garcia**  
Monash University | Associate Professor,  
School of Psychological Sciences |  
Australia

### SPEAKERS

**Adrian Carter**  
**Ethics and Policy**  
Monash University | Senior Research  
Fellow, School of Psychological Sciences |  
Australia

**Andreas Heinz**  
**Neurobiology and Treatment**  
Charité – Universitätsmedizin Berlin |  
Director, Clinic for Psychiatry and  
Psychotherapy | Germany

**Michael T. Lynskey**  
**Addiction and Adolescence**  
King's College London | Professor,  
National Addictions Centre |  
United Kingdom

**David Nutt**  
**Neuropsychopharmacology**  
Imperial College London | Director,  
Neuropsychopharmacology Unit |  
United Kingdom

### DISCUSSANT

**Karsten Lunze**  
Boston University | Assistant Professor,  
School of Medicine | United States of  
America

Substance use and behavioural addictive disorders are major health problems with high personal impact and societal costs. These addictive disorders involve changes in the brain of those affected. Individual differences in brain networks relevant to reward/punishment learning and executive functions predict vulnerability to addiction, and continued exposure to drugs and other powerful incentives weakens the function of these systems.

This workshop features a panel of experts on the neurobiological and neuropharmacological underpinnings of drugs and drug addiction, and social policy concerning addictive disorders, to discuss a range of issues such as new trends in diagnosis, treatment and recovery and the need to apply new thinking to how society can best deal with the growing problem of addiction.



Adrian  
Carter

David  
Nutt



Andreas  
Heinz

Antonio  
Verdejo-Garcia



Michael T.  
Lynskey

**WS07**

ROOM 4 | STRESEMANN

13:00 - 14:30

OVERFLOW SCREEN 4

WORLD  
HEALTH  
SUMMIT**WORKSHOP****FROM ARCHEOLOGY AND GENOMES  
TO EVOLUTIONARY MEDICINE****HOSTS****Humboldt Forum Berlin****World Health Summit****CHAIRS****Detlev Ganten**World Health Summit President  
Charité Foundation | Honorary Chairman  
of the Board | Germany**Hermann Parzinger**Prussian Cultural Heritage Foundation |  
President | Germany**SPEAKERS****Johannes Krause****Genomes in the Evolution of Homo  
Sapiens in Health and Disease**Max Planck Institute for the Science of  
Human History | Director | Germany**Albert Zink****Ötzi – An Example of Detailed Medical  
Analysis of Mummies**EURAC – Institute for Mummies and the  
Iceman | Scientific Director | Italy**DISCUSSANTS****Frank Rühli**University Zurich | Director, Institute of  
Evolutionary Medicine | Switzerland**Johannes Vogel**Museum für Naturkunde |  
Director-General | Germany**Christina Warinner**Laboratories of Molecular Anthropology  
and Microbiome Research (LMAMR) |  
Co-Director | United States of America

The application of genomics in archeology has allowed for unexpected insights into the anthropology, cultural history as well as health and diseases of homo sapiens. Genetic analysis on a population-basis also provides vital information about how homo sapiens migrated and settled, developing from hunter-gatherer societies to sedentary cultures. With the help of biological material from e.g. bones or stomach, it is possible to make statements about the nutritional habits of early humans and thus aid us in understanding their way of life. Dentures newly allow us to find the traces of pathogens such as plague or tuberculosis, which in the future should allow us to reconstruct the evolutionary history of diseases.

The progression in the scientific methods of archeology, genomics, genetics and molecular-biological analysis will allow for further questions to be answered in this area. The field is developing into a

new concept of darwinian evolutionary medicine. This revolutionary approach is driving important advances not only in the history of health and disease, but also in the evolutionary causes of susceptibility, risk factors, and in the long term, new approaches to preventive medicine. This will be based on an interdisciplinary holistic approach of health as a function of our evolutionary understanding of biology and the complex interactions of the individual with the environment determined by culture and lifestyle. The dissociation and gap of modern lifestyles and our old biology is leading to diseases of civilization.

The workshop serves the purpose of bringing together experts in archaeology, biology, genomics, medicine and global health, for a professional exchange to discuss the latest interdisciplinary findings and common ground between these diverse fields.



Detlev  
Ganten

Hermann  
Parzinger



Johannes  
Krause

Albert  
Zink

## WS08

ROOM 5 | RATHENAU  
13:00 – 14:30  
OVERFLOW SCREEN 5



ICRC



### WORKSHOP

## CONFLICT AND HEALTH

THE COSTS TO HEALTH AND HEALTH SERVICES IN CONFLICT ZONES

### HOSTS

**British Medical Journal (BMJ)**  
Case Reports

**International Committee  
of the Red Cross (ICRC)**

**International Institute for  
Strategic Studies (IISS)**

### CHAIRS

**Seema Biswas**  
BMJ Case Reports | Editor-in-Chief |  
United Kingdom

**Esperanza Martinez**  
International Committee of the  
Red Cross (ICRC) | Head, Health  
Assistance Division | Switzerland

### SPEAKERS

**Katri Bertram**  
**Children on the Move: How Conflict  
and the Refugee Crisis are Affecting the  
Health and Well-Being of Vulnerable  
Populations**  
Save the Children Deutschland e.V. |  
Head, Advocacy and Policy | Germany

**Virginia Comolli**  
**Patterns in Conflict Across the World**  
International Institute for Strategic  
Studies (IISS) | Senior Fellow, Security  
and Development | United Kingdom

**Anke Hoeffler**  
**What are the Costs of Conflict?**  
Oxford University | Research Officer,  
Centre for the Study of African Eco-  
nomies | United Kingdom

**Ahmad Tarakji**  
**The Challenges of Meeting Health Needs  
of Individuals in Conflict Zones**  
Syrian American Medical Society |  
President | United States of America



The increase in civil (intrastate) conflicts across the world has resulted in unprecedented numbers of people displaced from their homes, injured and unsupported as infrastructure around them is destroyed.

Meeting the health needs of these populations involves improvising health care in the face of the flight of health care personnel and the destruction of local health services, humanitarian assistance provided by local and international organisations, and the care of refugees in neighbouring countries.

Health needs include acute care of the injured, medication and follow up for chronic disease, the treatment and prevention of communicable diseases and vaccination, and the delivery of essential health services for women and children.



Katri  
Bertram



Anke  
Hoeffler



Seema  
Biswas



Esperanza  
Martinez



Virginia  
Comolli



Ahmad  
Tarakji

**PD03**

ROOM 1 | EUROPASAAL

15:00 - 16:30

OVERFLOW SCREEN 1

Munich Security  
Conference **msc**  
Münchner Sicherheitskonferenz

 NATIONAL ACADEMY OF MEDICINE  
Leadership • Innovation • Impact | for a healthier future

---

**PANEL DISCUSSION**

---

**GLOBAL HEALTH SECURITY**PREPAREDNESS AND RESPONSE

---

**HOSTS****Munich Security Conference Foundation (MSC)****National Academy of Medicine (NAM)****CHAIR****Ambassador Wolfgang Ischinger**

Munich Security Conference Foundation (MSC) | Chairman of the Board | Germany

**SPEAKERS****Sarbani Chakraborty**

Merck Group | Head of Global Health Policy, Government Affairs and Policy | Germany

**Tedros Adhanom Ghebreyesus**

Ministry of Foreign Affairs | Minister of Foreign Affairs | Ethiopia

**Victor J. Dzau**

National Academy of Medicine | President | United States of America

Global Health Security has become a priority for world leaders. The Ebola outbreak brought attention to the weaknesses in the systems of preparedness and response at the national, regional and global level. In response the UN, the WHO, the G7 and G20 as well as regional organizations such as the EU and the African Union have increased their resolve to address the global health security challenge at all levels of governance.

In order to deal with the gaps a number of significant steps have been taken: WHO has been reformed to have better emergency capacity, the Global Health Security Agenda has been strengthened and now works as a partnership of over 60 countries to implement the International Health Regulations and meet measurable targets.

A joint assessment tool has been developed with the WHO to enable external assessments of a country's capacity to prevent, detect and respond. The commitment to Universal Health coverage has been reaffirmed. Private stakeholders – be it the International Aviation Association or the pharmaceutical industry – have become active to define their role and the research community is galvanized to strengthen the commitment to new vaccines, diagnostics and treatments. Especially other sectors – like security, agriculture, travel and tourism – need to become a part of the global effort.

The challenge now is to create synergies between nation-states, international organizations and public & private stakeholders to accelerate progress toward a world that is safe from threats posed by infectious disease, and to promote global health security as an international security priority.



Sarbani  
Chakraborty



Tedros Adhanom  
Ghebreyesus



Victor J.  
Dzau



Wolfgang  
Ischinger

**WS09**

ROOM 3 | ADENAUER  
15:00 - 16:30  
OVERFLOW SCREEN 3

**WORKSHOP****ACCESS TO MEDICINES AND  
INTELLECTUAL PROPERTY RIGHTS**

A DISCUSSION ON NEW APPROACHES & REMAINING CHALLENGES

**HOST**

**World Health Organization (WHO)**

**CHAIR**

**Peter Beyer**

World Health Organization (WHO) |  
Senior Advisor, Essential Medicines  
& Health Products | Switzerland

**SPEAKERS**

**Danny Edwards**

**Encouraging Access-Oriented  
IP Management in the Industry**

Access to Medicine Foundation |  
Research Programme Manager |  
The Netherlands

**Lorraine Misquith**

**Access to and Prices of Hepatitis C  
Treatment in Asia**

United Nations | Senior Legal and  
Advocacy Officer, Lawyers Collective |  
India

**Jayashree Watal**

**The Economics of Innovation:  
Trends in Management of IP in  
Pharmaceutical Innovation**

World Trade Organization | Counselor,  
Intellectual Property | Switzerland

The protection of intellectual property is the essential concept underlying the current innovation model in the pharmaceutical field. Where this model leads to dominant market positions and high prices, this can pose a number of ethical challenges.

This conflict became very apparent with the HIV/AIDS crisis some 20 years ago that led to intense debates and negotiations around this issue in a number of international organizations, including WTO, WIPO and WHO.

In the past years, a lot of progress has been made: there is international funding, prices came down, treatment guidelines were issued, procurement systems streamlined, supply chain management improved to mention just a few. Companies also changed their policies and have started to pay more attention on to facilitate access to treatment in low- and middle income countries where HIV is endemic. The rise of the new cures for hepatitis and their high prices have been compared with the HIV pandemic.

This workshop will shed light on the current situation and how all players have learned from their experience in HIV using different instruments to increase access to life saving medicines.



Peter  
Beyer



Jayashree  
Watal



Danny  
Edwards

**WS10**

ROOM 4 | STRESEMANN

15:00 – 16:30

OVERFLOW SCREEN 4

**WORKSHOP****PATIENT SAFETY****PREVENTING HEALTHCARE ASSOCIATED INFECTIONS****HOSTS**

M8 Alliance:

**National University of Singapore (NUS)****VAMED AG****CHAIRS****Frances A. Hughes**International Council of Nurses |  
Chief Executive Officer | Switzerland**Swee Chye Quek**National University Hospital Singapore  
(NUHS) | Head of Cardiology, Paediatrics |  
Singapore**SPEAKERS****Dale Fisher**National University Hospital Singapore  
(NUHS) | Head and Senior Consultant,  
Infectious Diseases | Singapore**Judith Heepe**Charité – Universitätsmedizin Berlin |  
Director, Medical and Health Care |  
Germany**Swee Chye Quek**National University Hospital Singapore  
(NUHS) | Head of Cardiology, Paediatrics |  
Singapore**Silvia Türk**Federal Ministry of Health | Head, Health  
Systems Research | Austria**DISCUSSANT****Bernd W. Böttiger**University Hospital Köln | Director,  
Anaesthesiology and Intensive Care  
Medicine | Germany

Healthcare associated infections (HAIs) are a natural phenomenon occurring by way of institutionalizing vulnerable patients. A number of pathogens particularly multidrug resistant organisms are well adapted to healthcare settings, surviving in the environment and transmitting often via the hands of our staff.

The prevention of HAIs is the single largest challenge compromising patient safety and requires an organizational structure from senior government leaders to staff at the bedside.

This session will describe the scale of this problem, the necessary commitment and leadership for an adequate response the flow on effects of that leadership to the bedside.



Dale  
Fisher



Swee Chye  
Quek



Judith  
Heepe



Silvia  
Türk



Frances A.  
Hughes

## WS11

ROOM 5 | RATHENAU  
15:00 – 16:30  
OVERFLOW SCREEN 5



## WORKSHOP

## PERSONALIZED HEALTHCARE VISION IN ONCOLOGY

## HOSTS

**F. Hoffmann-La Roche Ltd.**

M8 Alliance:

**Charité – Universitätsmedizin Berlin**

## CHAIR

**Manfred Dietel**

Charité – Universitätsmedizin Berlin |  
Director, Institute of Pathology | Germany

## SPEAKERS

**Dietmar P. Berger**

**Major Advances in Health Technology  
and Cancer Treatment and the Impact  
on Public Health**

F. Hoffmann-La Roche Ltd. |  
Senior Vice-President / Global Head,  
Clinical Hematology / Oncology Product  
Development | United States of America

**Andreas Jenne**

NEO New Oncology | Chief Executive  
Officer | Germany

**Daniel H. Schmutz**

**Consequences for National and  
Worldwide Healthcare Systems**

Helsana-Gruppe | Chief Executive Officer |  
Switzerland

**Reuben Shaw**

**Precision Medicine (Targeted Therapy,  
Immune-Oncology etc.) – An Overview**

Salk Institute for Biological Studies |  
Director, National Cancer Institute |  
United States of America



In the very near future, a patient's cancer will be extensively characterized for mutations and other molecular abnormalities, and his or her treatment will be based on the identified molecular changes instead of where the cancer originated in the body. This approach is part of what is called precision (or personalized) medicine.

The greater molecular and mechanistic understanding of cancer that we are gaining – and applying toward the development of new therapies – is also directly applicable to cancer prevention and screening. Precision medicine uses the genetics of disease to identify effective therapies, and, thanks in large part to NCI-supported research, we know that cancer is a disease of the genome.



Dietmar P.  
Berger



Daniel H.  
Schmutz



Manfred  
Dietel



Reuben  
Shaw



Andreas  
Jenne

## KEY01

PLENARY HALL | WELTSAAAL  
17:00 – 18:30  
OVERFLOW EUROPASAAL  
AND SCREEN 1



Federal Foreign Office



Federal Ministry  
of Health



World Health  
Organization

**M8Alliance**  
Academic Health Centers, Universities and National Academies

### KEYNOTE

## OPENING CEREMONY

### HOSTS

**German Federal Foreign Office**

**German Federal Ministry of Health (BMG)**

**World Health Organization (WHO)**

**M8 Alliance**

### CHAIRS

**Antoine Flahault**

World Health Summit President  
University of Geneva | Director, Institute  
of Global Health | Switzerland

**Detlev Ganten**

World Health Summit President  
Charité Foundation | Honorary Chairman  
of the Board | Germany

### SPEAKERS

**Hermann Gröhe**

Federal Ministry of Health  
(Bundesministerium für Gesundheit) |  
Federal Minister of Health | Germany

**Alain Berset**

Swiss Confederation | Federal Councillor  
and Head, Federal Department of Home  
Affairs FDHA | Switzerland

**Ren Minghui**

World Health Organization (WHO) |  
Assistant Director-General, HIV/AIDS,  
Tuberculosis, Malaria and Neglected  
Tropical Diseases | Switzerland

**Erwin Paul Böttinger**

Berlin Institute for Health (BIH) |  
Chairman of the Board | Germany

**Emmanuelle Charpentier**

Max Planck Institute for Infection Biology |  
Director | Germany

### STATEMENTS OF YOUNG LEADERS IN HEALTH



Hermann  
Gröhe



Alain  
Berset



Ren  
Minghui



Erwin Paul  
Böttinger



Emmanuelle  
Charpentier



Antoine  
Flahault



Detlev  
Ganten



---

SUMMIT PROGRAM

---

**MONDAY, OCTOBER 10**

**PD04**

ROOM 1 | EUROPASAAL  
09:00 – 10:30  
OVERFLOW SCREEN 1

**PANEL DISCUSSION****UNIVERSAL HEALTH COVERAGE**

ASSURING ACCESS AND SUSTAINABILITY

**HOSTS**

**German Healthcare Partnership (GHP)**

M8 Alliance:

**The Graduate Institute Geneva –  
Global Health Center**

**Rabin Martin**

**CHAIRS**

**Ilona Kickbusch**

The Graduate Institute of International  
and Development Studies |  
Director, Global Health Center |  
Switzerland

**Michael Rabbow**

E&P Focus Africa Consulting GmbH |  
Senior Advisor | Germany

**SPEAKERS**

**Rosalinda Baldoz**

**The Role of the Private Sector in Health  
Workforce Development Towards  
Universal Health Care, Decent Work  
and Fair Migration**

Government of the Philippines |  
Former Secretary, Labor and  
Employment (DOLE) | Philippines

**Adalberto Campos Fernandes**

**The Portuguese NHS Experience:  
Scaling Up and Access**

Ministry of Health | Minister of Health |  
Portugal

**Ali Jafarian**

**Iran's National Health Network  
System and the Private Sector Pillar –  
A Model for Mixed Health Systems?**

Tehran University of Medical Sciences |  
Chancellor | Iran

**Justin P. McCarthy**

**What Role do Private Sector Actors Play  
in Achieving UHC as Part of the 2030  
Sustainable Development Agenda?**

Pfizer Inc. | Senior Vice-President, Global  
Policy and International Public Affairs |  
United States of America

## Matshidiso Rebecca Moeti

### Engaging the Private Sector in Building Sustainable Health Systems in Africa

WHO Regional Office for Africa |  
Regional Director | Botswana

The role for the private sector in health remains subject to much debate, especially within the context of achieving universal health coverage (UHC). Another reason for this debate stems from the multiple and complex processes implicated in achieving UHC. While the overarching aim of UHC is to ensure that everyone has access to affordable and quality health products and services regardless of background, in practice this requires strengthening health financing for and service provision of, an agreed package of basic health services across a broad population. Yet there remains no blueprint for how this might be accomplished.

## Heiko Warnken

### The New Health Economy and the Potential for Partnerships in Advancing UHC

Federal Ministry for Economic Cooperation and Development (BMZ) |  
Head, Health, Population Policy and Social Protection | Germany

This session will focus on the new economy of health and the existing and future contributions of the private sector toward the achievement of UHC in mixed health systems. It is the third session in a progressive series hosted by the World Health Summit exploring UHC and the dimensions of innovation, equity, and the new economy of health.



Rosalinda  
Baldoz



Justin P.  
McCarthy



Adalberto  
Campos Fernandes



Matshidiso Rebecca  
Moeti



Ali  
Jafarian



Michael  
Rabbow



Ilona  
Kickbusch



Heiko  
Warnken

## WS12

ROOM 2 | BRANDT  
09:00 - 10:30  
OVERFLOW SCREEN 2



European Federation of Pharm  
Industries and Associations



## WORKSHOP

## IMPROVING PROCESSES FOR ACCESS TO MEDICINES

DEVELOPING STRONGER COLLABORATION AND DIALOGUE

## HOSTS

**European Federation of Pharmaceutical  
Industries and Associations (EFPIA)**

**Sanofi**

## CHAIRS

**Richard Bergström**

European Federation of Pharmaceutical  
Industries and Associations (EFPIA) |  
Director-General | Belgium

**Ricardo Augustus Guerreiro Baptista Leite**

Catholic University Portugal | Head of  
Public Health, Institute of Health Sciences |  
Portugal

## SPEAKERS

**Chantal Belorgey**

French National Authority for Health  
(HAS) | Director, Medical, Economic and  
Public Health Evaluation | France

**Niklas Hedberg**

TLV, The Dental and Pharmaceutical  
Benefits Agency | Chief Pharmacist |  
Sweden

**Thomas Müller**

**How to Improve Drug Research Output  
and Patient Access by Early HTA/  
Industry Communication**

Federal Joint Committee | Head,  
Pharmaceuticals | Germany

**Pieter Stolk**

**The WHO Priority Medicines Report:  
A Public Health Based Medicines  
Development Agenda**

Exon Consultancy | Director | Netherlands



This session seeks to explore to what extent and under what conditions new and more structured approaches to collaboration and dialogue between the R&D based pharmaceutical industry and governments, regulators and civil society in Europe could make a positive contribution to improving medicines access processes in an environment characterized by economic uncertainty and budgetary pressures.

Debates on pharmaceutical pricing have reached a political and global dimension, often with an adversarial and acrimonious stance. At the same time, we have seen emerge a stronger interest from various stakeholders in developing more structured approaches to collaboration and dialogue aimed at better predictability for both the public authorities involved in making funding decisions and for the R&D based pharmaceutical companies that have to make important investment decisions. This session seeks to take a closer look at two areas in particular, both of which are based on the underlying idea of starting a dialogue well before the marketing authorization of a medicine:

So-called “Horizon-scans” or “pipeline scans” can help identify upcoming breakthrough innovations with high outcomes impact and initiate discussions on health system implications and funding.

The EU is currently exploring permanent models for joint ‘early dialogue’ which refers to the process of advice by HTA bodies (HTABs) and regulatory authorities sought at the initiative of a manufacturer on the appropriateness of study design during the development phase of a medicine. It helps companies address areas of uncertainty by better anticipating evidentiary needs for coverage decision-making by national authorities while bridging the evidentiary requirements for HTABs and regulatory approval.

What role can pipeline scans have in increasing budgetary predictability and planning in the pharmaceuticals sector? How can capabilities for pipeline scans be increased at national or even European level? What model for a permanent joint early dialogue would best meet the needs of all involved? Can joint dialogue accelerate a more harmonised approach to value assessment in Europe? Will any of this matter for an improved dialogue and ultimately for improved access to innovation for patients?



Chantal  
Belorgey



Thomas  
Müller



Richard  
Bergström



Pieter  
Stolk



Ricardo Augustus  
Guerreiro Baptista  
Leite

**WS13**

ROOM 3 | ADENAUER  
09.00 - 10.30  
OVERFLOW SCREEN 3

**CEPI****GOVERNMENT.NO**

Department of Biotechnology  
Government of India

**WORKSHOP**

## COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS

R & D PREPAREDNESS AND RESPONSE FOR EPIDEMIC OUTBREAKS

**HOSTS**

**Coalition for Epidemic Preparedness  
Innovations (CEPI)**

**Government of Norway**

**Department of Biotechnology,  
Government of India**

**CHAIRS**

**Gagandeep Kang**

Christian Medical College | Professor,  
Gastrointestinal Sciences | India

**John-Arne Røttingen**

University of Oslo | Director, Norwegian  
Institute of Public Health, Infectious  
Disease Control | Norway

**SPEAKERS**

**Mark Feinberg**

International AIDS Vaccine Initiative  
(IAVI) | President and Chief Executive  
Officer | United States of America

**Yves Levy**

The National Institute for Health and  
Medical Research (INSERM) |  
Director-General | France

**Line Matthiessen-Guyader**

European Commission | Head of Fighting  
Infectious Diseases and Global Epidemics,  
Research and Innovation | Belgium

**Gerd Sutter**

Ludwig Maximilians University Munich |  
Professor and Chair for Virology,  
Veterinary Sciences | Germany

**DISCUSSANT**

**Michel Chrétien**

University of Montréal |  
Professor Emeritus | Canada

The Ebola outbreak made obvious the need for a global mechanism to ensure development of biomedical counter-measures in situations of market failure. The way forward for such a mechanism will be explored in this session, including ties to the WHO R&D Blueprint and the existing ecosystem of organisations and mechanisms in global health, as well as financing requirements. There is an ongoing process aiming to establish a

global initiative called the Coalition for Epidemic Preparedness Innovations, better known as CEPI.

The session will explore the proposed plans for this coalition. John-Arne Røttingen and Gagandeep Kang will give an introduction to the topic and to CEPI. Mark Feinberg, Gagandeep Kang, Line Matthiessen, Yves Levy and Gerd Sutter will form an interactive panel, with Michel Chrétien joining as an expert discussant.



Mark  
Feinberg



Line Matthiessen-  
Guyader



Gagandeep  
Kang



John-Arne  
Røttingen



Yves  
Levy



Gerd  
Sutter

## WS14

ROOM 4 | STRESEMANN

09:00 - 10:30

OVERFLOW SCREEN 4



## WORKSHOP

## TUBERCULOSIS AND MIGRATION

HOW TO CONTAIN TB IN TIMES OF WAR AND NATURAL DISASTER

## HOSTS

Friends of the Global Fund

Koch-Metschnikow-Forum (KMF) e.V.

## CHAIR

Timo Ulrichs

Koch-Mechnikov-Forum | Founder |  
Germany  
Akkon University for Human Sciences |  
Head, Emergency Relief and Disaster |  
Germany

## SPEAKERS

Zaza Avaliani

Tuberculosis and Migration in Georgia

National Center for Tuberculosis and  
Lung Diseases | Director | Georgia

Holger Bartz

Tuberculosis and Migration:  
Challenges and Impact for the  
Healthcare Industry

Janssen-Cilag GmbH | Director,  
Infectiology & Immunology | Germany

Sam Loewenberg

Who is Accountable? Lessons from  
the Ground on how Refugee Camps  
became Incubators for Disease

Harvard University |  
Nieman Global Health Reporting Fellow |  
United States of America

Andris Piebalgs

Resistancies and Increased Migration:  
How do we Eliminate TB now?

Government of the Republic of Latvia |  
Special Advisor to the President of  
the Republic | Latvia  
Member of the Board | Friends of the  
Global Fund Europe

Martin van den Boom

Key Facts about TB in the  
WHO European Region

World Health Organization (WHO)  
Regional Office for Europe | Technical  
Officer, Joint TB, HIV/AIDS and Viral  
Hepatitis Programme | Denmark

Together with malaria and HIV/AIDS, tuberculosis belongs to the most threatening and killing infectious diseases. In our present times, the spread of tuberculosis is accelerated by migration of vulnerable groups and TB patients. Refugees, IDPs and other migrating groups are at special risk to develop and to transmit tuberculosis.

The already existing problems of multi-drug resistance and HIV-TB comorbidity are aggravated by migration, insecure containment structures and inadequate health care in refugee facilities. The workshop addresses these current challenges from different perspectives.



Zaza  
Avaliani

Andris  
Piebalgs



Holger  
Bartz

Timo  
Ulrichs



Sam  
Loewenberg

## WS15

ROOM 5 | RATHENAU  
09:00 - 10:30  
OVERFLOW SCREEN 5



## WORKSHOP

MIGRATION, CULTURES  
AND HEALTH

## HOSTS

All European Academies (ALLEA)

M8 Alliance

World Health Summit

## CHAIRS

**Ambassador Reinhard Schäfers**

World Health Summit - WHS Foundation  
GmbH | WHS Ambassador | Germany  
Former German Ambassador

**Günter Stock**

All European Academies (ALLEA)|  
President | Germany

**Jean-Yves K.Tano**

World Health Summit Foundation GmbH |  
Scientific Advisor | Germany

## SPEAKERS

**Aydan Özoğuz**

Federal Republic of Germany |  
Commissioner for Immigration,  
Refugees and Integration,  
Federal German Government | Germany

**Nils Fietje**

**Cultural Mediators in Refugee  
and Migrant Encounters:  
The Role of the WHO in Promoting  
Training and Guidelines**

World Health Organization (WHO)  
Regional Office for Europe |  
Research Officer, Information, Evidence,  
Research and Innovation | Denmark

**Ilhan Ilkilic**

**Interculturality and Ethics in  
the Health Care System**

Istanbul University | Chair, History  
of Medicine and Ethics | Turkey

**Anja Krumeich**

**Dutch Health Care Practice and its  
Impact on the Perception of Migrants  
as a Problematic Category**

Maastricht University - Faculty of Health,  
Medicine and Life Sciences | Associate  
Professor, Health, Ethics & Society |  
Netherlands

**David Napier**

**Cultural Competency and  
Why it Matters**

University College London | Director,  
Anthropology | United Kingdom

**Victoria Sultana****Towards Holistic Globalisation  
in Caring**

Mater Dei Hospital | Director,  
Nursing and Midwifery | Malta

**DISCUSSANTS****Luciano Saso**

Sapienza University of Rome |  
Vice-Rector for European  
Networks, Faculty of Pharmacy  
and Medicine | Italy

**Jalid Sehouli**

Charité – Universitätsmedizin  
Berlin | Director, Clinic for  
Gynecology | Germany

Cultural diversity is defined as the differences that exist in the world, a society or an institution. This concept is important to understand and take into account when trying to bring about transformative ideas to a society, especially concerning the health-care of the public.

The influx of immigrants, fleeing war, poverty and desolation, towards Europe has caused a great stir in 2015 with no end in sight thus far. These immigrants pose a challenge to the health-care system in their countries of arrival as the differences in the cultures leads to different understandings and expectations for both doctors and the immigrants as patients.

Culture thus needs to be an integral part of the discussions to provide proper healthcare to the migrants.

Recent catastrophic events such as the 2011 Earthquake and Tsunami in Japan, or the 2014 and continuing Ebola crisis in West Africa have highlighted the need for healthcare workers to be properly trained in respect to the cultural diversity in these countries in order to provide adequate help.

In the current climate of expansion of noncommunicable diseases in the world, it is very important for all the stakeholders to be aware and properly informed about this topic when developing.



Nils  
Fietje



David  
Napier



Günter  
Stock



İlhan  
İlkilic



Aydan  
Özoğuz



Victoria  
Sultana



Anja  
Krumeich



Reinhard  
Schäfers



Jean-Yves K.  
Tano

## KEY02

PLENARY HALL | WELTSAL  
11:00–12:30



ICRC



International Organization for Migration (IOM)



JOHNS HOPKINS  
BLOOMBERG SCHOOL  
of PUBLIC HEALTH

**M8Alliance**  
Academic Health Centers, Universities and National Academies

## KEYNOTE

## MIGRATION AND REFUGEE HEALTH

FROM CARE TO POLICY

## HOSTS

International Committee of  
the Red Cross (ICRC)

International Organization for Migration  
(IOM)

M8 Alliance:

Johns Hopkins Bloomberg  
School of Public Health

## CHAIR

Michael J. Klag

Johns Hopkins Bloomberg  
School of Public Health | Dean |  
United States of America

## SPEAKERS

Yves Daccord

See **The Person: Ensuring Continuity  
of Care in Fragile Environments**

International Committee of the  
Red Cross (ICRC) | Director-General |  
Switzerland

Ambassador William Lacey Swing

**The Place of Health in the Migrant  
and Refugee Global Compacts:  
A Multisector Partnership Agenda**

International Organization for Migration  
(IOM) | Director-General | Switzerland

Helle Thorning-Schmidt

**Migration and Refugee Health:  
Reaching Every Last Child**

Save the Children International |  
Chief Executive Officer | United Kingdom

Florian Westphal

**A Journey from Hell to the Unknown –  
The Human Cost of Policy Decisions**

Médecins Sans Frontières (MSF)  
Germany | Managing Director | Germany

Aydan Özoğuz

**Health Policy in the Immigrant Society**

Federal Republic of Germany |  
Commissioner for Immigration,  
Refugees and Integration,  
Federal German Government | Germany



The current migration wave to Europe is unmatched in the history of the continent, and therefore issues pertaining to migrant health have risen high on the agenda of many European countries in response. The current situation is a sign and symptom of the recent globalization process and the increasing political unrest in different parts of the world. This migration is massive, unprecedented, extremely diverse and mostly unregulated. In the future migration into Europe will become a routine for which Germany and other European countries ought to be prepared.

There are multiple driving forces like civil wars and political instability as well as environmental degradation due to extreme weather events and climate change in countries of origin. On the other hand these forces include better life and economic prospects for migrants and their families in countries of destination.

Established migration concepts like pull and push factors and the so-called healthy migrant effect are not sufficient to explain and understand the impacts on health and society of this global phenomenon. Simple care will no longer suffice, new concepts are needed to adapt health policy strategies that take into account the social transformation processes in sending and receiving regions.



Yves  
Daccord



William Lacey  
Swing



Michael J.  
Klag



Helle  
Thorning-Schmidt



Aydan  
Özoğuz



Florian  
Westphal

**PD05**

ROOM 1 | EUROPASAAL  
14:00–15:30  
OVERFLOW SCREEN 1

**PANEL DISCUSSION****PLANETARY HEALTH**

SAFEGUARDING BOTH HUMAN HEALTH AND  
THE NATURAL SYSTEMS THAT UNDERPIN IT

**HOSTS**

**Leopoldina –**  
**German National Academy of Science**

M8 Alliance:

**London School of Hygiene  
& Tropical Medicine**

**CHAIR**

**Sir Andrew Haines**  
London School of Hygiene & Tropical  
Medicine | Professor, Public Health and  
Primary Care | United Kingdom

**SPEAKERS**

**Anthony Capon**  
**The Future Earth Knowledge  
Action Network**

United Nations University | Director,  
International Institute for Global Health |  
Malaysia

**Samuel S. Myers**  
**The Case for Planetary Health:  
Why Accelerating Change to Earth's  
Natural Systems may be a Primary Driver  
of Future Burden of Disease Globally**  
Harvard T.H. Chan School of Public Health |  
Director, Planetary Health Alliance |  
United States of America

**Montira Pongsiri**  
**Applying Planetary Health Science  
to Policy and Decision-Making**  
Wildlife Conservation Society |  
HEAL Director | United States of America

**Robert Sebbag**  
**Consequences on Health of Climate  
Change**  
Sanofi Aventis | Vice-President,  
Access to Medicines | France

Despite health gains over recent decades, there is growing evidence that the planet's capacity to sustain the growing human population is declining. Climate change, biodiversity loss, freshwater depletion, overexploitation of fisheries and air, water and soil pollution threaten to halt and reverse these advances in health.

The concept of "Planetary health" recognises the interdependencies of human and natural systems, and that the integrity of natural systems is an essential precondition for human health, survival, and prosperity.

This session will discuss the potential health implications of environmental changes for example through their effects on food and agriculture, emerging diseases, disasters and displacement of populations, exposure to pollution and increased poverty.

The session will also debate potential policies that could promote environmental sustainability and safeguard health across a range of sectors such as energy, transport, urban planning, agriculture and food as well as health care.

Finally it will discuss the challenges of implementing such policies and how these can be addressed with a particular emphasis on the role of health professionals in researching, educating and advocating for policies to sustain Planetary Health.



Anthony  
Capon

Montira  
Pongsiri



Sir Andrew  
Haines

Robert  
Sebbag



Samuel S.  
Myers

**WS16**

ROOM 2 | BRANDT  
14:00 – 15:30  
OVERFLOW SCREEN 2

Max-Planck-Institut  
für Psychiatrie  
Deutsche Forschungsanstalt für Psychiatrie



UNIVERSITÄTS  
KLINIKUM  
TÜBINGEN

**WORKSHOP****GLOBAL MENTAL HEALTH**

THE QUESTION OF CULTURE

**HOSTS**

**Max Planck Institute for Psychiatry**  
**University Hospital Tübingen**

**CHAIRS****Niall Boyce**

The Lancet Psychiatry | Editor-in Chief |  
United Kingdom

**Stephan Zipfel**

University Hospital Tübingen |  
Head, Psychosomatic Medicine | Germany

**SPEAKERS****Elisabeth Binder**

Max Planck Institute of Psychiatry |  
Director | Germany

**Dixon Chibanda**

**The Friendship Bench Project –  
A Mental Health Intervention  
Delivered by Community Health  
Workers in Zimbabwe**

University of Zimbabwe |  
Consultant, Psychiatry | Zimbabwe

**Erminia Colucci**

**Breaking the Chains – Ethnographic  
Film-Making in Mental Health**

Queen Mary University of London |  
Lecturer and Leader, Transcultural Mental  
Healthcare | United Kingdom

**Valentina Iemmi**

**Global Mental Health Policy and Mental  
Disabilities, Both in Developed and  
Developing Countries**

London School of Economics and Political  
Sciences | Research Fellow, Personal  
Social Services Research Unit (PSSRU) |  
United Kingdom

**Jan Ilhan Kizilhan**

**Help for Yazidi Survivors of Sexual  
Violence in Northern Iraq**

Cooperative State University Baden-  
Württemberg | Head, Faculty of Social  
Studies | Germany

**Ulrich Schnyder**

**Trauma is a Global Issue**

University Hospital Zurich |  
Head, Psychiatry and Psychotherapy |  
Switzerland

The Workshop will focus on the issue of culture – the extent to which concepts of mental health care can translate and be implemented in different social, economic, and cultural settings around the world. Might the “friendship bench” concept in Zimbabwe translate to provide sustainable, effective mental health interventions in Europe?

And how do European concepts of trauma management work when applied to traumatized refugee populations from different cultures (eg, the Yezidi people from northern Iraq)?

Finally, by presenting an excerpt from the film project “Breaking the Chains”, we will give a brief insight into the use of physical restraint and confinement of people with mental illness in Indonesia, which has recently come to international attention.

With this workshop, we would like to discuss cultural entities such as “trauma” as a global issue rather than simply a psychological phenomenon. In our view, global mental health might be best understood using an interdisciplinary, multi-professional, biopsychosocial approach.



Elisabeth  
Binder



Valentina  
Lemmi



Niall  
Boyce



Jan Ilhan  
Kizilhan



Dixon  
Chibanda



Ulrich  
Schnyder



Erminia  
Colucci



Stephan  
Zipfel

## WS17

ROOM 3 | ADENAUER  
14:00–15:30  
OVERFLOW SCREEN 3



## WORKSHOP

## ONE HEALTH

TACKLING EMERGING INFECTIONS AT THE SOURCE

## HOSTS

M8 Alliance:  
**InterAcademy Partnership for Health (IAP)**

**One Health Platform**

## CHAIRS

**Peter McGrath**  
InterAcademy Partnership for Health (IAP) | Program Officer | Italy

**Albert Osterhaus**  
University of Veterinary Medicine Hannover | Professor, Wildlife Virology and Virus Discovery | Germany

## SPEAKERS

**Anthony Capon**  
**One Health and Planetary Health: What is the Difference?**  
United Nations University | Director, International Institute for Global Health | Malaysia

**Rajae El Aouad**  
**The Challenge of Implementing One Health in Developing Countries and the Way Forward**  
Hassan II Academy of Science and Technology | Resident Member, National Institute of Hygiene | Morocco

**Fabian Leendertz**  
**One Health at the Human-Wildlife Interface**  
Robert Koch Institute | Research Leader, Epidemiology of Highly Pathogenic Microorganisms | Germany

**Balakrishna Pisupati**  
**The Deja Vu Moment in Promoting One Health**  
United Nations Environment Programme (UNEP) | Head, Environmental Law and Conventions Programme | Kenya

The concept of 'One Health' has been defined as "the collaborative effort of multiple disciplines – working locally, nationally and globally – to attain optimal health for people, animals and the environment."

This session not only aims to link across disciplines, but also across continents and events – from the United Nations Environment Assembly held in Nairobi,

Kenya, in May 2016 ([web.unep.org/unea](http://web.unep.org/unea)), to the One Health EcoHealth congress scheduled for Melbourne, Australia, this coming December ([oheh2016.org](http://oheh2016.org)).

Indeed, we hope the outputs of this session will feed into a satellite symposium in Melbourne on 'Combating emerging infections at the source: from early detection to effective intervention strategies'.



Anthony  
Capon

Peter  
McGrath



Rajae  
El Aouad

Albert  
Osterhaus



Fabian  
Leendertz

Balakrishna  
Pisupati

## WS18

ROOM 4 | STRESEMANN

14:00–15:30

OVERFLOW SCREEN 4



## WORKSHOP

FOSTERING OPEN SCIENCE  
IN GLOBAL HEALTH

THE CASE OF PUBLIC HEALTH EMERGENCIES

## HOSTS

**Centre Virchow-Villermé  
for Public Health**

M8 Alliance:

**Charité – Universitätsmedizin Berlin**

## CHAIRS

**Antoine Flahault**

World Health Summit President  
University of Geneva | Director,  
Institute of Global Health | Switzerland

**Tobias Kurth**

Charité – Universitätsmedizin Berlin |  
Director, Institute of Public Health |  
Germany  
Centre Virchow-Villermé (CVV) |  
Co-Director | Germany

## SPEAKERS

**Michael Baffi**

**The Role of Open Detection Platforms  
and Analytics in Outbreak Mitigation**

Thermo Fisher Scientific Inc. |  
Global Director, Public Health |  
United States of America

**Alpha Ahmadou Diallo**

**Why Both Public and the Scientific  
Community Benefits From Sharing.**

Ministry of Health | Head of Department |  
Guinea

**Katherine Littler**

**Funders' Strategies to Foster  
Collaboration in Global Health**

Wellcome Trust | Senior Policy Adviser |  
United Kingdom

**Ben Meghreblian**

**OpenTrials: An Open, Linked Database  
of Information About the World's  
Clinical Trials**

Open Knowledge International |  
Community Manager, OpenTrials |  
United Kingdom

**Ali Sié**

**Researcher's Perspective:  
The Importance of Open Science  
in a Global Health**

Research Center for Health of Nouna |  
Director | Burkina Faso



## DISCUSSANT

### Ilaria Montagni

University of Bordeaux | Post-doc |  
France

This Workshop aims to address collaboration and open dialogue in Global Health related research using the example of data and results sharing during public health emergencies. In February 2016, the World Health Organization has declared that the clusters of brain-damaged babies born in Brazil – linked to but not yet proven to be caused by the Zika virus – constitute a public health emergency of international concern.

This became the first test to the proposed WHO global norm of transparent sharing of data and results during public health emergencies – only weeks after publishing the results of this consultation.

Key questions to be discussed:

- What can we learn from past public health emergencies?
- How can open research approaches improve the management of global health crisis?
- What is the role of each actor in this area of open science/research?



Michael  
Baffi



Tobias  
Kurth



Alpha Ahmadou  
Diallo



Katherine  
Littler



Antoine  
Flahault



Ben  
Meghrebian

**WS19**

ROOM 5 | RATHENAU  
14:00–15:30  
OVERFLOW SCREEN 5

**WORKSHOP****NEXT GENERATION MEDICAL LOGISTICS**

THE ROLE OF UAVS IN OVERCOMING SUPPLY CHAIN CHALLENGES

**HOST**

**KfW Development Bank**

**CHAIRS**

**Annika Calov**

KfW Development Bank | Head, Health  
Education & Social Protection | Germany

**Ambassador Hinrich Thölken**

Permanent Representation of the  
Federal Republic of Germany to the  
International Organisations in Rome |  
Ambassador | Italy

**SPEAKERS**

**Andreas Bicking**

**Technical Possibilities/Requirements  
of UAVs – Role of Commercial Providers**  
DHL Parcel | Vice-President, DHL Product  
Development | Germany

**Wolfgang Herbinger**

**Logistics for a Sustainable Development  
in Global Health**  
UN World Food Programme WFP | Senior  
Advisor, Pandemic Supply Chain | Italy

**Jonathan Ledgard**

**Bridging the Middle Mile in Health  
Supply Chains With UAVs**  
Afrotech-EPFL | Director | Switzerland

**Oriol Lopez**

**Sustainable Operation of UAVs on the  
Last Mile of Health Supply Chains**  
Médecins Sans Frontières (MSF) |  
Field Logistician | Spain

**DISCUSSANTS**

**Gregory Rockson**

mPharma Data Inc. | Chief Executive  
Officer | Ghana

**Daniel Shoukimas**

mPharma Data Inc. | Chief Product  
Officer, Co-Founder | Israel

Worldwide, at least 400 million people do not have access to essential health services, many of them in rural hard to reach regions. This is a major impediment to achieving Universal Health Coverage (UHC). Amongst others, overcoming it requires reliable transport links between remote health centers and provincial/central hospitals. Technologically, this is now realistic.

Unmanned Aerial Vehicles (UAVs) can contribute to solving the existing supply chain challenges by making deliveries of urgently needed, lifesaving supplies to off-grid communities faster and cheaper

while allowing for better tracking. Initial pilot payload delivery projects utilizing UAVs were launched in e.g. Rwanda, Papua New Guinea and Germany. The planned session aims at bringing experts (e.g. innovators, developers, industry, governments, NGOs) with practical experience together to share lessons learned for future cargo UAV medical applications.

Besides the technical and regulatory aspects, ways of embedding the technology into the existing health infrastructure, as well as locally sustainable business models will be discussed.



Andreas  
Bicking



Oriol  
Lopez



Annika  
Calov



Hinrich  
Thölken



Wolfgang  
Herbinger

## KEY03

PLENARY HALL | WELTSAL  
16:00–18:00



**PHILIPS**

### KEYNOTE

## TECHNOLOGICAL INNOVATION FOR HEALTH

IMPROVING HEALTHCARE DIAGNOSTICS AND DELIVERY

### HOSTS

M8 Alliance:

**Clinical Research Institute Montreal  
(IRCM)**

**Royal Philips NV**

### CHAIR

**Tarik Mörröy**

Clinical Research Institute Montreal  
(IRCM) | President and Scientific Director |  
Canada

### SPEAKERS

**Jutta Allmendinger**

**The World We Live to See. How People  
Picture Futures of Health Technology**

Berlin Social Science Center (WZB) |  
President | Germany

**Yukiya Amano**

**The Role of Nuclear Technology and  
the IAEA Contribution to Expanding  
Access to Quality Health Care in  
Developing Countries**

International Atomic Energy Agency |  
Director-General | Austria

**Pascale Ehrenfreund**

**Space Research for Health Applications**

German Aerospace Center (DLR) |  
Chairman of the Board | Germany

**Lloyd B. Minor**

**The Precision Health Revolution:  
From Silicon Valley to the World**

Stanford University | Dean, School  
of Medicine | United States of America

**Steve Singh**

**The Power of the Network:  
Lessons from the World of Modern  
Business Applications**

SAP SE | President, Business Networks  
and Applications | United States of  
America

**Frans van Houten**

**Creating Healthcare Systems for All**

Royal Philips NV | Chief Executive  
Officer | Netherlands

Successful health care delivery requires effective medical devices as tools for prevention, diagnosis, treatment and rehabilitation. As the digital and genetics revolutions converge with healthcare we are increasingly able to track, manage, and improve both our own health and that of our loved ones. Technological innovation in the field of health is also helping to reduce inefficiencies in health-care delivery, while at the same time streamlining access, reducing costs, improving quality and making medicine more personalized and precise.

The essential elements that are making this development a reality include wireless devices, hardware sensors and software sensing technologies, micro-processors and integrated circuits, the

Internet, social networking, mobile and body area networks, health information technology, genomics, and personal genetic information.

Despite the exponential growth of scientific and technological development, low- and middle-income countries are still largely excluded from access to appropriate and affordable health technologies. Therefore novel technological devices need to be developed that can address health problems and improve quality of life. Of particular interest are technologies that have the ability to enhance the access to essential health products and services leading to improved health for the population most in need.



Jutta  
Allmendinger

Tarik  
Mörröy



Yukiya  
Amano

Steve  
Singh



Pascale  
Ehrenfreund

Frans  
van Houten



Lloyd B.  
Minor

**PD05a**

ROOM 1 | EUROPASAAL  
16:00 - 18:30  
OVERFLOW SCREEN 1



## PANEL DISCUSSION

# THE CONTRIBUTION OF BIOLOGIC MEDICINES TO PUBLIC HEALTH

### HOSTS

**F. Hoffmann-La Roche Ltd.**

**World Health Summit**

### CHAIRS

**Janis Bernat**

International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Associate Director, Biotherapeutics & Scientific Affairs | Switzerland

**Matthias Wienold**

International Alliance of Patients Organizations | Board Treasurer | United Kingdom

### KEYNOTE

**Georg Marckmann**

**Current and Future Role of Biologics**

Ludwig Maximilians University Munich | President, Institute for Ethic, History and Theory in Practice | Germany

### SPEAKERS

**Paul Declerck**

**Focus on the Biologics' Story**

KU Leuven University | Dean, Faculty of Pharmaceutical Sciences | Belgium

**Axel C. Mühlbacher**

**Focus on the Health Economics**

Hochschule Neubrandenburg | Professor, Health Economics and Healthcare Management | Germany

**Brendan Shaw**

**Focus on the Value to Public Health**

International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Assistant Director General | Switzerland

**Durhane Wong-Rieger**

**Focus on the Patient Perspective**

International Alliance of Patients' Organizations | Past Chair | United States of America

This Session will feature panel presentations and facilitated discussion to discuss stakeholders perspectives, roles and responsibilities in ensuring sustainability of innovation. Listen to perspectives from: the clinic, the patient community, industry, and health economics:

- The role of biologics in addressing complex and hard to treat diseases such as cancer and the overall value offered by this class of medicines to patients, their caregivers, and their healthcare providers.
- The special characteristics of biologics that hold implications for decisions regarding R&D, approval and use
- What is being done to expand appropriate patient access to needed biologic medicines in a financially sustainable way and what more can be done.
- How stakeholders can work together to ensure that the appropriate use of biologics deliver maximum benefit and value to patients and societies and preserve incentives for continued innovation



Janis  
Bernat



Brendan  
Shaw



Paul  
Declerck



Matthias  
Wienold



Georg  
Marckmann



Durhane  
Wong-Rieger



Axel C.  
Mühlbacher

ALLIANZ FORUM BERLIN  
PARISER PLATZ 6  
19:00 – 23:00



## SOCIAL EVENT

---

# WHS NIGHT AT THE ALLIANZ FORUM BERLIN

---

## HOST

**M8 Alliance**

## SPEAKER

**Hermann Gröhe**

Federal Ministry of Health  
(Bundesministerium für Gesundheit BMG) |  
Federal Minister of Health | Germany



---

After two days of intense work with fellow World Health Summit participants from all over the world, take an evening to relax at the WHS Night, right next to Brandenburg Gate.

Highlight of this event will be the WHS Startup Track Award Ceremony: German Federal Minister of Health Hermann Gröhe will award the winner and finalists.

Snacks and drinks will be served, whilst a DJ will satisfy the needs of those who wish to dance. A shuttle service will be available for transportation between the Summit venue and the AllianzForum, where the WHS Night will be hosted.

Please note that you must register separately ([www.registration-whs.com/](http://www.registration-whs.com/)) to attend the WHS Night, taking place at the Allianz Forum Berlin (Pariser Platz 6). There is a €39 entrance fee.



Hermann  
Gröhe



---

SUMMIT PROGRAM

---

**TUESDAY, OCTOBER 11**

PD06

ROOM 1 | EUROPASAAL  
9:00–10:30  
OVERFLOW SCREEN 1

BCG

THE BOSTON CONSULTING GROUP

WORLD  
ECONOMIC  
FORUM

## PANEL DISCUSSION

# VALUE IN HEALTHCARE

## DRIVERS OF SYSTEM REFORM

### HOSTS

The Boston Consulting Group (BCG)

World Economic Forum

### CHAIRS

**Stefan Larsson**

The Boston Consulting Group (BCG) |  
Senior Partner & Managing Director |  
Sweden

**Olivier Oullier**

World Economic Forum | Head, Strategy,  
Global Health and Healthcare |  
Switzerland

### SPEAKERS

**Eric Hans Eddes**

**The Dutch Acceleration to  
Value-Based Healthcare –  
Establishing a National Platform**

Dutch Institute for Clinical Auditing  
(DICA) | Director | Netherlands

**Norbert Hauser**

**Challenges in Emerging Markets and  
Opportunities for Leapfrogging**

The Global Fund to Fight AIDS,  
Tuberculosis and Malaria | Chairman of  
the Board of the Board | Switzerland

**Paul Hudson**

**Rethinking the Role of Pharma in  
Improving Healthcare Value**

Novartis Pharmaceuticals |  
Chief Executive Officer | Switzerland

**Jan Kimpen**

**Digital Innovation to Address Barriers  
in Both Emerging and Developed  
Markets**

Royal Philips NV | Chief Medical Officer |  
Netherlands

**Christina Rångemark Åkerman**

**Outcomes Measurement is the  
Foundation – From Standardization  
to Implementation**

ICHOM International Consortium for  
Health Outcomes Measurement |  
President | United States of America

### What is the issue?

Global healthcare spending has reached an estimated USD 7–8 trillion, a third of which is reported to be “wasted”. The misalignments of incentives, interests, strategies and behaviours of parties engaged in healthcare delivery (i.e. policy makers, regulators, private sector, R&D, providers, suppliers and individuals) are at the core of this inefficiency. Healthcare – in countries where people can benefit from it – is therefore imprecise and inequitable. The misalignments amongst healthcare stakeholders have led to dead ends at the financial (unsustainable costs), human (outcomes far from delivering the expected quality of care) and systemic levels (high degrees of variability between delivery systems).

### How can this issue be addressed?

What is known as value-based health care (VBHC) has aimed to redefine how care is organized, measured, and reimbursed. Today, the concept is pushed further with the massive spread of technology, systems and devices allowing for almost real-time evidence-informed strategies and decision-making in healthcare that, in principle, could allow tailoring of care to the needs and differences of each individual and ecosystem.

### What is the role of the World Economic Forum?

The World Economic Forum is The International Organization for Public-Private Cooperation. In this capacity, the Forum has initiated a project “Value in Healthcare,” in collaboration with the Boston Consulting Group. The project’s goal is to develop global roadmaps toward value-based health care while initiating transformative pilots to accelerate system-level change. To date, the team has identified 5 core building blocks of a value-based health care system

1. Focus on defined populations segments
2. Measurement of value: both outcomes and costs
3. Population interventions along the fully cycle of care
4. Payments and incentives aligned to value
5. Continuous improvement

While these building blocks are now well defined, the question remains as to how public-private cooperation can most effectively drive system reform toward achieving these critical building blocks.



Eric Hans  
Eddes



Stefan  
Larsson



Norbert  
Hauser



Olivier  
Oullier



Paul  
Hudson



Christina Rånge-  
mark Åkerman



Jan  
Kimpen

## WS20

ROOM 2 | BRANDT  
09:00 - 10:30  
OVERFLOW SCREEN 2



### WORKSHOP

---

## BETTER LEADERSHIP: IMPROVED HEALTHCARE

YOUNG PHYSICIAN LEADERS: "THE LEADERSHIP WE WANT"

---

### HOSTS

**European School of Management  
and Technology (ESMT)**

**InterAcademy Partnership for Health  
(IAP)**

**M8 Alliance**

**Young Physician Leaders (YPL)**

### CHAIRS

**Jo Ivey Boufford**

New York Academy of Medicine |  
President | United States of America

**Thomas Zeltner**

Swiss Academy of Medical Sciences |  
Head, International Affairs | Switzerland

### SPEAKER

**Nora Ilona Grasselli**

ESMT- European School of Management  
and Technology GmbH | Program  
Director | Germany

### SELECTED

**YOUNG PHYSICIAN LEADERS**

Successful institutions need good leaders. And whether they are in high income countries or poorer countries, institutions providing healthcare, educating future physicians or promoting the public's health are no different. Yet decision-makers in such institutions are often appointed from among people trained in medicine, not leadership.

The Inter-Academy Partnership (IAP for Health) Young Physician Leaders (YPL) programme aims to bridge this gap. Launched in 2011, to date some 107 young physicians from more than 30 countries have participated in 5 international and one regional edition of this personalized leadership training

programme (a dedicated IAMP YPL Directory is available here: [www.iamp-online.org/iamp-young-physician-leaders-directory](http://www.iamp-online.org/iamp-young-physician-leaders-directory)). In addition, a group of alumni were introduced to the recent World Health Assembly in Geneva.

IAP for Health YPL training events take place immediately prior to WHS meetings. This session will be designed by the 20 participants of the 2016 event taking place on 7–9 October. Discussions will likely focus on leadership challenges for young physicians and their solutions in countries with different socio-economic conditions. The session is open to everyone – students, young medical personnel at the start of their careers, as well as delegates holding more senior positions.



Jo Ivey  
Boufford



Thomas  
Zeltner



Nora Ilona  
Grasselli

## WS21

ROOM 3 | ADENAUER  
09:00 - 10:30  
OVERFLOW SCREEN 3

**vfa.** Die forschenden  
Pharma-Unternehmen

**GKKE**  
Gemeinsame Konferenz  
Kirche und Entwicklung  
Joint Conference Church  
and Development



### WORKSHOP

## STRENGTHENING HEALTH SYSTEMS FOR EDUCATION AND TRAINING

CAPACITY BUILDING THROUGH MULTI-STAKEHOLDER PARTNERSHIPS

### HOSTS

**Association of Research-Based  
Pharmaceutical Companies (vfa)**

**Joint Conference Church and  
Development (GKKE)**

### CHAIRS

**Gertrud Casel**

Joint Conference Church and  
Development (GKKE) | Director-General,  
Catholic Division | Germany

**George M. Kuria**

Boehringer Ingelheim Kenya |  
Key Account Manager | Kenya

### SPEAKERS

**Karim Bendhaou**

**Education and Training to Fight  
Counterfeit Drugs in Resource-poor  
Settings**

Merck S.A.R.L | Managing Director,  
North West Africa Group Merck KGaA |  
Tunisia

**Maria Kipele**

**The Education of a Neuro Surgeon  
in Tanzania – Perspectives and  
“Brain Gain”**

University Würzburg | Scholar KAAD |  
Germany

**Bernhard Köhler**

**The Importance of Trilateral Multi-Stake-  
holder Dialogue in Development Policy**

Medical Mission Institute Würzburg |  
Medical Consultant | Germany

**Wilson Mlaki**

**PPPs in Education & Training of  
Non-Academic Pharmaceutical Staff**

Saint Luke Foundation |  
Executive Director | Tanzania

**Elisabeth Shekhalage**

**Challenges in the Education, Training  
and Employment of Non-Academic  
Pharma Staff**

Government of Tanzania |  
Registrar, Pharmacy Council | Tanzania



The session aims at highlighting the contribution of a cross-sector cooperation of different stakeholders in education and training in several areas of the healthcare sector with the aim of strengthening the health sector. The organizers are representatives of faith-based organizations and the research-based pharmaceutical industry.

There is a focus on the education of skilled non-academic pharmaceutical staff in pharmaceutical distribution in Tanzania (pharmaceutical dispensers, assistants and technicians). Dr. Kipele is an example of a young Tanzanian

physician who is a candidate to work everywhere in the world. What are the challenges in her education and work, what are her perspectives? The specific challenges of fighting counterfeit drugs in resource-poor settings is the third area that this session highlights.

In all the addressed issues the cross-sectoral cooperation of multi-stakeholder partnerships (government, civil society and private sector) is the underlying principle. The needs, opportunities and challenges of such cooperations for development policy may be part of the discussion in this session.



Karim  
Bendhaou



George M.  
Kuria



Gertrud  
Casel



Wilson  
Mlaki



Maria  
Kipele



Elisabeth  
Shekhalage



Bernhard  
Köhler

## WS22

ROOM 4 | STRESEMANN

09:00-10:30

OVERFLOW SCREEN 4



**M8Alliance**  
Academic Health Centers, Universities and National Academies

---

### WORKSHOP

## POLIO ERADICATION

CHALLENGES, LESSONS AND LEGACY

---

### HOSTS

M8 Alliance:

**The Graduate Institute Geneva –  
Global Health Center**

### CHAIR

**Stephen Matlin**

The Graduate Institute of International  
and Development Studies | Senior Fellow,  
Global Health Center | Switzerland  
Imperial College London |  
Adjunct Professor | United Kingdom

### SPEAKERS

**Nellie Bristol**

Center for Strategic & International  
Studies (CSIS) | Senior Fellow, Global  
Health Policy Center | United States  
of America

**Ambassador Suraya Dalil**

Permanent Mission of Afghanistan to the  
United Nations Office | Ambassador |  
Switzerland

**Ilona Kickbusch**

The Graduate Institute of International  
and Development Studies | Director,  
Global Health Center | Switzerland

**Matshidiso Rebecca Moeti**

World Health Organization (WHO)  
Regional Office for Africa |  
Regional Director | Botswana

The endgame of polio eradication (final interruption of wild poliovirus transmission is targeted by the end of 2016) has presented technical and financial challenges and also the need to overcome social, political, religious and cultural hurdles in the last disease-endemic countries (Afghanistan and Pakistan).

There are critical issues to be tackled in learning the lessons of this 30-year effort and ensuring that the legacy of polio eradication is captured at both national and global levels.

This session will present the results of a one-year study of the polio endgame lessons and legacy and will provide the opportunity following the presentation of research findings to comment and debate how these can best be used for the benefit of national health systems and global health and the implications for health governance.

The session will include a brief presentation summarising the key study findings and reactions from a distinguished panel (45 min); and a dialogue with the audience (45 min).



Nellie  
Bristol



Stephen  
Matlin



Suraya  
Dalil



Matshidiso Rebecca  
Moeti



Ilona  
Kickbusch

## WS23

ROOM 5 | RATHENAU  
09:00 - 10:30  
OVERFLOW SCREEN 5



### WORKSHOP

---

## CARDIOVASCULAR DISEASES

THE HYPERTENSION PARADIGM

---

### HOSTS

M8 Alliance:  
**Charité – Universitätsmedizin Berlin**

**European Society of Cardiology**  
**German Heart Institute Berlin**

### CHAIR

**Axel Radlach Pries**  
Charité – Universitätsmedizin Berlin |  
Dean | Germany

### SPEAKERS

**Ann Aerts**  
Novartis Foundation | Director |  
Switzerland

**Daniel T. Lackland**  
World Hypertension League | President |  
United States of America

**Stefan M. Schulz**  
University Würzburg | Post-Doc,  
Psychology | Germany

Hypertension is quantitatively the most important risk factor for premature cardiovascular disease, being more common than cigarette smoking, dyslipidemia, and diabetes, which are other major risk factors. Hypertension accounts for an estimated 54 percent of all strokes and 47 percent of all ischemic heart disease events globally. Since hypertension does not evoke direct symptoms and may thus remain unnoticed by the individual patient it has been named the 'silent killer'. Hypertension increases the risk

for a variety of cardiovascular diseases, including stroke, coronary artery disease, heart failure, atrial fibrillation, and peripheral vascular disease with coronary disease in men and stroke in women being typical first cardiovascular events noted after hypertension onset. In view of the evidence that the hypertension incidence and hypertension related mortality rates are rising even in younger people, greater attention must be given to prevention, diagnosis and treatment of this disease.



Ann  
Aerts

Axel Radlach  
Pries



Daniel T.  
Lackland

Stefan M.  
Schulz

## KEY04

PLENARY HALL | WELTSAAAL  
11:00 – 12:30



### KEYNOTE

## TRANSLATIONAL RESEARCH

ADVANCING INNOVATIVE TREATMENT

### HOSTS

**Berlin Institute of Health (BIH)**

M8 Alliance:

**Monash University**

M8 Alliance:

**National University of Singapore (NUS)**

### CHAIR

**Christina Mitchell**

Monash University | Academic Vice-President & Dean, Faculty of Medicine Nursing & Health Sciences | Australia

### SPEAKERS

**Elizabeth Blackburn**

**It is really a Two-Way Street**

Salk Institute for Biological Studies | President | United States of America

**Dario Campana**

**Cell Therapy of Cancer**

National University Cancer Institute | Director, Immunopathology and Cell Therapy | Singapore

**Angelika Eggert**

**Personalized Medicine Approaches in Pediatric Oncology**

Charité – Universitätsmedizin Berlin | Director, Department of Pediatrics, Division of Oncology and Hematology | Germany

**Stephen M. Jane**

**Novel Therapies for the Hemoglobinopathies**

Monash University | Head, Central Clinical School | Australia

Translational research helps turn early-stage innovations into new health products, advancing the innovation to the point where it becomes attractive for further development by the medical industry or healthcare agencies. Although research in academia and in companies produces many new discoveries and inventions that have the potential to improve health, turning those ideas into deliverable products can prove extremely difficult.

This calls for an additional strategy in translational research, securing the translation of results from clinical studies into everyday clinical practice and health decision making, while ensuring that new treatments and research knowledge

actually reach the patients or populations for whom they are intended. This development is a two-way street; basic scientists therefore have to provide clinicians with new tools for use in patients and for assessment of their impact, and clinical researchers need to make novel observations about the nature and progression of disease that often stimulate basic investigations.

Central for this is the effective translation of the new knowledge, mechanisms, and techniques generated by advances in basic science research into new approaches for prevention, diagnosis, and treatment of disease, so that the essential goal of improving health from bench to bedside can be reached.



Elizabeth  
Blackburn



Stephen M.  
Jane



Dario  
Campana



Christina  
Mitchell



Angelika  
Eggert

## WS28

ROOM 5 | RATHENAU  
12:45 – 13:45  
OVERFLOW SCREEN 5



### WORKSHOP

---

## ACTION:SDG – ALL FOR HEALTH EQUITY

INTERSECTORAL ACTIONS TOWARDS SDGS

---

### HOST

**World Health Organization (WHO)**

### CHAIR

**Nicole Valentine**

World Health Organization (WHO) |  
Senior Technical Officer, Department  
of Public Health, Environmental  
and Social Determinants of Health, |  
Switzerland

### SPEAKERS

**Julian Fisher**

THEnet Training for Health Equity |  
Director, Advocacy and Networks |  
Germany

**Ilona Kickbusch**

The Graduate Institute of International  
and Development Studies | Director,  
Global Health Center | Switzerland

**Charlotte Marchandise**

City of Rennes | Deputy Mayor for Health |  
France

**Martina Merten**

Ärzte Zeitung Verlags GmbH |  
Healthcare Journalist | Germany

**Viktoria Sargsyan**

World Vision International |  
Health Learning Hub Lead, Regional  
Health and HIV Unit | United Kingdom

**Michaela Told**

The Graduate Institute of International  
and Development Studies | Executive  
Director, Global Health Programme |  
Switzerland



The World Health Organization (WHO) Social Determinants of Health (SDH) unit is seeking to scale-up globally available e-based information services on the SDH. It is therefore supporting coordination between different e-platform and SDH information services providers, considered as leaders in the field of SDH. Numerous tools developed in previous years by these providers (including WHO) share the principles of the 2030 Sustainable Development Agenda and therefore can be helpful for the accomplishment.

For that purpose Action:SDG SharePoint platform has been under development, able to provide all these and advance (where needed) action-oriented information services on the social determinants of health framed into the context of the

Sustainable Development Goals. It is user-oriented platform, offering a common logic model for action on the SDH to key stakeholders with an influence to people's health and health equity.

The World Health Summit, as a multi-stakeholder conference, is recognized as a great opportunity to present this valuable platform to broader audiences, gain their interest in further collaboration for the action on the SDGs, as well as receiving suggestions for the platform's improvement. With this idea, WHO/SDH Unit is organizing a panel with academic, government and private sector representatives, elaborating their experiences, views and potential contributions framed into the logic model of the Action:SDG platform.



Julian  
Fisher



Martina  
Merten



Ilona  
Kickbusch



Viktoria  
Sargsyan



Charlotte  
Marchandise



Nicole  
Valentine

**PD07**

ROOM 1 | EUROPASAAL  
14:00–15:30  
OVERFLOW SCREEN 1



Federal Ministry  
of Health

## PANEL DISCUSSION

# ANTIMICROBIAL RESISTANCE

INNOVATIONS IN ANTIMICROBIAL RESEARCH AND DRUG DEVELOPMENT

### HOST

**German Federal Ministry of Health  
(BMG)**

### CHAIR

**Lothar Wieler**

Robert Koch Institute | President |  
Germany

### SPEAKERS

**Helge Braun**

Federal Chancellery | Minister of State |  
Germany

**Peter Hammann**

Sanofi-Aventis Deutschland |  
Head, Therapeutic Area Infectious  
Diseases (TA ID) | Germany

**Line Matthiessen-Guyader**

European Commission | Head of Fighting  
Infectious Diseases and Global Epidemics,  
Research and Innovation | Belgium

**Jim O'Neill**

The Review on Antimicrobial Resistance |  
Chairman of the Board | United Kingdom

**Jaqueline Shea**

Aeras | Chief Executive Officer |  
United States of America

**Marc Sprenger**

World Health Organization (WHO) |  
Director, Antimicrobial Resistance  
Secretariat | Switzerland

**Bernd-Alois Tenhagen**

Federal Institute for Risk Assessment (BfR) |  
Private Lecturer, Biological Safety |  
Germany

The increasing development of resistance of pathogenic microorganisms is one of the major challenges in medical care for the next decade. The intensified exchange of knowledge strongly supports the research of pathogens, resistance mechanisms and new drug target and is therefore one prerequisite for developing innovative approaches for antimicrobial treatments.

In this respect, the German Ministry of Health will host an international network conference as a back-to-back event to the World Health Summit 2016 to expand existing networks between international experts. The primary goal of the event is to provide a sustainable basis for a multilateral knowledge transfer between related players, complementing already existing networks.

Focusing on the "one health approach", to which the G7 Health Ministers have committed to in 2015, interdisciplinary experts will discuss the context of uprising resistances, the availability of

antibiotics and the use of antimicrobial drugs in human and veterinary medicine, the role improved tuberculosis vaccines can play in the fight against antimicrobial resistance. Health care scientists from academia and drug industry, agriculture and veterinary experts and scientists as well as regulatory authorities and international organisations will aim for promising approaches and possibilities to overcome hurdles to foster efficiency and transparency in health care, science and the veterinary use of antibiotics. Exchange about the current state of science, e.g. of new diagnostics and vaccines and their impact for veterinary and human medicine, shall result in tangible outcomes e.g. a list of the most threatening microorganisms.

This session will consist of an open discussion following the outcome of the Global Expert Network Conference on innovations in antimicrobial drug research and development, Berlin, 10 October. Active participation of the audience is very welcome.



Helge  
Braun

Jaqueline  
Shea



Peter  
Hammann

Marc  
Sprenger



Line Matthiessen-  
Guyader

Bernd-Alois  
Tenhagen



Jim  
O'Neill

Lothar  
Wieler

## WS24

ROOM 2 | BRANDT  
14:00–15:30  
OVERFLOW SCREEN 2



---

**KU LEUVEN**

---

### WORKSHOP

---

## STRATEGIC PRIORITIES IN R&D FOR GLOBAL HEALTH

---

### HOSTS

**European Commission and the  
Horizon 2020 Scientific Panel for Health**  
**KU Leuven University**

### CHAIR

**Karin R. Sipido**  
University Leuven | Head, Experimental  
Cardiology | Belgium

### SPEAKERS

**Bernhard Fleckenstein**  
Friedrich Alexander University Erlangen-  
Nürnberg | Professor Emeritus, Virology |  
Germany

**Ildiko Horvath**  
National Koranyi Institute for  
Pulmonology | Strategic Director |  
Hungary

**Michael J. Klag**  
Johns Hopkins Bloomberg School  
of Public Health | Dean | United States  
of America

**Tana Wuliji**  
World Health Organization (WHO) |  
Technical Officer, Health Workforce |  
Switzerland

The European Commission's Scientific Panel for Health (SPH) is a science-led expert group based on the provisions of the Horizon 2020 Specific Programme that has been tasked with helping to achieve better health and wellbeing for all. The changing parameters in health and disease prevention (chronic diseases, infectious diseases, mental disorders and an aging population) are expected to decrease the labor force and raise healthcare costs around the globe.

Therefore international discussions on health research priorities are warranted because of the concern about loss of competitiveness and a reduced drive towards innovation. Efforts for setting strategic priorities in R&D for Global Health have to be made because of the transnational dimension of research, with distributed expertise and human

resources, infrastructure, and the need to reach critical mass. To address these concerns, strong input from the international scientific and stakeholders community is needed.

In 2015 the SPH set out its vision on the future of health and biomedical research in a working document that described future challenges and proposed a way forward through intensified cross-border collaboration.

To further build on these recommendations the SPH wishes to connect more directly to the stakeholders in health research through an interactive workshop taking place at the World Health Summit, discussing strategic priorities with representatives from international research organizations.



Bernhard  
Fleckenstein

Karin R.  
Sipido



Ildiko  
Horvath

Tana  
Wuliji



Michael J.  
Klag

## WS025

ROOM 3 | ADENAUER  
14:00–15:30  
OVERFLOW SCREEN 3

---

**DZG** DEUTSCHE ZENTREN  
DER GESUNDHEITSFORSCHUNG

---

### WORKSHOP

---

## DATA WAREHOUSE SYSTEMS AS A BASIS FOR PRECISION MEDICINE

---

### HOST

**German Centers for Health Research  
(DZG)**

### CHAIR

**Werner Seeger**

German Center for Lung Research (DZL) |  
Chairman of the Board | Germany  
University Hospital Giessen |  
Medical Director | Germany

### SPEAKERS

**Erwin Paul Böttinger**

**Berlin Health Data Platform for Systems  
Medicine and Digital Health**  
Berlin Institute of Health (BIH) |  
Chairman of the Board | Germany

**Roland Eils**

**Data Warehouse Systems at the German  
Centers for Health Research (DZG)**  
German Cancer Research Center DKFZ |  
Head, Theoretical Bioinformatics |  
Germany

**Hans-Ulrich Prokosch**

**Reforming Medical Informatics in  
Germany – Basis for Precision Medicine**  
University Hospital Erlangen |  
Chief Information Officer | Germany  
FAU Erlangen-Nürnberg |  
Chair of Medical Informatics | Germany

**Fabian Theis**

**From Data Storage to Data Mining  
in Biomedicine**  
Helmholtz Zentrum Munich | Director,  
Institute of Computational Biology |  
Germany  
TU Munich | Associate Professor,  
Mathematical Modelling of Biological  
Systems | Germany

### DISCUSSANTS

**Thomas Eschenhagen**

University Hospital Hamburg-Eppendorf |  
Director, Experimental Pharmacology  
and Toxicology | Germany

**Martin Hrabé de Angelis**

Helmholtz Zentrum Munich | Director,  
German Center for Diabetes Research |  
Germany

**Marcus Mall**

German Center for Lung Research (DZL) |  
Director | Germany

**Sven Maurmann**

German Center for Neurodegenerative  
Diseases (DZNE) | Director, IT |  
Germany

**Matthias Nauck**

University Medicine Greifswald |  
Director, Clinical Chemistry and  
Laboratory Medicine | Germany

**Jörg Janne Vehreschild**

German Center for Infection Research  
(DZIF) | Coordinator, Biobank | Germany

Quantity and quality of health data is growing rapidly. In order to utilize data warehouses for biomedical research and patient care, open access and interchange of data are mandatory. This is particularly true for the German Centers for Health Research (DZG), devoted to translational research with the common goal to combat the leading diseases causing modern era morbidity and mortality.

Distinguished key note speakers will introduce the audience to the hot topics of the field: volume/velocity/variety challenges, quality management and reproducibility of data in the field of data warehouses. Conclusively, implications for cooperative research initiatives will be discussed in order to achieve important progress towards precision medicine.

The six DZG (German Centers for Cardiovascular Research, Diabetes Research, Infection Research, Lung Research, Neurodegenerative Diseases, and German Consortium for Translational Cancer Research) are funded by the German Federal Ministry of Education and Research (BMBF) and the ministries of the German Federal States of the partner sites. The DZG are structured as long-term partnerships between universities with university hospitals and non-university research institutions and throughout Germany, focusing on the prevention, diagnosis and treatment of widespread diseases.



Erwin Paul  
Böttinger



Werner  
Seeger



Roland  
Eils



Fabian  
Theis



Hans-Ulrich  
Prokosch

## WS26

ROOM 4 | STRESEMANN  
14:00–15:30  
OVERFLOW SCREEN 4

#WomeninGH



### WORKSHOP

## GENDER RESPONSIVE GOVERNANCE

A KEY PILLAR FOR WOMEN'S HEALTH AND EMPOWERMENT

### HOSTS

**Women in Global Health**

**USAID**

### CHAIRS

**Roopa Dhatt**

Women in Global Health | Co-Founder  
and Director | United States of America

**Sally Theobald**

Liverpool School of Tropical Medicine |  
Chair, Social Science and International  
Health | United Kingdom

### SPEAKERS

**Lourdes de la Peza**

**How Can Women's Leadership Capacity  
be Developed?**

Management Science for Health (MSH) |  
Principal Technical Advisor, Management  
and Leadership | United States of America

**Temitayo Ifafore-Calfee**

**(Wo)man in the Mirror: 5 Strategies to  
Educate Yourself About Reducing  
Gender Discrimination and Promoting  
Gender Equality in the Health Workplace**

USAID/PHI | Technical Advisor, Health  
Workforce | United States of America

**Désirée Lichtenstein**

**How do we Work Gender Equally  
for Gender Equality**

Women in Global Health | Co-Founder |  
Sweden

**Niyati Shah**

**HOW Do We Integrate Gender into  
Programming: Operationalizing =  
Getting to Equal**

USAID | Senior Gender Advisor, Global  
Health Bureau | United States of America



Women play a vital role in the advancement of global health, yet men still remain the majority holders of leadership positions. Leadership is key for improving performance, strengthening workforce capacity, enhancing connection enhancing connections with target populations, and increasing the ability to respond effectively to change and thus key to achieving sustainable development goals (SDGs) targets.

The Women Leaders in Global Health Initiative, a joint initiative of Women in Global Health and the Global Health Council, envisions a world where women are represented in equal numbers to men at the highest levels of decision making and visibility.

The initiative strives to address the individual, institutional and political challenges that impede women's positioning as leaders in global health through strategic advocacy, networking, mentorship and capacity building.



Lourdes  
de la Peza



Désirée  
Lichtenstein



Roopa  
Dhatt



Niyati  
Shah



Temitayo  
Ifafore-Calfee



Sally  
Theobald

## WS27

ROOM 5 | RATHENAU  
14:00 – 15:30  
OVERFLOW SCREEN 5



INSTITUT DE HAUTES  
ETUDES INTERNATIONALES  
ET DU DEVELOPPEMENT  
GRADUATE INSTITUTE  
OF INTERNATIONAL AND  
DEVELOPMENT STUDIES



Think Tank Initiative



### WORKSHOP

## IMPLEMENTING THE HEALTH-RELATED SDGS

BRIDGING THE GLOBAL-NATIONAL GAP

### HOSTS

M8 Alliance:  
**The Graduate Institute Geneva –  
Global Health Center**

**Think Tank Initiative Canada (TTI)**

### CHAIRS

**Ilona Kickbusch**  
The Graduate Institute of International  
and Development Studies | Director,  
Global Health Center | Switzerland

**Peter Taylor**  
International Development Research  
Centre (IDRC) | Associate Director,  
Think Tank Initiatives | Canada

### SPEAKERS

**Johanna Hanefeld**  
**Ensuring Intersectoral Action to  
Achieve the SDGs, the Trade and Health  
Agenda – What Role for Think Tanks  
and Universities?**

London School of Hygiene & Tropical  
Medicine | Head of Anthropology,  
Politics and Policy Group, Global Health  
and Development | United Kingdom

### Ashish K.Jha

**Translating the Global to the National:  
What Accountability Frameworks Does  
the Global Community Have or Need  
to Create to Accelerate SDG implemen-  
tation?**

Harvard T.H.Chan School of Public Health |  
Director, Harvard Global Health Institute |  
United States of America

### Christian Kroll

**The SDG Index and Major Regional  
Challenges to SDG Implementation –  
How can Think Tanks and Academic  
Institutions Help Fill these Gaps?**  
Bertelsmann Foundation and SDSN |  
Scientific Director, SDG Index | Germany

### Joy Phumaphi

**Setting Priorities and Ensuring  
Accountability for SDG Implementation  
at the National Level – What Role for  
Civil Society?**  
African Leaders Malaria Alliance (ALMA) |  
Executive Secretary | Tanzania

The Sustainable Development Goals (SDGs) set a global agenda for development but what is the added value of such an agenda for each country? How can a commitment be gained at national level to implement the SDGs, especially those related to health, and what are the means available at global level to exercise accountability? What is the role think tanks and academic institutions can play to bridge the gap between global and national?

This workshop will frame the debate around the available accountability mechanisms which could and should accelerate the implementation of the health-related SDGs. Given the great number of goals and targets which impact on health, accountability may work better at national level once priorities are set and may be far more challenging at global level: the implementation of the health-related SDGs requires to recognize them as a global responsibility and requires the application of a global public goods lens.



Johanna  
Hanefeld



Christian  
Kroll



Ashish K.  
Jha



Joy  
Phumaphi



Ilona  
Kickbusch



Peter  
Taylor

## KEY05

PLENARY HALL | WELTSAAAL  
16:00–18:00



### KEYNOTE

## WOMEN, EMPOWERMENT AND HEALTH: EQUITY AND AGENCY

CLOSING CEREMONY

### HOSTS

M8 Alliance:  
**Clinical Research Institute Montreal (IRCM)**

M8 Alliance:  
**The Graduate Institute Geneva – Global Health Center**

M8 Alliance:  
**University Hospital Geneva**

M8 Alliance:  
**University of Geneva**

M8 Alliance:  
**University of Montreal**

### CHAIR

**Hélène Boisjoly**  
University of Montreal | Dean,  
Faculty of Medicine, | Canada

### SPEAKERS

**Karen Linehan**  
Sanofi | Executive Vice-President,  
Legal Affairs and General Counsel |  
France

**Matshidiso Rebecca Moeti**  
WHO Regional Office for Africa |  
Regional Director | Botswana

**Heidemarie Wieczorek-Zeul**  
Friends of the Global Fund Europe |  
Vice-President | France

In recent decades, women's empowerment and equity have been increasingly recognized as crucial components of efforts to achieve a myriad of health and development objectives. The empowerment and autonomy of women, and improvements in their political, social, economic and health status, are therefore becoming accepted as highly important ends in themselves.

Disparities in educational access, limited economic opportunities, and low relative status of women all shape women's ability to control their health and their futures. Improving women's agency is therefore essential not only for success-

ful family planning and reproductive health, but also for improving development, and global organizations are increasingly taking note.

In addition, they are seen as essential for the achievement of sustainable development. Greater equality for girls in regard to health, nutrition and education is the first step in ensuring that women realize their full potential and become equal partners in development. Access to health and education is one of the most important means of empowering women with the knowledge, skills and self-confidence necessary to participate fully in the development process.



Hélène  
Boisjoly



Matshidiso Rebecca  
Moeti



Karen  
Linehan



Heidemarie  
Wieczorek-Zeul




---

## GENERAL INFORMATION

The World Health Summit will be taking place at the Federal Foreign Office. Please be advised that due to security reasons, all delegates will be subject to a security check including a passport identification confirmation.

Please be aware: You will not be able to enter the Summit venue, if you are not able to present your passport or ID-card. Unfortunately, this procedure may produce a slight delay for entrance into the building. We therefore kindly ask you to refrain from bringing your luggage to the Summit venue, as this will slow down the security check process.





## HOW TO GET TO THE SUMMIT VENUE

### Federal Foreign Office (Auswärtiges Amt)

Entrance: Unterwasserstraße 10

#### Arriving by public transportation:

- From the underground station “Spittelmarkt” (Line U2): Walk along the left side of the water canal. Shortly after the antique draw bridge, the Summit entrance will be on your left.
- From the underground station “Hausvogteiplatz” (Line U2): Turn into “Oberwallstraße”, turn right onto Werderscher Markt, go past the Auswärtiges Amt and turn right again directly afterwards. Continue along the side of the building to the Summit entrance.

#### Arriving by air:

- From Tegel Airport: Take the bus line X9 to “Ernst-Reuter-Platz”, connect to the underground line U2 in the direction of Pankow and exit at “Spittelmarkt”.
- From Schönefeld Airport: Take the S-Bahn (train) to “Friedrichstraße”, connect to bus line 147 in the direction of Ostbahnhof and exit at “Spittelmarkt”. Alternatively take the S-Bahn line S9 to “Schönhauser Allee”, connect to the line U2 (underground train) in the direction of Ruhleben and exit at “Spittelmarkt”.
- Transfer time by taxi is approximately 25 minutes from Tegel Airport and 50–60 minutes from Schönefeld Airport.

#### Arriving by train:

From Berlin Hauptbahnhof (main station): Take bus line 147 in the direction of U Märkisches Museum and exit at “Spittelmarkt”. Please check the area-map on page 123 for further orientation.



Hotel Name	Address	Distance to Summit Venue	Category	Single Room	Double Room
1 Westin Grand Berlin	Friedrichstraße 158–164	0.8 km	5*	€ 189.00	€ 209.00
2 Sofitel Berlin	Charlottenstraße 50	0.6 km	5*	€ 215.00	
3 Arcotel John F.	Werderscher Markt 11	0.2 km	4*	€ 129.00	€ 159.00
4 Cosmo Hotel Berlin Mitte	Spittelmarkt 13	0.4 km	4*	€ 114.00	€ 124.00
5 Courtyard by Marriott Berlin	Axel-Springer-Straße 55	0.6 km	4*	€ 135.00	€ 145.00
6 Motel One Spittelmarkt	Leipziger Straße 50	0.4 km	2*	€ 76.50	€ 99.00
7 Radisson Blu	Karl-Liebknecht-Straße 3	0.9 km	5*	€ 149.00	€ 199.00

**VENUE:**  
Federal Foreign Office  
Werderscher Markt 1  
10117 Berlin

**ENTRANCE:**  
Unterwasserstraße 10

**CONTACT:**  
Email: [contact@worldhealthsummit.org](mailto:contact@worldhealthsummit.org)





## BERLIN – A METROPOLIS FOR SCIENCE

Today, Berlin is not only Germany's largest location for science and IT start-ups; the city can also look back at a 300-year tradition in medical research. More than a dozen Nobel Prize winners have worked here, including Rudolf Virchow and Robert Koch. One of its most famous medical institutions is the renowned Charité, Europe's largest university hospital and one of Germany's

For more information  
about Berlin, go to  
[convention.visitBerlin.com](http://convention.visitBerlin.com)



leading hospitals. The doctors and scientists at the Charité are well recognised in international medicine, and co-operate with foreign research institutes like the Johns Hopkins Bloomberg School of Public Health in Baltimore, USA.

Berlin has become one of Europe's centres for start-ups and even major international players like Google are setting up in Berlin. The scene is well-linked with other cities like New York, Washington and San Francisco and also maintains strong links with Tel Aviv, the IT centre of Israel.

This environment makes Berlin a popular international destination for meetings and conventions: With 195 events hosted last year, the city is the top location choice for gatherings of international associations, as revealed in latest statistics by the "International Congress & Convention Association" (ICCA). It is the first time that Berlin is at the top of the list. In the last years, the German capital has also positioned itself as a location for events in science and medicine: fourteen per cent of the approximately 63,000 meetings, conventions and events held in the first half of 2016 were in the fields of medicine, science and research. International conferences such as the World Health Summit show that the German capital has been able to consolidate its strong position as a destination for medical events.

## BERLIN – CAPITAL OF CULTURE

Along with scientific conferences, Berlin also provides varied cultural experiences. From ancient art by the Old Masters to avant-garde design, from classical opera to musicals to pop concerts, Berlin's cultural calendar leaves nothing to be desired. Visitors to the capital can choose from around 1,500 events a day.

Culture and art enthusiasts can also admire new styles and prominent works from all eras every day in Berlin's over 180 museums and approximately 440 galleries. The city's best known museums include the five buildings at Museum Island (Museumsinsel), which is in the historic centre. All buildings display valuable artistic treasures from 3000 years of human history, e.g. the famous bust of Nefertiti in the New Museum, while the New National Gallery and Martin-Gropius-Bau present contemporary art.

Berlin is the world's only city to have three opera houses: the Berlin State Opera (Berliner Staatsoper), the Deutsche Oper and the Komische Oper. Classical music lovers can choose from a repertoire of famous works, such as Mozart's Don Giovanni, or new and experimental operas. Apart from these opera houses, the city's eight large orchestras, including the world famous Berlin Philharmonic conducted by Sir Simon Rattle, also make for high-class musical enjoyment.



Among the cultural highlights this year is “El Siglo de Oro: Spanish Painting and Sculpture of the 17<sup>th</sup> Century” at the Gemäldegalerie. The exhibition is an opportunity to become familiar with one of the most important periods of European cultural history.

Every autumn, two lighting festivals “Berlin leuchtet” and the “Festival of Lights” let the German capital shine in new, brighter colours. For more than two weeks, well-known landmarks such as the Brandenburg Gate, the TV Tower, and Berlin Cathedral become impressive canvases for the lighting artists.

For more events, visit  
[events.visitBerlin.com](https://www.visitberlin.com)

## THE HOUSE ON WERDERSCHER MARKT

Since its return to Berlin in 1999, the Federal Foreign Office has been located in the “Haus am Werderscher Markt” (House on Werderscher Markt). After the former Tempelhof airport terminal, this is the second largest building in Berlin with its 550,000 m<sup>3</sup> of enclosed space. Like many other buildings in Germany’s capital, the building and surrounding area is a Berlin icon which has witnessed Germany’s eventful and turbulent history.

### 1690

A court building was constructed to the south west of Werderscher Markt.

### 1765

The “Royal Savings and Loan Bank”, (Königliche Giro- und Lehnbank) founded by Frederick the Great, moved into the building. Thanks to considerable economic growth and development in Prussia the following decades saw a number of modifications and extensions to the building.

### 1846

First as the “Prussian Bank” (Preußische Bank) and then starting in 1876 as the “Reichsbank” (Reichsbank) the building continued to grow until 1903 when it took up the entire block between Jäger-, Kur-, Oberwall- and Kleiner Jägerstraße.

### In 1913

Even before the First World War, the premises of the “Reichsbank” were too small. In 1913 the bank began to buy land in the surrounding area.

### 1932

Plans were formulated for a new building close by, and two years later the foundation stone was laid.

### 1940

After six years of construction, the building was completed and the “Reichsbank” moved in, at which time its main task had changed to primarily funding the war. The new bank building was located on the opposite side of the road from Werderscher Markt, but a bridge was built between the two which provided access to the first floor of each building.



**1945**

During the Second World War the “Reichsbank” extension suffered severe damage. After the initial repairs were carried out, the “Berlin City Office” (Stadtkontor) took over several rooms in the house.

**1949**

In autumn, the Ministry of Finance of the newly-founded German Democratic Republic (GDR) took over the building.

**1959**

In summer, the Central Committee of the SED (Socialist Unity Party) moved in. With this move, the building on Werderscher Markt came to be at the center of political power in the GDR.

**1989**

In the course of the political demise of the GDR, the central committee of the SED was dissolved on December 8.

**1990**

In the first few weeks of the year, the house on Werderscher Markt was vacated. A little later the building was renamed the “House of Parliamentarians” (Haus der Parlamentarier). This new name came about on March 18 when the members had a free election to select their new “People’s Chamber” (Volkskammer), which would now occupy the space.

**1999**

Thanks in part to the design by Berlin architects Thomas Müller and Ivan Reimann, a new building was added on Werderscher Markt to accommodate the Federal Foreign Office (Auswärtiges Amt). The two buildings are connected by a shared courtyard. A photovoltaic system on the roof of the older building with a connection to the newer building’s heating network provides an environmentally-friendly energy supply.

---

## INTERIOR VIEWS – THE FEDERAL FOREIGN OFFICE

---

The old and new buildings of the Federal Foreign Office provide 62,500 m<sup>2</sup> office space for more than 2,000 employees. In addition, the two buildings house several conference halls, the political archives, medical and social services, a canteen, as well as the library.

The nerve center of the Federal Foreign Office is the old building erected in 1934, which served as the Reichsbank from 1934 to 1938. In 1959, the building became the headquarters of the Socialist Unity Party of Germany, the ruling party in the GDR. The Central Committee and the Politbüro met there. In 1995 it was decided to locate the Federal Foreign Office in this building and to add a new building on Werderscher Markt.



The new building was designed by the architects Thomas Müller and Ivan Reimann and constructed from 1997 to 1999. The transparent facade of glass and travertine stone invites visitors to enter the atrium and its visitor center, which is open to the public. All in all, the new building with its three partially open inner courts recalls the link between the old building and the Spree Canal, Schlossplatz and Werderscher Markt.

The architect commissioned to refurbish and alter the old building, Hans Kollhoff, faced a three-fold task. Firstly, he had to make it evident that Germany's new foreign policy had nothing to do with the policies pursued in this building during the two German dictatorships. On the other hand, however, he could not simply wipe out all traces of the past. What is more, the building had to be redesigned to meet the Federal Foreign Office's spatial and functional requirements.

To this end, Hans Kollhoff developed the three-layer concept. The first layer highlights the modern aspects of the old building, which should not be transformed solely as an embodiment of National Socialist architecture. The second layer preserves in an exemplary fashion the building's design during the GDR era. For the third layer, a color concept which developed in collaboration with the artist Gerhard Merz whose large monochrome surfaces lend the building a modern flair.

---

## THE WELTSAAL (WORLD HALL)

---

At the heart of the old building on the first floor lies a large conference center, almost 900m<sup>2</sup> in size. The former Reichbank Hall 1 was considerably altered for use by the SED leadership as a conference hall. During this process the luminous ceiling was covered over. When the Federal Foreign Office was refurbished, however, it was uncovered, as was the original wood paneling in the central part of the ceiling.

The entire room can be divided by a 9 meter high and 16 meter wide mobile partition. It was designed by Gerhard Merz as part of the three layer concept. The surface consists of numerous small squares in various colors. This deviation here in the Weltsaal from the monochrome surface principle applied in the rest of the Old Building was intended to highlight the world's cultural diversity.

The lower part of the walls and the doors to the lounges are clad in German cherrywood. The interpretation booths, screened off from the hall, are situated on top. This screen is divided into three monochrome sections, each of which has a slim aluminum frame. The lower sections consist of black glass, the larger middle sections of a white screen, while the upper sections are mirrors.





## World Health Summit 2015

Hermann  
Grohe



---

**ACCESS TO THE VENUE/SECURITY**

To enter the World Health Summit venue (Federal Foreign Office), participants are required to present a valid identity card/passport or a similar personal identification document (photo included). Please be advised that due to security reasons, all participants will be subject to a security check including a passport identification confirmation. This procedure may cause a slight delay for entrance into the building. We therefore kindly ask you to refrain from bringing your luggage to the venue, as this will slow down the security check process.

---

**AVAILABILITY**

Please note that the capacity of the venue and of single session rooms is limited. If the maximum number of participants is reached, the organizers reserve the right to refuse access.

---

**BERLIN WELCOMECARD**

The Berlin WelcomeCard enables free travelling with all public transport services, discounts of at least 25% and up to 50% at around 200 participating partners, and a travel guide with various tour suggestions and insider tips. You can order your ticket at [www.berlin-welcomecard.de/en](http://www.berlin-welcomecard.de/en)

---

**CLOAKROOM**

A cloakroom will be open in the back of the venue (next to the “Weltsaal”) during the registration opening times.

---

**COFFEE BREAKS**

Refreshments will be served during the coffee breaks.

---

**CURRENCY**

The currency used in Berlin is the Euro (€ or EUR). Automated teller machines (ATMs), are located everywhere in Berlin and they accept most main credit cards such as Visa, Mastercard and American Express.

---

**CASH POINT/ATM**

BBBank eG Berlin  
Hausvogteiplatz 3-4  
10117 Berlin

---

**EMERGENCY NUMBERS**

Fire:                112  
Ambulance:    112  
Police:            110

---

## FILMING AND TAKING PICTURES

---

The organizer will provide a broad spectrum of pictures and other graphical material for the representation of all World Health Summit events. These files will be made available at [www.worldhealthsummit.org](http://www.worldhealthsummit.org).

## HOMEPAGE

---

For up-to-date information regarding the World Health Summit, please visit [www.worldhealthsummit.org](http://www.worldhealthsummit.org).

## INSURANCE AND LIABILITY

---

The organizers cannot accept liability for personal injury, loss of or damage to belongings of participants, either during or as a result of the Summit. Please check the validity of your own insurance. Attendees are advised to arrange their own adequate travel and medical insurance for medical treatment, accidents, cancellation of bookings etc. No responsibility will be accepted by the World Health Summit organizers.

## INTERNET/WIRELESS LAN

---

Complimentary Wi-Fi will be available within the venue:

Name: WorldHealthSummit

Password: #WHS2016

## LANGUAGE

---

The official World Health Summit language is English. There will be no simultaneous translation.

## LUNCHES

---

Lunches will be available during the lunch breaks.

## MEDIA

---

Media representatives have access to all official sessions of the World Health Summit. Prior accreditation is required via [www.worldhealthsummit.org/press-media/accreditation](http://www.worldhealthsummit.org/press-media/accreditation).

## MOBILE PHONES

---

As a courtesy to speakers and other attendees, we kindly request that all mobile phones and similar devices will be turned to silent mode before entering a session.

## NAME BADGE

---

A badge is required for admittance to all World Health Summit sessions and events. Each participant is asked to present the badge in order to gain access to the Summit.

---

### PEOPLE WITH DISABILITIES

The venue is accessible to participants with disabilities. Please contact the Secretariat for assistance: Phone: +49 30 49855031 or [contact@worldhealthsummit.org](mailto:contact@worldhealthsummit.org)

---

### LOST AND FOUND

Lost items can be collected at the registration desk during the Summit. Any objects found during the event and not claimed will remain at the venue.

---

### LIVE-STREAM/WEBCASTS

All sessions in the “Weltsaal” and “Europasaal” will be available as live-stream at [www.worldhealthsummit.org](http://www.worldhealthsummit.org). Recorded webcasts will be available online after the event.

---

### OVERFLOW

To serve the interests of all participants, Panel Discussions and Workshops will be available as live broadcasts on-site. Room 1 (“Europasaal”) will be broadcasted on screens in the “Europa-Foyer”, Workshop rooms 2–5 to screens 2–5 inside the “Weltsaal”.

---

### PARKING

Please note that there are no public parking facilities at the venue.

---

### PROGRAM CHANGES

The organizers cannot assume liability for any changes in the program due to external or unforeseen circumstances. Please check the website for regular updates. The organizers reserve the right to cancel, postpone, relocate or change any of the sessions.

---

### POSTERS

A poster exhibition will be located at the poster area in front of Workshop rooms 2–5.

---

### PUBLIC TRANSPORTATION

Berlin's public transport provides safe and comfortable rides to almost all destinations in the city. Tickets can be purchased directly at most train stations and in all busses.

#### Fees:

Short Trip 1,70 € (max. 3 stations, one way only)

Single Trip AB 2,70 € (one way only)

Single Trip BC 3,00 € (one way only)

Single Trip ABC 3,30 € (one way only)

Day Ticket ABC 7,60 € (all directions)

(AB, BC, ABC are indicating the travel zone.)

Detailed information regarding public transportation is available at [www.bvg.de](http://www.bvg.de)

REGISTRATION

The registration desk is open during the following times:

Sunday, October 09, 2016	08:00 – 22:00
Monday, October 10, 2016	08:00 – 19:00
Tuesday, October 11, 2016	08:00 – 19:00

SMOKING POLICY

It is forbidden to smoke in any part of the World Health Summit venue.

SPEAKER CENTER

All speakers and presenters must report to the Speaker Center, located at the “Europasaal”, at least two hours prior to their presentation in order to check and upload their presentation. Please provide the data on a USB Memory Stick or a CD-ROM. Please note that you cannot run the presentation from your personal laptop in the session room. Video support is at the sole responsibility of the speaker.

The Speaker Center is open during the following times:

Sunday, October 09, 2016	08:00 – 18:00
Monday, October 10, 2016	08:00 – 18:00
Tuesday, October 11, 2016	08:00 – 18:00

TAXIS

All official taxis are colored off-white with a yellow taxi sign on the roof. The meter starts at a set minimum price.

Major Taxi Hotlines:	
Taxi Berlin	+49 30 202020
Taxi Würfelfunk	+49 30 210101
Taxi Funk	+49 30 443322

If there is no taxi available, please ask the registration desk staff for assistance.

---

**MEDIA INFORMATION**

---

**Media Registrations**

Media Registrations are available free of charge to journalists (pending proof of affiliation). Prior to the Summit, please establish your accreditation online via [www.worldhealthsummit.org/press-media/accreditation](http://www.worldhealthsummit.org/press-media/accreditation).

During the Summit, please contact the media accreditation counter at the registration desk.

**PRESS CONTACT**

Tobias Gerber, Daniela Levy  
[tobias.gerber@charite.de](mailto:tobias.gerber@charite.de)  
[daniela.levy@charite.de](mailto:daniela.levy@charite.de)  
Tel.: +49 30 450 572 114

**PRESS CONFERENCE**

Date: Sunday, October 9, 15:15 – 16:00  
Room: Brandt

**Media Access**

Media has access to all official sessions of the World Health Summit.

**Media Office**

Location: Room “Europasaal”

Sunday, October 09, 2016	09:00 – 20:00
Monday, October 10, 2016	08:30 – 17:30
Tuesday, October 11, 2016	08:30 – 17:30

It is possible to arrange interviews with our speakers in a designated interview-area.



Partner and Co-Host



Federal Foreign Office

### WHS Foundation GmbH

c/o Charité –  
Universitätsmedizin Berlin  
Charitéplatz 1  
10117 Berlin, Germany

### WHS Presidents

Antoine Flahault  
Detlev Ganten

### Managing Directors

Jörg Heldmann  
[joerg.heldmann@charite.de](mailto:joerg.heldmann@charite.de)  
Tel.: +49 30 450 572 118  
Fax: +49 30 450 517 911

Alexander Hewer  
[alexander.hewer@charite.de](mailto:alexander.hewer@charite.de)

### Program Director

Julian Kickbusch  
[julian.kickbusch@charite.de](mailto:julian.kickbusch@charite.de)  
Tel.: +49 30 450 572 102  
Fax: +49 30 450 517 911

### Press & Public

#### Relations Director

Tobias Gerber  
[tobias.gerber@charite.de](mailto:tobias.gerber@charite.de)  
Tel.: +49 30 450 572 114  
Fax: +49 30 450 517 911

### Strategic Communications

Daniela Levy  
[daniela.levy@charite.de](mailto:daniela.levy@charite.de)  
Tel.: +49 30 450 572 114  
Fax: +49 30 450 517 911

### Strategic Development

Cara Pries  
[cara.pries@charite.de](mailto:cara.pries@charite.de)

### Secretariat

Pascale Schulte  
[pascale.schulte@charite.de](mailto:pascale.schulte@charite.de)

### Conference Manager/Office Assistant

Sarah-Maria Riedel  
[sarah-maria.riedel@charite.de](mailto:sarah-maria.riedel@charite.de)  
Tel: +49 30 450 572 219  
Fax: +49 30 450 517 911

### PA to the Managing Director

Petra Neitzel  
[petra.neitzel@charite.de](mailto:petra.neitzel@charite.de)  
Tel: +49 30 450 572 219  
Fax: +49 30 450 517 911

### Organizing Secretariat

Agentur WOK GmbH  
Palisadenstraße 48  
10243 Berlin

### Project Manager

Julia Egloff

### Registration Department

Felix Heller, Anna Blattner



---

## KEYNOTE SPEAKERS AND CHAIRS

**TEDROS ADHANOM GHEBREYESUS**

Dr. Adhanom Ghebreyesus was appointed Minister of Foreign Affairs in 2012. He is an internationally renowned malaria researcher who joined the Ministry of Health in 1986. As Minister of Health, he initiated health reforms that improved access to health services especially for women and children.

**FIONA ADSHEAD**

Dr. Fiona Adshead is Bupa's Chief Wellbeing and Public Health Officer, and is responsible for the clinical leadership of partnerships, prevention and health promotion. She previously was Director of Chronic Disease and Health Promotion at the World Health Organization.

**ANN AERTS**

Dr. Ann Aerts has been Head of the Novartis Foundation since January 2013, where she has played a key role in devising new policy recommendations. In July 2014, she was nominated by PharmaVOICE as one of the 100 Most Inspiring People in the life science industry.

**CHRISTINA RÅNGE-MARK ÅKERMAN**

Dr. Christina Rånge-Mark Åkerman is President of the International Consortium for Health Outcomes Measurement (ICHOM), a non-profit organization with the purpose to transform health care systems worldwide by measuring and reporting patient outcomes in a standardized way.

**JUTTA ALLMENDINGER**

Prof. Jutta Allmendinger is President of the Berlin Social Science Center (WZB) and Professor of educational sociology and labor market research at Humboldt University Berlin. She has held both positions since 2007.

**YUKIYA AMANO**

Dr. Yukiya Amano is Director-General of the International Atomic Energy Agency (IAEA), assuming office in 2009. He was endorsed by the IAEA General Conference for a second term as Director-General on 16 September 2013.



**ROSALINDA BALDOZ**

Rosalinda Dimapilis-Baldoz is the former Secretary of Labor and Employment and a Commissioned Officer in the Reserved Force of the Philippine Army with the rank of Lieutenant Colonel. A Lawyer by training and holder of the Master Degree on National Security Administration.

**JANIS BERNAT**

Janis Bernat is currently Associate Director for the policy and technical work in the area of biotherapeutic and biosimilar medicines and leads the organization's regulatory team. Prior to joining IFPMA, she worked for a US-based multi-national food company in quality assurance and regulatory compliance.

**ALAIN BERSET**

Dr. Alain Berset is Federal Councilor and Head of the Federal Department of Home Affairs FDHA since 2012. He was President of the Council of States from 2008-2009 and Vice-President of the parliamentary Social Democratic Group from 2005-2011.

**ELIZABETH H. BLACKBURN**

Prof. Elizabeth H. Blackburn, President of Salk Institute for Biological Studies, is a leader in the area of telomere and telomerase research. She won the Nobel Prize in Physiology or Medicine in 2009 for discovering the molecular nature of telomeres.

**HÉLÈNE BOISJOLY**

Prof. Hélène Boisjoly is appointed Dean of Medicine at University of Montreal since June 2011. She is the first woman to hold the position of Dean of a Faculty of Medicine at both the University of Montreal (UdeM) and in the province of Québec.

**ERWIN P. BÖTTINGER**

Prof. Erwin P. Böttinger currently serves as Chief Executive Officer of the Berlin Institute of Health and Professor for Personalized Medicine at Charité – Universitätsmedizin Berlin. He is the PI of Mount Sinai's landmark BioMe hospital-based Biobank where electronic health records for over 30,000+ patients can be linked with their genomic and molecular marker datasets.

**HELGE BRAUN**

Dr. Helge Braun is Minister of State for the German Chancellor since December 2013. Prior to this appointment, he was parliamentary Minister of State for the Federal Ministry of Education and Research (2009-2013). He is Member of the German Bundestag since 2009.

**CHRISTIAN BRÉCHOT**

Prof. Christian Bréchet has been appointed President of Institut Pasteur in 2013. From 2001 to 2007 Christian Bréchet was General-Director of Inserm.

**DARIO CAMPANA**

Prof. Dario Campana is Director of the Immunopathology and Cell Therapy Unit at National University Cancer Institute Singapore. A hematologist with laboratory training in immunology, his translational research aims at developing more effective and less toxic cancer therapies.

**ADALBERTO CAMPOS FERNANDES**

Dr. Campos Fernandes is the current Minister of Health in Portugal. He is also Professor at the National School of Public Health, at Universidade Nova de Lisboa, where he teaches and coordinates several university institutions in management and health administration.

**ANTHONY CAPON**

Prof. Capon is the Director for the International Institute for Global Health at the United Nations University. He is a public health physician and an authority on environmental health and health promotion. He was the founding convener of the Climate Change Adaptation Research Network for Human Health in Australia.

**SARBANI CHAKRABORTY**

Dr. Sarbani Chakraborty is Head of Global Health Policy in the Department of Government Affairs and Policy. She works closely with the general medicine section of Merck that focuses on health solutions for diabetes, CVD and thyroid disorders. She lectures on Global Health at the Center for International Health, Munich University.

**EMMANUELLE CHARPENTIER**

Prof. Emmanuelle Charpentier currently holds position as Director at the Max Planck Institute for Infection Biology in Berlin. Following research positions in New York, at The Rockefeller University, and in New York and Memphis, she returned to Europe in 2002 and established a research group at the Max F. Perutz Laboratories, University of Vienna.

**OLEG CHESTNOV**

Dr. Oleg Chestnov was appointed Assistant Director-General for Noncommunicable Diseases and Mental Health at WHO in February 2012. Prior to that, Dr. Chestnov was Deputy-Director for International Relations at the Ministry of Health and Social Development of the Russian Federation, a post he occupied from 2005.

**AGNÈS COUFFINHAL**

Dr. Agnès Couffinhal is a Senior Economist at the OECD, specialized in the analysis of health systems and policies. Her current work focuses on ineffective care and waste through the preparation of a background report to a 2017 meeting of OECD Health Ministers.

**YVES DACCORD**

Dr. Yves Daccord holds position as Director-General of the ICRC since 2010, with a prior appointment as Director of Communications since 2002. As a former journalist, he joined the ICRC in 1992 and worked in Israel and the occupied and autonomous territories, Sudan, Yemen, the northern Caucasus and Georgia.

**ANDREW DANIELS**

Andrew Daniels is currently Head of the Anti-Bribery and Corruption Centre of Excellence at GlaxoSmithKline PLC, a science-led global healthcare company. He started his career at the aerospace, defence and security company BAE Systems.

**PAUL DECLERCK**

Prof. Declerck is Dean of the Faculty of Pharmaceutical Sciences of the KU Leuven and President of the International Society for Fibrinolysis and Proteolysis. He is Research Director of the Laboratory for Therapeutic and Diagnostic Antibodies at the Department of Pharmaceutical and Pharmacological Sciences (KU Leuven).

**COBUS DE SWARDT**

Cobus de Swardt joined Transparency International in 2004 and was appointed Managing Director in 2007. He is also a member and former Chair of the World Economic Forum (WEF) Global Agenda Council on Transparency & Anti-Corruption. In addition, he serves on the Board of the WEF Partnering against Corruption Initiative (PACI).

**VICTOR J. DZAU**

Prof. Victor J. Dzau is President of The Institute of Medicine at National Academy of Sciences, USA. He is also Chancellor of Health Affairs, Director of Molecular and Genomic Vascular Biology and President and Chief Executive Officer at Health System of Duke University Medical Center.

**ERIC HANS EDDES**

Dr. Eric Hans Eddes is GastroIntestinal Surgeon at the Deventer Hospital, a teaching hospital in the Netherlands and Director of the Dutch Institute for Clinical Auditing, an organization facilitating 23 clinical registries with a nationwide coverage in the Netherlands.

**ANGELIKA EGGERT**

Prof. Angelika Eggert is Director at Charité Center for Gynecology, Perinatal, Pediatric & Adolescent Medicine with Perinatal Center & Human Genetics. She started her scientific career 1977 at the Children's Hospital of Philadelphia, University of Pennsylvania. Her main interest is the molecular biology and genetics of neuroblastoma, a common solid tumor of childhood.

**PASCALE EHRENFREUND**

Prof. Pascale Ehrenfreund has been Chair of the DLR Executive Board since August 2015. Since 2008, she has been Professor of Space Policy and International Affairs at the Elliott School of International Affairs, George Washington University and Lead Investigator at the NASA Astrobiology Institute.

**VOLKMAR FALK**

Prof. Volkmar Falk is Medical Director and Director of the DHZB Department of Cardiothoracic and Vascular Surgery of the Deutsches Herzzentrum Berlin and Chair of the Division of Cardiovascular Surgery at Charité Berlin.

**ANTOINE FLAHAULT**

Prof. Antoine Flahault is Professor of Public Health at University Descartes, Sorbonne Paris Cité. He was appointed Chair of the Centre Virchow Villermé de Santé Publique Paris-Berlin (CVV) and is Founding Director of the Institute of Global Health, University of Geneva.

**DETLEV GANTEN**

Prof. Detlev Ganten is Founding President of the World Health Summit since 2009. From 1991 to 2004 he was Founding Director and President of Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch. He currently is Honorary Chairman of the Board at Charité Foundation.

**HERMANN GRÖHE**

Hermann Gröhe is Minister of Health of the Federal German Republic. From 2005 to 2008, he acted as legal counsel to the CDU/CSU parliamentary group and, from 2006–2008 he was the spokesperson of the CDU/CSU parliamentary group in the First Committee of Inquiry.

**ANDREW HAINES**

Sir Andrew Haines is Professor of Public Health and Primary Care. He formerly held position as Director of LSHTM (2001–2010) as well as Professor of Primary Health Care and Head of the Department of Primary Care and Population Sciences at University College London.

**PETER HAMMANN**

Prof. Peter Hammann is Member of the Management Board of the Therapeutic Area Infectious Diseases, responsible for the German research activities in this area at Sanofi-Aventis. In 2005 after Sanofi was created he was one of the key leaders to rebuild infectious disease research within the company.

**NORBERT HAUSER**

Norbert Hauser is Chair of the Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria. As a former Member of Parliament and international Auditor from Germany Mr. Hauser previously served as interim Inspector-General at the Global Fund (2012–13) and as a Member of the High-Level Panel. Until 2011, he served as Vice-President of Germany's Supreme Audit Institution.

**SUZANNE HILL**

Dr. Suzanne Hill, the Director of Essential Medicines and Health Products Department at WHO, is a clinical pharmacologist and public health physician, trained at the University of Newcastle, Australia. Prior to this appointment, she was Chair of the Australian Pharmaceutical Benefits Committee as well as Visiting Professor at the University of Melbourne Medical School.

**PETER J. HOTEZ**

Dr. Peter J. Hotez is Dean of the National School of Tropical Medicine and Professor of Pediatrics and Molecular Virology & Microbiology at Baylor College of Medicine where he is also the Texas Children's Hospital Endowed Chair of Tropical Pediatrics. He is President of the Sabin Vaccine Institute.

**PAUL HUDSON**

Paul Hudson has been Chief Executive Officer at Novartis Pharmaceuticals since July 2016. He is a Member of the Executive Committee of Novartis. He began his career at GlaxoSmithKline UK and Sanofi-Synthelabo UK with roles in sales and marketing.

**WOLFGANG ISCHINGER**

H. E. Prof. Wolfgang Ischinger is Chairman of the Munich Security Conference. He has been appointed ambassador to the United States of America and to the United Kingdom. As a Political Director he was Head of the German Delegation during the Bosnian Peace negotiations in Dayton/Ohio in 1995, the negotiations on the NATO-Russia Founding Act in 1996/97, and during the Kosovo crisis in 1998.

**JAYASREE K. IYER**

Dr. Jayasree K. Iyer is a specialist in global health and neglected tropical diseases. She is the Executive Director at the Access to Medicine Foundation. She has a career in malaria and neglected tropical disease research and development and in public-private partnerships strategy.

**ALI JAFARIAN**

Prof. Jafarian was appointed Chancellor of Tehran University of Medical Sciences in 2013. He is also a member of Supreme council for Science, Research and Technology and National Council of Evaluation of State Education. He was Executive Advisor for the chancellor of TUMS in 2005-2008, Dean of Medical School in 2008-2009 and Vice-Chancellor in 2009-2011.

**STEPHEN M. JANE**

Prof. Stephen M. Jane was appointed Head of Central Clinical School, Professor of Medicine, Monash University and Director of Research of Alfred Hospital in 2011. He also is Member of the Clinical Hematology Department.

**STEFAN H. E. KAUFMANN**

Prof. Stefan H. E. Kaufmann is Founding Director and Member of Max Planck Institute for Infection Biology in Berlin, where he heads the Department of Immunology. He is Professor of Microbiology and Immunology at Charité University Clinics in Berlin.

**ILONA KICKBUSCH**

Prof. Ilona Kickbusch is Director of the Global Health Center at the Graduate Institute of International and Development Studies, Geneva. She is a leading contributor to academic and political debates on governance for health on national and global level.

**JAN KIMPEN**

Prof. Kimpén joined Philips from the University Medical Center Utrecht (UMC Utrecht) in the Netherlands, where he was Chairman of the Executive Board. He has been the driving force behind partnerships with Philips and Eindhoven University of Technology, where he is a Member of the strategic advisory board health.

**MICHAEL J. KLAG**

Prof. Michael J. Klag is Dean of the Johns Hopkins Bloomberg School of Public Health. He is an internist and epidemiologist. Prof. Klag is a world-renowned kidney disease epidemiologist whose scientific contributions have been in the prevention and epidemiology of kidney disease, hypertension and cardiovascular disease.

**HON. SURESH KUMAR**

Hon. Suresh Kumar currently serves as Member of the Executive Committee and the Global Leadership Team as well as Head of Government Relations US ad interim. He has more than 30 years of experience in the healthcare industry beginning in 1978 in India with Johnson and Johnson.

**STEFAN LARSSON**

Dr. Stefan Larsson joined BCG in 1996 and is Senior Partner and Managing Director. He is the Global Leader of BCG's Health Care Payor and Provider sector and Member of the Global Health Care leadership team. Mr. Larsson has worked across all aspects of the Health Care industry.

**YVES LEVY**

Prof. Yves Levy is Chief Executive Officer and Chairman of INSERM, the National Institute of Health and Medical Research, since June 2014. He also leads since July 2014 Aviesan, the French Alliance for Health and Life Sciences. He is Professor of Clinical Immunology at Henri Mondor Hospital/ Université Paris Est. Créteil since 1996.

**KAREN LINEHAN**

Dr. Karen Linehan is Executive Vice-President, Legal Affairs and General Counsel at Sanofi since 2007. Ms. Linehan leads Sanofi's Legal, Ethics & Business Integrity departments and sits on the Executive Committee. She has been instrumental in inciting the diversity conversation within Sanofi and was one of the Founding Members of the Diversity Council in 2009.

**LINE MATTHIESSEN-GYADER**

Dr. Line Matthiessen leads the Unit responsible for Fighting Infectious Diseases and Advancing Public Health in the Directorate-General for Research and Innovation. The unit promotes and supports EU research and innovation activities in the area of global health issues.

**JUSTIN P. MCCARTHY**

Justin McCarthy is the Senior Vice-President of Global Policy and International Public Affairs at Pfizer Inc. He serves on the Boards of the Business Council for International Understanding, The Global Intellectual Property Center (GIPC), and the United States Council for International Business.

**TEWODROS MELESSE**

As IPPF Regional Director for Africa, Tewodros Melesse played a pivotal role in providing technical and management support to the African Union in the development and adoption of the Continental Sexual and Reproductive Health Policy Framework and the Maputo Plan of Action.



**REN MINGHUI**

Dr. Ren Minghui was appointed WHO Assistant Director-General for HIV/AIDS, Tuberculosis, Malaria and Neglected Tropical Diseases on January 2016. Prior to that, he was Director-General for International Cooperation in the National Health and Family Planning Commission of the People's Republic of China.

**LLOYD B. MINOR**

Prof. Lloyd B. Minor is a scientist, surgeon, and academic leader. He is the Carl and Elizabeth Naumann Dean of Stanford University School of Medicine, a position he has held since December 2012. He is also Professor of Otolaryngology – Head and Neck Surgery and Professor of Bioengineering and of Neurobiology at Stanford University.

**CHRISTINA MITCHELL**

In 2006 Prof. Mitchell became Head of School of Biomedical Sciences at Monash University, which is the largest of the Schools within the Faculty of Medicine. In 2011 she was promoted to the position of Dean of Medicine, Nursing and Health Sciences.

**MATSHIDISO REBECCA MOETI**

Dr. Matshidiso Moeti from Botswana is the first female WHO Regional Director for Africa. Dr. Moeti is a public health veteran, with more than 35 years of national and international experience. She joined WHO's Africa Regional Office in 1999 and has served as Deputy Regional Director and Assistant Regional Director.

**TARIK MÖRÖY**

Prof. Tarik Möröy is current President and Scientific Director of the Clinical Research Institute Montreal (IRCM), a position he holds since March 2006. He is also Director of the Hematopoiesis and Cancer Research Unit at the IRCM.

**SAMUEL S. MYERS**

Prof. Samuel Myers is Senior Research Scientist for Environmental Health at Harvard School of Public Health as well as Director, Planetary Health Alliance at Harvard Center for the Environment. He won the Prince Albert II of Monaco – Institut Pasteur 2015 Award: For “outstanding work and publications in the field of the impact of environmental and climatic changes on human health.”

**JIM O'NEILL**

Dr. Jim O'Neill is Chairman of the Board at The Review on Antimicrobial Resistance. Lord O'Neill is currently the Commercial Secretary of the Treasury and his duties include leading the work for the Government on the Northern Powerhouse, city devolution and infrastructure. In May 2015 he was also made Life Peer to the House of Lords.

**OLIVIER OULLIER**

Dr. Olivier Oullier is Professor of Behavioural and Brain Sciences at Aix-Marseille University in France. As a consultant for public and private organizations, he designs and implements evidence-informed behaviour change and engagement strategies.

**AYDAN ÖZOĞUZ**

Aydan Özoğuz is Minister of State to the Federal Chancellor and Federal Government Commissioner for Migrants, Refugees and Integration since December 2013. She holds a MA in English Language and Literature, Spanish Language and Literature, and Personnel Management.

**JOY PHUMAPHI**

Joy Phumaphi is the Executive Secretary of the African Leaders Malaria Alliance. She served as Member of the UNSG's High-Level Panel on the Global Response to Health Crises and Chair of the Global Leaders Council for Reproductive Health. She has served on a number of commissions and expert groups and sits on the Board of several international non-profit organizations.

**MONTIRA PONGSIRI**

Dr. Montira Pongsiri is HEAL Director and Health Science Policy Advisor. She has worked before as Environmental Health Scientist at the U.S. Environmental Protection Agency as well as Science Advisor at the U.S. Mission to the Association of Southeast Asian Nations (ASEAN).

**AXEL RADLACH PRIES**

Prof. Axel Radlach Pries is Dean of Charité – Universitätsmedizin Berlin since 2005. He is Head of the Charité Institute for Physiology since 2001. In the European Society of Cardiology (ESC), he was Chair of the Working Group for Coronary Pathophysiology and Microcirculation and of the Council for Basic Cardiovascular Science (CBCS).

**MICHAEL RABBOW**

Dr. Michael Rabbow is Chairman at the Privat Sector Advisory Board at GIZ (Deutsche Gesellschaft für Internationale Zusammenarbeit) and holds position as Senior Advisor at E&P Focus Africa Consulting.

**ROBERT SEBBAG**

Dr. Robert Sebbag is Vice-President for Access to Medicines at Sanofi. Dr. Sebbag is also teaching public health courses within the Paris hospital system, focusing on tropical parasitic diseases. He is active within the French Red Cross and has participated in numerous health missions in the Southern Hemisphere.

**BRENDAN SHAW**

Dr. Brendan Shaw is Assistant Director General at IFPMA since 2014. He assists the Director General in leading on a range of policy and representational functions particularly in innovation policy, intellectual property, trade, health technology assessment, ethics, compliance and vaccines.

**JAQUELINE SHEA**

Dr. Shea is Chief Executive Officer at Aeras. She is well known and widely respected in the TB vaccine development community, where she plays a leading role for Aeras in advancing new TB vaccines for the world.



**STEVE SINGH**

Steve Singh is Member of the Executive Board of SAP SE and President, Business Networks and Applications. He has been named one of the 25 Most Influential People of the Year by Business Travel News seven times. He began his career in technology with Apple Computer.

**FRANCIS E. SMIT**

Prof. Francis E. Smit presently is Head of the Department of Cardiothoracic Surgery at the University of the Free State. He specializes in adult and paediatric cardiac surgery.

**MARC SPRENGER**

Dr. Marc Sprenger is Director of the World Health Organization (WHO) Secretariat for Antimicrobial Resistance. Dr. Sprenger was Director of the European Centre for Disease Prevention and Control (ECDC) in Stockholm, Sweden.

**WILLIAM LACEY SWING**

H.E. William Lacy Swing of the United States is now on his second five-year term as Director-General of the International Organization for Migration (IOM). During a long diplomatic career at the US Department of State, Mr. Swing was a six-time ambassador, managing some of the largest diplomatic missions and foreign development and humanitarian aid programs.

**BERND-ALOIS TENHAGEN**

Dr. Bernd-Alois Tenhagen is Senior Researcher at the Group for Epidemiology, Zoonoses and Antimicrobial Resistance, Department of Biological Safety at the Federal Institute for Risk Assessment, BfR. He is an European Veterinary Specialist in Bovine Health Management.

**HELLE THORNING-SCHMIDT**

Currently Chief Executive Officer of Save the Children International, Helle Thorning-Schmidt joined the organization after a formidable political career. Formerly the Prime Minister of Denmark, Helle led a coalition government from 2011 until 2015. She was Member of Parliament and Leader of the Social Democratic Party for 10 years.

**FRANS VAN HOUTEN**

Frans van Houten is Chief Executive Officer and Chairman of the Executive Committee and the Board of Management of Royal Philips, a position he has held since April 2011. He strengthened Philips activities in health technology through the acquisition of US image-guided therapy leader, Volcano, and the fostering of emerging businesses such as Digital Pathology and Health informatics.

**HEIKO WARNKEN**

Heiko Warnken is Head of Division for Health, Social Security and Population Policy at the Federal Ministry for Economic Cooperation and Development (BMZ), Germany. He has served in multiple positions in the German Federal Ministry for Economic Cooperation and Development (BMZ) since 1991.

**FLORIAN WESTPHAL**

Florian Westphal currently works as Managing Director at Médecins Sans Frontières Germany. He worked for 15 years as a Member of the International Committee of the Red Cross (ICRC) in various countries such as Democratic Republic of Congo, Sierra Leone and Kenya and subsequently served as the ICRC's Head of Media.

**HEIDEMARIE WIECZOREK-ZEUL**

Heidemarie Wieczorek-Zeul is Vice-President of Friends of the Global Fund Europe. She also serves on the Board of Directors of the International Partnership for Microbicides (IPM). She was Germany's Minister for Economic Cooperation and Development and Governor of the World Bank from 1998 to 2009.

**LOTHAR H. WIELER**

Prof. Lothar H. Wieler is President of Robert Koch Institute, the central institution responsible for disease control and prevention in Germany. He is also Professor at the Centre for Infection Medicine, Institute of Microbiology and Epizootics at Freie Universität (FU) in Berlin.

**MATTHIAS WIENOLD**

Dr. Matthias Wienold (MD, MPH) is a physician from Germany who engages in patient orientation and patients' rights. He has been a patient advocate since 1986. He is a Founding Member of the European AIDS Treatment Group (EATG).

**DURHANE WONG-RIEGER**

Dr. Wong-Rieger is immediate Past-Chair of the International Alliance of Patient Organizations and President & Chief Executive Officer of the Canadian Organization for Rare Disorders, the umbrella organization of patients and patient groups, and chair of the Consumer Advocare Network, a national network for patient engagement in healthcare policy and advocacy.

**CHARLES YANKAH**

Prof. Charles Yankah is President of African Cultural Institute (ACI) and Pan-African Society for Cardiothoracic Surgery. As a retired pioneer cardiothoracic and vascular surgeon at the Deutsches Herzzentrum Berlin – DHZB (German Heart Institute Berlin) and Professor of Surgery at Charité, he is still active as a global player in the profession as a consultant heart specialist.

**ROLF ZINKERNAGEL**

Dr. Rolf Zinkernagel is Professor at the University of Zurich, University Hospital Zurich and former Head of Institute of Experimental Immunology, Zurich. He was awarded the Nobel Prize in Physiology or Medicine in 1996 for the discovery of how the immune system recognizes virus-infected cells.

## SPEAKER INDEX



**ANA  
ABRUNHOSA**

European  
Commission |  
Portugal



**AYOLA AKIM  
ADEGNIKA**

Centre de Re-  
cherches Medicales  
de Lambarene |  
Gabon



**TEDROS  
ADHANOM  
GHEBREYESUS**

Ministry of Foreign  
Affairs | Ethiopia



**FIONA  
ADSHEAD**

BUPA |  
United Kingdom



**ANN  
AERTS**

Novartis Founda-  
tion | Switzerland



**CHRISTINA RÅNGE-  
MARK ÅKERMAN**

ICHOM International  
Consortium for Health  
Outcomes Measure-  
ment | United States  
of America




**JUTTA  
ALLMENDINGER**

Berlin Social  
Science Center  
(WZB) | Germany



**YUKIYA  
AMANO**

International Atomic  
Energy Agency |  
Austria



**JOHN  
AMUASI**

African Research  
Network for  
Neglected Tropical  
Diseases (ARNTD) |  
Ghana



**ZAZA  
AVALIANI**

National Center for  
Tuberculosis and  
Lung Diseases |  
Georgia



**MICHAEL  
BAFFI**

Thermo Fisher  
Scientific Inc. |  
United States of  
America



**ROSALINDA  
BALDOZ**

Government  
of the Philippines |  
Philippines



**HOLGER  
BARTZ**

Janssen-Cilag  
GmbH | Germany



**CHANTAL  
BELORGEY**

French National  
Authority for Health  
(HAS) | France



**KARIM  
BENDHAOU**

Merck S.A.R.L |  
Tunisia



**DIETMAR P.  
BERGER**

F. Hoffmann-  
La Roche Ltd. |  
United States  
of America



**RICHARD  
BERGSTRÖM**

European Federa-  
tion of Pharma-  
ceutical Industries  
and Associations  
(EFPIA) | Belgium



**JANIS  
BERNAT**

International Federa-  
tion of Pharmaceu-  
tical Manufacturers &  
Associations (IFPMA) |  
Switzerland





**ADALBERTO  
CAMPOS  
FERNANDES**  
Ministry of Health |  
Portugal



**BEN  
CANNY**  
University of  
Tasmania | Tasmania



**ANTHONY  
CAPON**  
United Nations  
University | Malaysia



**ADRIAN  
CARTER**  
Monash University |  
Australia



**GERTRUD  
CASEL**  
Joint Conference  
Church and  
Development  
(GKKE) | Germany



**SARBANI  
CHAKRABORTY**  
Merck Group |  
Germany



**CHANG-CHUAN  
CHAN**  
National Taiwan  
University (NTU) |  
Taiwan



**EMMANUELLE  
CHARPENTIER**  
Max Planck Institute  
for Infection Biology |  
Germany



**OLEG  
CHESTNOV**  
World Health  
Organization  
(WHO) |  
Switzerland



**DIXON  
CHIBANDA**  
University of  
Zimbabwe |  
Zimbabwe



**ERMINIA  
COLUCCI**  
Queen Mary  
University of  
London |  
United Kingdom



**VIRGINIA  
COMOLLI**  
International  
Institute for Strate-  
gic Studies (IIS) |  
United Kingdom



**AGNÈS  
COUFFIGNAL**  
Organisation for  
Economic Coopera-  
tion and Develop-  
ment (OECD) |  
France



**YVES  
DACCORD**  
International  
Committee of the  
Red Cross (ICRC) |  
Switzerland



**SURAYA  
DALIL**  
Permanent Mission  
of Afghanistan to  
the United Nations  
Office | Switzerland



**ANDREW  
DANIELS**  
GlaxoSmithKline  
Pharmaceuticals  
Europe | United  
Kingdom



**PAUL  
DECLERCK**  
KU Leuven  
University | Belgium



**LOURDES  
DE LA PEZA**  
Management  
Science for Health  
(MSH) | United  
States of America





**COBUS  
DE SWARDT**

Transparency  
International |  
Germany



**ROOPA  
DHATT**

Women in Global  
Health | United  
States of America



**ALPHA AHMADOU  
DIALLO**

Ministry of Health |  
Guinea



**MANFRED  
DIETEL**

Charité-Universitäts-  
medizin Berlin |  
Germany



**VICTOR J.  
DZAU**

National Academy  
of Medicine | United  
States of America



**KAI-UWE  
ECKARDT**

University Hospital  
Erlangen | Germany



**ERIC HANS  
EDDES**

Dutch Institute for  
Clinical Auditing  
(DICA) |  
Netherlands



**ANGELIKA  
EGGERT**

Charité-Universitäts-  
medizin Berlin |  
Germany




**PASCALE  
EHRENFREUND**

German Aerospace  
Center (DLR) |  
Germany



**ROLAND  
EILS**

German Cancer  
Research Center  
DKFZ | Germany



**RAJAE  
EL AOUD**

Hassan II Academy  
of Science and  
Technology |  
Morocco



**DIRK  
ENGELS**

World Health  
Organization  
(WHO) |  
Switzerland



**VOLKMAR  
FALK**

German Heart  
Institute Berlin  
(DHZB) | Germany



**MARK  
FEINBERG**

International AIDS  
Vaccine Initiative  
(IAVI) | United  
States of America



**NILS  
FIETJE**

World Health  
Organization  
(WHO) Regional  
Office for Europe |  
Denmark



**DALE  
FISHER**

National University  
Hospital Singapore  
(NUHS) | Singapore



**JULIAN  
FISHER**

THEnet Training  
for Health Equity |  
Germany



**ANTOINE  
FLAHAULT**

University  
of Geneva |  
Switzerland



**BERNHARD  
FLECKENSTEIN**

Friedrich Alexander  
University  
Erlangen-Nürnberg |  
Germany



**SHUNICHI  
FUKUHARA**

Kyoto University |  
Japan



**DETLEV  
GANTEN**

World Health  
Summit President,  
Charité Foundation |  
Germany



**ROLAND  
GÖHDE**

German Healthcare  
Partnership (GHP) |  
Germany



**REI  
GOTO**

Keio University |  
Japan



**RAYMONDE  
GOUDOU COFFIE**

Ministry of Health  
and Public Hygiene |  
Ivory Coast



**NORA ILONA  
GRASSELLI**

ESMT-European  
School of Manage-  
ment and Tech-  
nology GmbH |  
Germany



**EVA  
GREITEMANN**

action medeor e.V. |  
Germany



**HERMANN  
GRÖHE**

Federal Ministry  
of Health | Germany



**RICARDO  
AUGUSTUS  
GUERREIRO  
BAPTISTA LEITE**

Catholic University  
Portugal | Portugal



**SIR ANDREW  
HAINES**

London School of  
Hygiene & Tropical  
Medicine |  
United Kingdom



**PETER  
HAMMANN**

Sanofi-Aventis  
Deutschland |  
Germany



**JOHANNA  
HANEFELD**

London School of  
Hygiene & Tropical  
Medicine | United  
Kingdom



**BERHARD S.  
HAUFIKU**

Ministry of Health  
and Social Services |  
Namibia



**NORBERT  
HAUSER**

The Global Fund to  
Fight AIDS, Tuber-  
culosis and Malaria |  
Switzerland



**JUDITH  
HEEPE**

Charité-Universitäts-  
medizin Berlin |  
Germany



**ANDREAS  
HEINZ**

Charité-Universitäts-  
medizin Berlin |  
Germany



**WOLFGANG  
HERBINGER**

UN World Food  
Programme WFP |  
Italy



**SUZANNE HILL**  
World Health Organization (WHO) | Switzerland



**ANKE HOEFFLER**  
Oxford University | United Kingdom



**ILDIKO HORVATH**  
National Koranyi Institute for Pulmonology | Hungary



**PETER J. HOTEZ**  
Sabin Vaccine Institute | United States of America



**SHENG-JEAN HUANG**  
Taipei City Hospital | Taiwan



**PAUL HUDSON**  
Novartis Pharmaceuticals | Switzerland



**FRANCES A. HUGHES**  
International Council of Nurses | Switzerland



**ASELA IDDAWELA**  
Government of the Democratic Socialist Republic of Sri Lanka | Sri Lanka



**VALENTINA IEMMI**  
London School of Economics and Political Sciences | United Kingdom



**TEMITAYO IFAFORE-CALFEE**  
USAID/PHI | United States of America



**ILHAN ILKILIC**  
Istanbul University | Turkey



**WOLFGANG ISCHINGER**  
Munich Security Conference Foundation (MSC) | Germany



**JAYASREE IYER**  
Access to Medicine Foundation | Netherlands



**ALI JAFARIAN**  
Tehran University of Medical Sciences | Iran



**STEPHEN M. JANE**  
Monash University | Australia



**ANDREAS JENNE**  
NEO New Oncology | Germany



**ASHISH K. JHA**  
Harvard T.H. Chan School of Public Health | United States of America



**GAGANDEEP KANG**  
Christian Medical College | India





**STEFAN  
KAUFMANN**

Max Planck Institute  
for Infection Biology |  
Germany



**ILONA  
KICKBUSCH**

The Graduate  
Institute of Interna-  
tional and Develop-  
ment Studies |  
Switzerland



**JAN  
KIMPEN**

Royal Philips NV |  
Netherlands



**MARIA  
KIPELE**

University  
Würzburg |  
Germany



**JOHANNES  
KIRCHGATTER**

WWF Germany |  
Germany



**JAN ILHAN  
KIZILHAN**

Cooperative State  
University Baden-  
Württemberg |  
Germany



**MICHAEL J.  
KLAG**

Johns Hopkins  
Bloomberg School  
of Public Health |  
United States  
of America



**BERNHARD  
KÖHLER**

Medical Mission  
Institute Würzburg |  
Germany



**CARSTEN  
KÖHLER**

University Hospital  
Tübingen | Germany



**JOHANNES  
KRAUSE**

Max Planck Institute  
for the Science of  
Human History |  
Germany



**EDUARDO MOACYR  
KRIEGER**

Faculty of Medicina  
of the University of  
São Paulo (FMUSP) |  
Brazil



**CHRISTIAN  
KROLL**

Bertelsmann  
Foundation and  
SDSN | Germany



**ANJA  
KRUMEICH**

Maastricht Univer-  
sity - Faculty of  
Health, Medicine  
and Life Sciences |  
Netherlands



**HON. SURESH  
KUMAR**

Sanofi | United  
States of America



**GEORGE M.  
KURIA**

Boehringer  
Ingelheim Kenya |  
Kenya



**TOBIAS  
KURTH**

Charité-Universitäts-  
medizin Berlin  
Centre Virchow-  
Villermé (CVV) |  
Germany



**DANIEL T.  
LACKLAND**

World Hypertension  
League | United  
States of America



**STEFAN  
LARSSON**

The Boston  
Consulting Group  
(BCG) | Sweden



**FABIAN  
LEENDERTZ**

Robert Koch  
Institute | Germany



**YVES  
LEVY**

The National  
Institute for Health  
and Medical  
Research (INSERM) |  
France



**DÉSIRÉE  
LICHTENSTEIN**

Women in Global  
Health | Sweden



**KEITH  
LIM**

National University  
of Singapore (NUS) |  
Singapore



**KAREN  
LINEHAN**

Sanofi | France



**KATHERINE  
LITTLER**

Wellcome Trust |  
United Kingdom



**SAM  
LOEWENBERG**

Harvard University |  
United States of  
America



**ORIO  
LOPEZ**

Médecins Sans  
Frontières (MSF) |  
Spain



**LUIZ  
LOURES**

UNAIDS |  
Switzerland



**MICHAEL T.  
LYNSKEY**

King's College  
London | United  
Kingdom



**CLEOPA  
MAILU**

Ministry of Health |  
Kenya



**CHARLOTTE  
MARCHANDISE**

City of Rennes |  
France



**GEORG  
MARCKMANN**

Ludwig Maximilians  
University Munich |  
Germany



**ESPERANZA  
MARTINEZ**

International  
Committee of the  
Red Cross (ICRC) |  
Switzerland



**STEPHEN  
MATLIN**

The Graduate  
Institute of Inter-  
national and  
Development  
Studies | Switzerland



**LINE  
MATTHIESSEN-  
GUYADER**

European Commis-  
sion | Belgium



**JUSTIN P.  
MCCARTHY**

Pfizer Inc. |  
United States of  
America



**PETER  
MCGRATH**

InterAcademy  
Partnership for  
Health (IAP) |  
Italy



**BEN  
MEGHREBLIAN**  
Open Knowledge  
International |  
United Kingdom



**TEWODROS  
MELESSE**  
The International  
Planned Parent-  
hood Federation  
(IPPF) | United  
Kingdom



**MARTINA  
MERTEN**  
Ärzte Zeitung  
Verlags GmbH |  
Germany



**REN  
MINGHUI**  
World Health  
Organization  
(WHO) | Switzer-  
land



**LLOYD B.  
MINOR**  
Stanford University |  
United States of  
America



**CHRISTINA  
MITCHELL**  
Monash University |  
Australia



**WILSON  
MLAKI**  
Saint Luke  
Foundation |  
Tanzania



**MATSHIDISO  
REBECCA  
MOETI**  
WHO Regional  
Office for Africa |  
Botswana



**TARIQ  
MÖRÖY**  
Clinical Research  
Institute Montreal  
(IRCM) | Canada



**AXEL C.  
MÜHLBACHER**  
Hochschule Neu-  
brandenburg |  
Germany



**THOMAS  
MÜLLER**  
Federal Joint  
Committee |  
Germany



**SAMUEL S.  
MYERS**  
Harvard T.H. Chan  
School of Public  
Health | United  
States of America



**DAVID  
NAPIER**  
University College  
London |  
United Kingdom



**DAVID  
NUTT**  
Imperial College  
London |  
United Kingdom



**JIM  
O'NEILL**  
The Review  
on Antimicrobial  
Resistance |  
United Kingdom



**ALBERT  
OSTERHAUS**  
University  
of Veterinary  
Medicine Hannover |  
Germany



**OLIVIER  
OULLIER**  
World Economic  
Forum | Switzerland



**AYDAN  
ÖZOĞUZ**  
Federal Republic  
of Germany |  
Germany



**SACHIE  
PANAWELA**

The Coordinating  
Secretariat for  
Science, Technol-  
ogy and Innovation  
(COSTI) | Sri Lanka



**HERMANN  
PARZINGER**

Prussian Cultural  
Heritage Founda-  
tion | Germany



**DOROTHEA  
PHILIPPS**

Protestant Church  
Dortmund |  
Germany



**JOY  
PHUMAPHI**

African Leaders  
Malaria Alliance  
(ALMA) | Tanzania



**ANDRIS  
PIEBALGS**

Government of the  
Republic of Latvia |  
Latvia



**BALAKRISHNA  
PISUPATI**

United Nations  
Environment  
Programme (UNEP) |  
Kenya



**MONTIRA  
PONGSIRI**

Wildlife Conserva-  
tion Society | United  
States of America



**ELISABETH  
POTT**

German AIDS  
Foundation |  
Germany



**AXEL RADLACH  
PRIES**

Charité-Universitäts-  
medizin Berlin |  
Germany



**HANS-ULRICH  
PROKOSCH**

University Hospital  
Erlangen | Germany  
FAU Erlangen-Nürn-  
berg | Germany



**SWEE CHYE  
QUEK**

National University  
Hospital Singapore  
(NUHS) | Singapore



**MICHAEL  
RABBOW**

E&P Focus Africa  
Consulting GmbH |  
Germany



**ASANGA  
RANASINGHE**

Anuradhapura  
General Hospital |  
Sri Lanka



**CATARINA  
RESENDE DE  
OLIVEIRA**

Hospital and  
University Center  
Coimbra | Portugal



**JOHN-ARNE  
RØTTINGEN**

University of Oslo |  
Norway




**RAFAEL  
RUIZ DE  
CASTANEDA**

University  
of Geneva |  
Switzerland



**VIKTORIA  
SARGSYAN**

World Vision  
International |  
United Kingdom



**REINHARD  
SCHÄFERS**

World Health  
Summit - WHS  
Foundation GmbH |  
Germany



**DANIEL H. SCHMUTZ**

Helsana-Gruppe | Switzerland



**ULRICH SCHNYDER**

University Hospital Zurich | Switzerland



**STEFAN M. SCHULZ**

University Würzburg | Germany



**EVA-MARIA SCHWIENHORST-STICH**

DAHW German Leprosy and Tuberculosis Relief Association | Germany



**ROBERT SEBBAG**

Sanofi Aventis | France



**WERNER SEEGER**

German Center for Lung Research (DZL) University Hospital Giessen | Germany



**NIYATI SHAH**

USAID | United States of America



**BRENDAN SHAW**

International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Switzerland




**REUBEN SHAW**

Salk Institute for Biological Studies | United States of America



**JAQUELINE SHEA**

Aeras | United States of America



**ELISABETH SHEKHALAGE**

Government of Tanzania | Tanzania



**STEVE SINGH**

SAP SE | United States of America



**KARIN R. SIPIDO**

University Leuven | Belgium



**FRANCIS E. SMIT**

University of the Free State (UOFS) | South Africa



**MARC SPRENGER**

World Health Organization (WHO) | Switzerland



**GÜNTER STOCK**

All European Academies (ALLEA) | Germany



**PIETER STOLK**

Exon Consultancy | Netherlands



**VICTORIA SULTANA**

Mater Dei Hospital | Malta





**GERD  
SUTTER**

Ludwig Maximilians  
University Munich |  
Germany



**WILLIAM LACEY  
SWING**

International  
Organization for  
Migration (IOM) |  
Switzerland



**AMIRHOSSEIN  
TAKIAN**

Tehran University  
of Medical Sciences |  
Iran



**JEAN-YVES K.  
TANO**

World Health  
Summit Foundation  
GmbH | Germany



**AHMAD  
TARAKJI**

Syrian American  
Medical Society |  
United States of  
America



**PETER  
TAYLOR**

International  
Development  
Research Centre  
(IDRC) | Canada



**BERND-ALOIS  
TENHAGEN**

Federal Institute  
for Risk Assessment  
(BfR) | Germany



**FABIAN  
THEIS**

Helmholtz Zentrum  
Munich  
TU Munich |  
Germany



**SALLY  
THEOBALD**

Liverpool School of  
Tropical Medicine |  
United Kingdom



**HINRICH  
THÖLKEN**

Permanent Represen-  
tation of Germany  
to the International  
Organisations in  
Rome | Italy



**HELLE  
THORNING-  
SCHMIDT**

Save the Children  
International |  
United Kingdom



**SILVIA  
TÜRK**

Federal Ministry  
of Health | Austria



**TIMO  
ULLRICHS**

Koch-Mechnikov-  
Forum  
Akkon University for  
Human Sciences |  
Germany



**NICOLE  
VALENTINE**

World Health  
Organization  
(WHO) |  
Switzerland



**FRANS  
VAN HOUTEN**

Royal Philips NV |  
Netherlands



**ANTONIO  
VERDEJO-GARCIA**

Monash University |  
Australia



**HEIKO  
WARNKEN**

Federal Ministry  
for Economic  
Cooperation and  
Development (BMZ) |  
Germany



**JAYASHREE  
WATAL**

World Trade  
Organization |  
Switzerland



**FLORIAN  
WESTPHAL**

Médecins Sans  
Frontières (MSF)  
Germany | Germany



**HEIDEMARIE  
WIECZOREK-ZEUL**

Friends of the  
Global Fund Europe |  
Franc



**LOTHAR  
WIELER**

Robert Koch  
Institute | Germany



**MATTHIAS  
WIENOLD**

International  
Alliance of Patients  
Organizations |  
United Kingdom



**DURHANE  
WONG-RIEGER**

International  
Alliance of Patients'  
Organizations |  
United States of  
America



**TANA  
WULIJI**

World Health  
Organization  
(WHO) |  
Switzerland



**CHARLES  
YANKAH**

African Cultural  
Institute (ACI) |  
Germany



**THOMAS  
ZELTNER**

Swiss Academy of  
Medical Sciences |  
Switzerland



**ALBERT  
ZINK**

EURAC - Institute  
for Mummies and  
the Iceman | Italy



**ROLF  
ZINKERNAGEL**

University Hospital  
Zurich | Switzerland



**STEPHAN  
ZIPFEL**

University Hospital  
Tübingen | Germany

## SPEAKER LIST

### A

Abrunhosa, Ana 58  
 Adegnika, Ayola Akim 54  
 Adhanom Ghebreyesus,  
 Tedros 66  
 Adshead, Fiona 46  
 Aerts, Ann 46, 116  
 Åkerman, Christina  
 Rångemark 108  
 Allmendinger, Jutta 100  
 Amano, Yukiya 100  
 Amuasi, John 54  
 Avaliani, Zaza 84

### B

Baffi, Michael 96  
 Baldoz, Rosalinda 78  
 Bärnighausen, Till 50  
 Bartz, Holger 84  
 Belorgey, Chantal 80  
 Bendhaou, Karim 112  
 Berger, Dietmar P. 72  
 Bergström, Richard 80  
 Bernat, Janis 102  
 Berset, Alain 74  
 Bertram, Katri 64  
 Beyer, Peter 68  
 Bicking, Andreas 98  
 Binder, Elisabeth 92  
 Biswas, Seema 64  
 Blackburn, Elizabeth 118  
 Boisjoly, Hélène 132  
 Bosolo, Yoursen 52  
 Böttiger, Bernd W. 70  
 Böttinger, Erwin Paul 74, 126  
 Boufford, Jo Ivey 110

Boyce, Niall 92  
 Braun, Helge 122  
 Bréchet, Christian 56  
 Brill, Klaus 54  
 Bristol, Nellie 114

### C

Calov, Annika 98  
 Campana, Dario 118  
 Campos Fernandes,  
 Adalberto 78  
 Canny, Ben 48  
 Capon, Anthony 90, 94  
 Carter, Adrian 60  
 Casel, Gertrud 112  
 Chakraborty, Sarbani 66  
 Chan, Chang-Chuan 58  
 Charpentier, Emmanuelle 74  
 Chestnov, Oleg 46  
 Chibanda, Dixon 92  
 Chrétien, Michel 82  
 Colucci, Erminia 92  
 Comolli, Virginia 64  
 Couffinhal, Agnès 42

### D

Daccord, Yves 88  
 Dalil, Suraya 114  
 Daniels, Andrew 42  
 Declerck, Paul 102  
 de la Peza, Lourdes 128  
 de Swardt, Cobus 42  
 Dhatt, Roopa 128  
 Diallo, Alpha Ahmadou 96  
 Dietel, Manfred 72  
 Dzau, Victor J. 66

### E

Eckardt, Kai-Uwe 44  
 Eddes, Eric Hans 108  
 Edwards, Danny 68  
 Eggert, Angelika 118  
 Ehrenfreund, Pascale 100  
 Eils, Roland 126  
 El Aouad, Rajae 94  
 Engels, Dirk 54  
 Eschenhagen, Thomas 126

### F

Falk, Volkmar 46  
 Feinberg, Mark 82  
 Fietje, Nils 86  
 Fisher, Dale 70  
 Fisher, Julian 120  
 Flahault, Antoine 74, 96  
 Fleckenstein, Bernhard 124  
 Freund, Paul 49  
 Fukuhara, Shunichi 58

### G

Ganten, Detlev 62, 74  
 Göhde, Roland 50  
 Goto, Rei 58  
 Goudou Coffie,  
 Raymonde 50  
 Grasselli, Nora Ilona 110  
 Greitemann, Eva 52  
 Gröhe, Hermann 74, 104  
 Guerreiro Baptista Leite,  
 Ricardo Augustus 50, 80

### H

Haines, Sir Andrew 90

Hammann, Peter 122  
 Hanefeld, Johanna 130  
 Haufiku, Bernard S. 50  
 Hauser, Norbert 108  
 Hedberg, Niklas 80  
 Heepe, Judith 70  
 Heinz, Andreas 60  
 Herbinger, Wolfgang 98  
 Hill, Suzanne 42  
 Hoeffler, Anke 64  
 Horvath, Ildiko 124  
 Hotez, Peter J. 56  
 Hrabé de Angelis, Martin 126  
 Huang, Sheng-Jean 58  
 Hudson, Paul 108  
 Hughes, Frances A. 70

### I

Iddawela, Asela 44  
 Iemmi, Valentina 92  
 Ifafore-Calfee, Temitayo 128  
 Ilkilic, Ilhan 86  
 Ischinger, Wolfgang 66  
 Iyer, Jayasree 46

### J

Jafarian, Ali 78  
 Jane, Stephen M. 118  
 Jenne, Andreas 72  
 Jha, Ashish K. 130

### K

Kang, Gagandeep 82  
 Kaufmann, Stefan 56  
 Kickbusch, Ilona  
 78, 114, 120, 130



Kimpen, Jan 108  
 Kipele, Maria 112  
 Kirchgatter, Johannes 52  
 Kizilhan, Jan Ilhan 92  
 Klag, Michael J. 88, 124  
 Köhler, Bernhard 112  
 Köhler, Carsten 54  
 Krause, Johannes 62  
 Krieger, Eduardo Moacyr 54  
 Kroll, Christian 130  
 Krumeich, Anja 86  
 Kumar, Hon. Suresh 56  
 Kuria, George M. 112  
 Kurth, Tobias 96

## L

Lackland, Daniel T. 116  
 Larsson, Stefan 108  
 Ledgard, Jonathan 98  
 Leendertz, Fabian 94  
 Leroux-La Pierre, Maxime 49  
 Levy, Yves 82  
 Lichtenstein, Désirée 128  
 Lim, Keith 48  
 Linehan, Karen 132  
 Littler, Katherine 96  
 Loewenberg, Sam 84  
 Lopez, Oriol 98  
 Loures, Luiz 50  
 Lunze, Karsten 60  
 Lynskey, Michael T. 60

## M

Mailu, Cleopa 50  
 Mall, Marcus 127  
 Marchandise, Charlotte 120

Marckmann, Georg 102  
 Martinez, Esperanza 64  
 Matlin, Stephen 114  
 Matthiessen-Guyader,  
 Line 82, 122  
 Maurmann, Sven 127  
 McCarthy, Justin P. 78  
 McGrath, Peter 94  
 Meghreblian, Ben 96  
 Melesse, Tewodros 42  
 Merten, Martina 120  
 Minghui, Ren 55, 74  
 Minor, Lloyd B. 100  
 Misquith, Lorraine 68  
 Mitchell, Christina 118  
 Mlaki, Wilson 112  
 Mochly-Rosen, Daria 55  
 Moeti, Matshidiso  
 Rebecca 79, 114, 132  
 Montagni, Ilaria 97  
 Möröy, Tarik 100  
 Mühlbacher, Axel C. 102  
 Müller, Thomas 80  
 Myers, Samuel S. 90

## N

Napier, David 86  
 Nauck, Matthias 127  
 Ng, Shi Hui 49  
 Nutt, David 60

## O

O'Neill, Jim 122  
 Osterhaus, Albert 94  
 Oullier, Olivier 108  
 Özoğuz, Aydan 86, 88

## P

Panawela, Sachie 44  
 Parzinger, Hermann 62  
 Philipps, Dorothea 52  
 Phumaphi, Joy 56, 130  
 Piebalgs, Andris 84  
 Pisupati, Balakrishna 94  
 Pongsiri, Montira 90  
 Pott, Elisabeth 50  
 Pries, Axel Radlach 48, 116  
 Prokosch, Hans-Ulrich 126

## Q

Quek, Swee Chye 70

## R

Rabbow, Michael 78  
 Ranasinghe, Asanga 44  
 Resende de Oliveira,  
 Catarina 58  
 Rockson, Gregory 98  
 Røttingen, John-Arne 82  
 Rühli, Frank 62  
 Ruiz de Castaneda,  
 Rafael 48

## S

Sargsyan, Viktoria 120  
 Saso, Luciano 87  
 Schäfers, Reinhard 86  
 Schmutz, Daniel H. 72  
 Schnyder, Ulrich 92  
 Schulz, Stefan M. 116  
 Schwienhorst-Stich,  
 Eva-Maria 54  
 Sebbag, Robert 90

Seeger, Werner 126  
 Sehouli, Jalid 87  
 Shah, Niyati 128  
 Shaw, Brendan 102  
 Shaw, Reuben 72  
 Shea, Jaqueline 122  
 Shekhalage, Elisabeth 112  
 Shoukimas, Daniel 98  
 Sié, Ali 96  
 Singh, Steve 100  
 Sipido, Karin R. 124  
 Smit, Francis E. 46  
 Smith, Neal 49  
 Sprenger, Marc 122  
 Stock, Günter 86  
 Stolk, Pieter 80  
 Sultana, Victoria 87  
 Sutter, Gerd 82  
 Swing, William Lacey 88

## T

Takian, Amirhossein 48  
 Tano, Jean-Yves K. 86  
 Tarakji, Ahmad 64  
 Taylor, Peter 130  
 Tenhagen, Bernd-Alois 122  
 Theis, Fabian 126  
 Theobald, Sally 128  
 Thölken, Hinrich 98  
 Thorning-Schmidt, Helle 88  
 Told, Michaela 120  
 Tsi, Sean 49  
 Türk, Silvia 70

## U

Ulrichs, Timo 84

## SUPPORTING INSTITUTIONS SESSION CO-HOSTS

### V

Valentine, Nicole 120  
van den Boom, Martin 84  
van Houten, Frans 100  
Vehreschild, Jörg Janne 127  
Verdejo-Garcia, Antonio 60  
Vogel, Johannes 62

### W

Warinner, Christina 62  
Warnken, Heiko 79  
Watal, Jayashree 68  
Westphal, Florian 88  
Wieczorek-Zeul, Heidemarie 132  
Wieler, Lothar 122  
Wienold, Matthias 102  
Wong-Rieger, Durhane 102  
Wuliji, Tana 124

### Y

Yankah, Charles 46

### Z

Zeltner, Thomas 110  
Zink, Albert 62  
Zinkernagel, Rolf 56  
Zipfel, Stephan 92

### A

All European Academies (ALLEA)  
Association of Research-Based Pharmaceutical Companies (vfa)

### B

Berlin Institute of Health (BIH)  
British Medical Journal (BMJ) Case Reports

### C

Centre Virchow-Villermé for Public Health  
Charité – Universitätsmedizin Berlin  
Clinical Research Institute Montreal (IRCM)  
Coalition for Epidemic Preparedness Innovations (CEPI)  
Coimbra Health

### D

Department of Biotechnology, Government of India

### E

European Commission and the Horizon 2020 Scientific  
Panel for Health  
European Federation of Pharmaceutical Industries and  
Associations (EFPIA)  
European School of Management and Technology (ESMT)  
European Society of Cardiology

### F

F. Hoffmann-La Roche Ltd.  
Friends of the Global Fund

### G

German Centers for Health Research (DZG)  
German Federal Foreign Office  
German Federal Ministry of Health (BMG)  
German Healthcare Partnership (GHP)  
German Heart Institute Berlin  
German Network against Neglected Tropical Diseases (DNTDs)  
Government of Norway  
Government of Sri Lanka

**H**

Humboldt Forum Berlin

**I**

Imperial College London

InterAcademy Partnership for Health (IAP)

International Committee of the Red Cross (ICRC)

International Institute for Strategic Studies (IISS)

International Organization for Migration (IOM)

**J**

Johns Hopkins Bloomberg School of Public Health

Joint Conference Church and Development (GKKE)

**K**

KfW Development Bank

Koch-Metschnikow-Forum (KMF) e.V.

KU Leuven University

Kyoto University

**L**

Leopoldina – German National Academy of Science

London School of Hygiene & Tropical Medicine

**M**

M8 Alliance

Max Planck Institute for Psychiatry

Monash University

Munich Security Conference Foundation (MSC)

**N**

National Academy of Medicine (NAM)

National Taiwan University

National University of Singapore (NUS)

**O**

One Health Platform

**P**

Protestant Church of the Rheinland (EKIR)

**R**

Rabin Martin

Royal Philips NV

**S**

Sabin Vaccine Institute

Sanofi

**T**

The Boston Consulting Group (BCG)

The Graduate Institute Geneva – Global Health Center

Think Tank Initiative Canada (TTI)

Transparency International

**U**

UNAIDS

University Hospital Geneva

University Hospital Tübingen

University of Geneva

University of Montreal

University of São Paulo (USP)

USAID

**V**

VAMED AG

**W**

Women in Global Health

World Economic Forum

World Health Organization (WHO)

World Health Summit

WWF Germany

**Y**

Young Physician Leaders (YPL)

# SUMMIT PARTNERS

## SPONSORING PARTNERS

---

### Strategic Partners

---



### General Partners

---



## Supporting Partners



## Service Aides



## POLICY MAKERS

Partner & Co-Host:



Federal Foreign Office



Federal Ministry  
of Education  
and Research



Federal Ministry  
for Economic Cooperation  
and Development



World Health  
Organization

## ACADEMIA



## CIVIL SOCIETY



BertelsmannStiftung



Robert Bosch Stiftung



## ASSOCIATES



## MEDIA PARTNERS







---

---

#### Photo Credits

Federal Foreign Office, Page 2 © photothek/Auswärtiges Amt  
Angela Merkel, Page 8 © Bundesregierung/S.Kugler  
Berlin by Night, Page 13 © bbsferrari/iStockphoto  
Reichstag, Page 21 © Matthew Dixon/iStockphoto  
Eckart von Hirschhausen, Page 23 © Frank Eidel  
Bärbel-Maria Kurth, Page 23 © Robert Koch-Institut/Dugnus  
Molecule Men, Page 26 © lechatnoir/iStockphoto  
Hermann Gröhe, Pages 34, 75, 105, 156, 167 © BMG/Jochen Zick (action press)  
WHS Night, Page 38, © World Health Summit/S.Kugler  
Timo Ulrichs, Page 85, 175 © Akkon Monbijou  
Charité, Page 140 © Charité-Universitätsmedizin Berlin  
Bodemuseum, Page 141 © 2009 BTM/Scholvien  
Federal Foreign Office, Page 142 © photothek/Auswärtiges Amt  
Weltsaal, Page 145, © World Health Summit/S.Kugler

#### Layout

Eta Friedrich, Berlin

#### Printer

Laserline, Berlin



---

**SAVE THE DATES!**



WORLD  
HEALTH  
SUMMIT

WHS REGIONAL MEETING

---

**NORTH AMERICA, MONTREAL  
MAY 8-9, 2017**

WORLD HEALTH SUMMIT

---

**BERLIN, GERMANY  
OCTOBER 15-17, 2017**



WORLD  
HEALTH  
SUMMIT

[www.worldhealthsummit.org](http://www.worldhealthsummit.org)

---

**Summit Organizer/Academic Office**

WHS Foundation GmbH  
World Health Summit  
c/o Charité – Universitätsmedizin Berlin  
Charitéplatz 1  
10117 Berlin  
Germany

Tel.: +49 30 450 572102

Fax: +49 30 450 572911

[secretariat@worldhealthsummit.org](mailto:secretariat@worldhealthsummit.org)

[www.worldhealthsummit.org](http://www.worldhealthsummit.org)